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Resumo 
A informação de alta qualidade é a base para a provisão de cuidados de saúde de alta 
qualidade. O objectivo deste estudo foi analisar as características das fontes de informação 
sobre medicamentos dirigidas a profissionais de saúde. 
Inicialmente, avaliámos as preferências dos profissionais de saúde e investigadores de todo 
o mundo aquando da selecção de fontes de informação sobre medicamentos. Tendo como 
objectivo abranger a população global, desenhámos um questionário online para o efeito. 
Obtivemos respostas válidas de 107 países diferentes (56.5% dos 191 países analisados, 
após terem sido excluídos dois), compreendendo 88.3% da população mundial. Os 
resultados mostraram que na generalidade os livros de referência de medicamentos, 
também designados compêndios de medicamentos, são as principais fontes de informação 
utilizadas entre os profissionais de saúde, seguidas da informação de Internet e as revistas 
científicas. Variáveis demográficas e socio-económicas como ser membro da Organização 
para a Cooperação e Desenvolvimento Económico (OCDE), Produto Interno Bruto (PIB) per 
capita, percentagem do PIB como despesa da saúde e Índice de Desenvolvimento Humano 
(IDH) foram significativamente associados com a escolha de livros de referência de 
medicamentos como fontes preferenciais de informação. Na Europa, os livros de referência 
de medicamentos foram as fontes preferenciais de informação, seguidos da informação de 
Internet e dos Resumos das Características dos Medicamentos (RCMs).  
A publicação de compêndios de medicamentos no mundo foi igualmente avaliada e, dos 193 
países existentes no mundo, 84 reportaram publicar um compêndio nacional. Estes países 
representaram aproximadamente 62% da população mundial. Numa análise multivariada, 
verificou-se que ser membro da OCDE estava positivamente associado e Francês como 
língua oficial negativamente associado com a publicação de compêndios. Não se encontrou, 
contudo, qualquer associação significativa entre outras covariáveis demográficas e 
socioeconómicas, tais como população, PIB per capita e indicadores de cuidados de saúde, 
e a publicação de compêndios pelos países. Países sem compêndios nacionais referiram 
utilizar compêndios estrangeiros de países desenvolvidos, sendo o British National 
Formulary (BNF) o mais citado, seguido do Dictionnaire Vidal. Em 2002, a Organização 
Mundial de Saúde (OMS) publicou a primeira edição do Formulário Modelo da OMS, cujo 
objectivo era servir como ‘modelo’ para os governos nacionais e instituições que quisessem 
desenvolver os seus próprios compêndios e complementar a Lista Modelo de Fármacos 
Essenciais da OMS. Nenhum dos países sem um compêndio nacional reportou o uso do 
iv 
 
Formulário Modelo da OMS. Existe, por isso, oportunidade para criar um compêndio 
internacional de medicamentos sob a alçada da OMS. 
Na Europa, a fonte de informação oficial sobre medicamentos para profissionais de saúde é 
o Resumo das Características do Medicamento (RCM). Os RCMs foram definidos como “a 
base da informação para profissionais de saúde de como utilizar o produto medicinal de 
forma segura e efectiva”. O RCM representa uma posição acordada sobre o produto 
medicinal entre as entidades reguladoras e os fabricantes, resultante de um processo de 
avaliação do produto. Primeiro, procurámos analisar o conteúdo da informação 
farmacológica nos RCMs e compará-la com a informação farmacológica contida em outras 
fontes oficiais de informação: os folhetos informativos. Com este intuito, utilizámos uma 
checklist desenvolvida por Spyker et al. contendo 31 itens de informação. Os resultados 
obtidos mostraram que a informação farmacológica encontrada nos RCMs analisados não 
poderia ser considerada suficiente. A média da classificação obtida para os RCMs atingiu 
apenas 35.2% da classificação máxima possível. Comparando com estudos anteriores 
realizados nos Estados Unidos, o conteúdo da informação do Physicians’ Desk Reference 
(PDR) foi muito semelhante aos resultados obtidos para os RCMs. A média de classificação 
dos folhetos informativos foi apenas 15.9% da classificação máxima possível. O conteúdo 
em informação farmacológica neste caso é escasso, mas como os folhetos informativos se 
destinam aos doentes em geral, essa informação não se revela necessária. Na verdade, a 
inclusão de informação científica aprofundada iria influenciar negativamente a legibilidade 
dos folhetos informativos, pelo que se prefere o uso de termos concisos, úteis e 
compreensíveis. 
Um outro objectivo da investigação foi analisar a informação contida nos RCMs referente ao 
uso de medicamentos na gravidez, lactação e em mulheres com potencial para engravidar. 
Para tal, foi desenhado um formulário ad-hoc incluindo 18 questões relativas à informação 
contida nos RCMs sobre estudos pré-clínicos, ensaios clínicos, vigilância pós-
comercialização, passagem da barreira placentária, influência do fármaco na fertilidade, uso 
do fármaco em mulheres com potencial para engravidar, manejo da exposição, excreção no 
leite materno, potenciais reacções adversas em lactentes e recomendações para o uso 
durante a gravidez e aleitamento. Os resultados revelaram que menos de 17% dos RCMs 
possuíam informação sobre experiência clínica em mulheres grávidas. De entre os RCMs 
que relatavam ter conduzido ensaios clínicos em mulheres grávidas ou mencionavam dados 
de vigilância pós-comercialização, 86% forneciam uma descrição de reacções adversas 
obtidas no decurso dos ensaios clínicos ou resultante da experiência clínica. A percentagem 
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de RCMs incluindo informação acerca da passagem (ou não) do fármaco através da barreira 
placentária foi de 10%. No que toca à fertilidade, 79% dos RCMs não forneciam qualquer 
informação sobre os efeitos do produto medicinal na fertilidade humana e 18% declaravam 
que estes efeitos não eram conhecidos. A informação acerca de potenciais efeitos do 
produto medicinal em mulheres com potencial para engravidar não foi fornecida em 71% dos 
RCMs. Cerca de 13% dos RCMs mencionaram alguma informação sobre o manejo da 
exposição ao produto medicinal em mulheres grávidas. A informação acerca da excreção 
(ou não) do fármaco no leite materno estava presente em 17% RCMs. Dos RCMs que 
referiam a excreção do fármaco no leite materno, 89% não forneciam qualquer informação 
sobre reacções adversas em lactentes. Uma percentagem elevada de RCMs continha 
declarações não conclusivas em relação ao uso do produto medicinal durante a gravidez 
(57%) e aleitamento (17%). O uso do produto medicinal foi restringido em 95% dos RCMs 
durante a gravidez e 92% durante o aleitamento. 
Após a análise das características específicas de determinadas fontes de informação sobre 
medicamentos, propusemo-nos criar uma ferramenta universal que permitisse avaliar o 
conteúdo e a compleção de qualquer tipo de fonte de informação direcionada a profissionais 
de saúde. Para tal, criou-se uma lista de 162 itens de informação estruturados em 11 
secções (características do produto medicinal, uso do fármaco, contraindicações, reacções 
adversas, interacções, sobredosagem, propriedades farmacodinâmicas, propriedades 
farmacocinéticas, dados de segurança, evidência, e dados de prescrição), a qual foi 
avaliada e refinada recorrendo a uma técnica Delphi em 3 rondas que contou com a 
participação de 29 peritos de 18 países Europeus, recrutados de entre profissionais de 
saúde com conhecimento e experiência em informação sobre medicamentos. A aplicação da 
técnica de Delphi resultou em 126 itens de informação definidos pelos participantes como 
informação essencial a constar em qualquer fonte de informação sobre medicamentos para 
profissionais de saúde. Os peritos chegaram também a um consenso no que toca à 
ponderação de cada item de informação com base na sua importância. Para avaliar a 
compleção de qualquer fonte de informação para profissionais de saúde, a presença de 
cada item de informação deverá ser confirmada na fonte analisada, e a classificação final 
deverá ser obtida pelo somatório dos itens tendo em conta a respectiva ponderação. Esta 
ferramenta permite apresentar a compleção de uma fonte de informação expressa em 
percentagem da fonte de informação ideal. 
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Abstract 
Our objective was to assess the characteristics of medicines information sources designed 
for healthcare professionals.  
Using a global web-based survey, we identified that medicines compendia are the leading 
information source among healthcare professionals, followed by Internet and scientific 
journals. Out of 193 countries in the world, 132 answered the survey, with 84 of them 
reporting that a national compendium is published in their country. Being member of the 
OECD was associated with publishing a national compendium. Other demographic and 
socio-economic covariates were not associated to this fact. Countries not publishing their 
national compendium reported the British National Formulary as the most commonly used 
compendium.  
When assessing Summaries of Product Characteristics (SmPCs), we found that their content 
on clinical pharmacology information is insufficient. Information on this topic was found to be 
very similar to the content of the US Physicians’ Desk Reference.  
Completeness and applicability of the information about the use of medicines in pregnancy 
and breastfeeding in SmPCs did not appear as remarkable. Information resulting from post-
marketing surveillance is sparse, as well as information on the management of exposure to 
the medicinal product in pregnant woman or excretion of the drug in human milk. The 
majority of the SmPCs contained non-conclusive statements regarding the use of the 
medicinal product during pregnancy and breastfeeding. The use of medicines during 
pregnancy and lactation is restricted for most SmPCs. 
A three-round Delphi technique with 29 experts from 18 European countries was used to 
design a tool to evaluate the completeness of any medicines information source for 
healthcare professionals. Starting from a 162-item list, experts identified 126 items as 
essential information to be included in any kind of medicines information source. The 
resulting scoring tool allows assessment of the completeness of a medicines information 
source as a percentage of the ideal source. 
Keywords2: Drug Information Services; Drug Labeling; Reference Books; Health Personnel; 
Quality Control 
                                                
2 Keywords extracted from the Medical Subject Headings database 
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Introduction 
Medicines information  
The word ‘information’, from the Latin informatio has the meaning of ‘giving form to 
materials’ and ‘transmitting or communicating knowledge’, activities which are 
intimately related.(1) References from the 14th century already link information to 
"formation or moulding of the mind or character, training, instruction, teaching".(2) In 
more recent analyses, authors relate information to knowledge, and more specifically to 
scientific knowledge. In 1976, Oeser places information as a key concept concerning 
the creation of scientific knowledge, and remarks that the objectivity of scientific 
knowledge is attained on the basis of the inter-subjective information process.(2) 
Accordingly, Dretske states that "knowledge is information-produced belief".(3) Heinz 
von Foerster defined information as “the observer's construction or a mental difference 
that makes and/or finds a difference in the external world”(4). 
Almost every scientific discipline today uses the concept of information within its own 
context and with regard to specific phenomena.(2) Indeed, the concept of information 
plays a key role in healthcare. Medicines are a core part of healthcare and their use 
during the last century has grown enormously with the aim of curing diseases, 
preventing illnesses and relieving symptoms. The use of drugs is so extended that the 
most common therapeutic intervention in medicine is writing a prescription.(5) Safe 
prescribing requires accurate information about medicines and practical advice on their 
use. (6)  
The huge increase in the number of drugs on the market makes it impossible for 
healthcare professionals to have the knowledge necessary for an appropriate use of 
medicines (7). This knowledge implies “providing the right medicine at the right dose 
when it is needed, and avoiding medicines that are unnecessary or are unlikely to 
result in health benefits”.(8) Not only is the information too extensive to be 
remembered, but it is also constantly changing. In fact, medical knowledge may 
increase four times during a professional lifetime (9), thus updating clinical knowledge 
is a constant need of practising healthcare professionals.(10) According to Haynes: 
“one of the most frustrating failings of the human mind is its Lilliputian capacity for 
storing and retrieving important but infrequently used information”.(11) Consequently, 
to choose the best available medicine as regards effectiveness and safety at the lowest 
cost of treatment, access to unbiased, complete and useful information about available 
treatments is required.(6) 
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Medicines information may be defined as “a system of knowledge and techniques that 
allows communication of data and experiences about medicines in order to promote 
their rational use by society”.(12) Gaebelein et al. defined and characterised medicines 
information as “the provision of data as they relate to any area of pharmacotherapy or 
pharmacy practice. At its best, medicines information should be cogent, reliable, 
impartial, well-referenced, and critically appraised before being disseminated to other 
healthcare providers or the lay public”.(13) 
Castillo defined medicines information as “any knowledge or message that may be 
used to improve or allow an intervention”, intervention being “any action taken by a 
healthcare professional in his/her practice”.(14) 
Medicines information aims to improve the safety of patient care by minimising 
medication errors.(7) According to the American Society of Health-System Pharmacists 
(ASHSP), a medication error is “any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of 
the healthcare professional practice, health care products, procedures, and systems 
including prescribing; order communication; product labelling; packaging and 
nomenclature; compounding; dispensing; administration; education; monitoring and 
use”.(15) Information sources providing good prescribing guidance should help to 
reduce these prescribing errors, thus decrease the burden of adverse reactions and 
optimise rational prescribing.(6) 
The importance of the information has been highlighted by several authors. Jimeno 
stated that “a medicine is not only a drug, but the drug together with its 
information”.(16) Phillips et al. also believe that providing medicines without information 
is like providing the information without the drug.(17) Likewise, Garcia also states that 
information about a drug is as important as its discovery (18), and other authors 
consider information about medicines as important as their quality.(19) Furthermore, 
Huth states that the strength of a profession lies in its expert generation of information 
and better management of it than other social groups (20), and Haynes highlights that 
“a contemporary, comprehensive store of medical knowledge is not a luxury for 
practising doctors: it is as vital as an efficient pathology laboratory”.(11) 
Medicines information for healthcare professionals 
In a broader context, we are all currently living in an information-driven society, and 
healthcare professionals are constantly bombarded with huge amounts of data about 
thousands of new or already existing medications. There are more than 20,000 journals 
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published annually. In 2004 alone there were 600,000 new biomedical journal 
articles.(21) This overwhelming amount of information makes it impossible for 
healthcare professionals to remain up-to-date in every aspect of clinical care. 
Additionally, healthcare professionals today also face the challenge of the informed 
patient, which influences prescribing and modifies the relationship between healthcare 
professionals and patients.(22) 
Healthcare professionals receive information regularly, and mostly through scientific 
and professional journals, followed by newsletters, e-mail alerts and discussion lists. 
Although there is an extensive range of information resources available, most 
healthcare professionals are not satisfied by current information provision and perform 
additional searches for information.(23)   
The search for information always begins with the generation of a need for information, 
that is, with the healthcare professional asking a question. Ely et al. have described the 
steps of asking and answering questions as following:(24) 
 Recognise a gap in knowledge: recognising gaps in knowledge generates 
information needs, which are associated with clinical work.(25) These needs 
can be classified as 'expressed needs' or ‘unexpressed needs’. The expressed 
need is the recognised need that demands an answer, and prior knowledge is 
needed to recognise these gaps in knowledge.(26) The unperceived or 
unexpressed need is not recognised as a gap in knowledge. Once the 
information need appears and is recognised, characteristics such as willingness 
and ability to search for an answer are linked to it.(25) 
 Formulate a question: most questions are easy to formulate. According to 
Davies et al., 60% of questions are simple ones that can be easily answered 
just by looking for a fact, (such as, for example, the dose of a drug) rather that 
performing an extensive literature search.(25) However, sometimes complex 
questions arise, and then the way a question is formulated influences the 
finding of an answer. In order to improve performance when formulating 
questions, some systems such as the ‘PICO’ system have been developed (for 
more information, please refer to the ‘Evidence’ section in this Introduction). 
 Search for relevant information: in general, there are two main reasons why the 
information is sought. One is because the professional considers that the 
patient’s problem is urgent, and the second is the belief that an answer exists 
and can be found to assist the decision making.(25) However, skills to find the 
answers to questions are needed. Selecting the source of information is one of 
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the critical steps in the process of answering any medicines information 
question. This decision about which resource should be selected is mainly 
based upon personal preference, accessibility and the level of detail needed to 
find a complete answer.(21) 
 Formulate an answer: once the source of information is selected, professionals 
expect to answer the question that motivated the search. However, a high 
percentage of questions remain unanswered, because one of the earlier stages 
fails. A deeper analysis of obstacles to answer questions successfully is shown 
below. 
 Use the answer in patient care: although prior knowledge is crucial and 
professionals cannot rely on looking everything up, they must accurately 
process substantial information and clinical judgement before making clinical 
decisions.(26) Once professionals have answered the question that motivated 
the search, this information should be applicable to health care, that is, the 
answer should be useful in patient care. 
All the above mentioned steps have been thoroughly analysed in the clinical setting. 
Studies show that medical practitioners generate between one and six questions per 
patient and answers are pursued for around 30% of these questions.(9, 27) According 
to Davies et al., although generation of questions varies among settings and 
professionals, they range from 0.16 to 1.27 questions per patient.(25) 
According to Magrabi et al. 40% of searches by physicians relate to diagnosis and 35% 
to treatments.(28) Several other authors concluded that questions about drugs were 
the most common type of question.(9, 29) According to Davies et al., top categories of 
information needs for physicians are therapies and treatments, followed by diagnosis 
and medicines information.(25) 
However, although about 60% of the answers are very specific and simple (25), most 
questions remain unanswered, either because healthcare professionals do not search 
for them or because they do not find them.(30)  
Ely et al. found that physicians do not seek 45% of their questions.(30) In a previous 
study Ely et al. concluded that only one third of questions are pursued.(29) Reasons for 
not seeking information include lack of time, lack of accessibility to reliable and up-to 
date evidence, lack of literature searching skills and difficulty in formulating search 
strategies.(23, 24, 30-32)  
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Even if healthcare professionals search for information, sometimes answers are not 
found. According to Ely et al., 41% of the pursued questions were not answered using 
either print or electronic resources.(30) 
Once the search for the information begins, the most common obstacles to answering 
a question successfully are:(24) 
 the excessive time required to find an answer 
 difficulty in formulating a question (often questions are subjective, open to 
interpretation and vague) 
 difficulty in designing a search strategy 
 failure of the selected resource to cover a topic 
 uncertainty about when sufficient relevant information has been found and the 
search can be halted  
 inadequate synthesis of the evidence into a clinically useful statement 
Some authors consider accessibility one of the main characteristics of information 
(please refer to the section: ‘Characteristics of the information and analysis of its 
quality’ in this Introduction). The timely access to clinical information sources is 
important for all healthcare professionals, but it is especially critical for primary care 
physicians, due to the broad scope of their practice. Primary care practice is of 
particular importance when accessing information about medicines, because this is 
where most of the treatments are prescribed. General practitioners prescribe 98% of 
medicines in primary care.(33) General practitioners receive relatively little training in 
prescribing and have limited time to assess the large amount of information they 
receive.(33) Some studies have shown that family physicians spend an average of less 
than two minutes finding an answer when using traditional textbooks and printed 
journals.(29).  
As far as information sources are concerned, several authors have aimed at describing 
the most used sources when searching for information. According to Jackson et al., 
healthcare professionals use the Internet as their principal medium for searches, 
followed by informal networks and library and written resources. This study concluded 
that the majority of healthcare professionals prefer the provision of information in 
electronic format, although general practitioners tend to prefer written materials.(23) 
However, the use of electronic sources by healthcare professionals varies among 
studies. According to McEntee et al. healthcare professionals infrequently use 
evidence-based electronic resources (33), and other authors claim that the most used 
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resources among physicians are textbooks, followed by colleagues and electronic 
resources.(25) 
Specific characteristics of each professional group also influence their behaviour when 
seeking information. Primary care physicians, for example, have limited access to 
colleagues compared to specialists, who can consult senior physicians in their own or 
other departments and work in a more teaching-oriented setting.(34) This may be one 
of the reasons why primary care physicians prefer journals as a source of information 
rather than colleagues, followed by meetings and websites.(35)  
The relationship between pharmacists and information is also a well-studied topic. 
Pharmacists have an important role as educators and providers of information on 
medicines. The American Association of Colleges of Pharmacy states that upon 
completing a Pharmacy degree, graduates must be able “to retrieve, analyse and 
interpret the professional, lay and scientific literature to provide medicines information 
to patients, their families and other involved healthcare providers”.(36) 
Providing medicines information is an important skill for all pharmacists, regardless of 
their setting, as pharmacists have become an integral part of patient care within the 
clinical team.(13) All pharmacists require medicines information skills, up-to-date 
relevant knowledge, and easy access to evidence-based medicines information to 
provide not only patient care, but also support to other professionals.(37)   
Among pharmacists, there are also specialists in drug information. Drug information 
specialists are those individuals who are trained to have the skills and clinical 
knowledge to provide clear, concise and accurate recommendations regarding drug 
use.(37) Their responsibilities are, among others, to use medicines information 
sources, report and monitor adverse drug events, perform drug use evaluations and 
manage policies in different settings to improve patient care.(37) 
Characteristics of the information and analysis of its quality 
The constant changing of medicines information and, in general, healthcare practice, 
leads to a need for continual growth and refinement of the standards of drug 
information practice.(37) According to Molloy et al., critically appraised, evidence-
based, comprehensive and up-to-date information leads to physicians prescribing 
safely, appropriately and effectively and thus, the satisfaction of physicians and patient 
outcomes should improve.(38) High quality information is the basis for high quality 
clinical care. 
 8
Several authors have aimed at describing and evaluating the quality of medicines 
information. To assess the quality, several aspects and characteristics of the 
information have been defined and analysed.  
Fernandez-Llimos described four main characteristics of medicines information:(39) 
 Accessibility 
 Reliability 
 Completeness 
 Applicability 
Accessibility is the capacity to retrieve the information in the specific moment it is 
needed.(39) It is the first barrier when choosing an information source: having easy 
access is essential when selecting information sources. Authors such as Shaughnessy 
et al. have considered accessibility as one of the three main characteristics that define 
the best source of information.(40) Hibble et al. highlighted the need for information to 
be highly accessible and usable at the point of clinical care, and suggests that these 
two characteristics should be ideally achieved by an electronic medium.(41) Although 
computerization has increased dramatically in healthcare during the last few decades, 
the access to electronic information resources is not universal and no standardization 
of electronic decision support systems for healthcare professionals has been achieved 
yet.(42, 43) 
Reliability is the capacity of the information to be perceived as having a trustworthy 
content.(39) The reliability of the information is strongly linked to the producer of the 
information and its reliability as a source of information. Some sources tend to 
overestimate the benefits of a drug, for example, promotion from the pharmaceutical 
industry. On the other hand, independent analyses and summaries by experts with 
complete access to all relevant data and no financial conflicts of interest are incredibly 
valuable because of their reliability.(44) An example of reliable sources of information 
are regulatory authorities. Information provided by regulatory authorities is reliable 
because they perform independent reviews of the raw data submitted by 
manufacturers. Although being reliable may appear as a very subjective characteristic, 
some authors have aimed at developing systems to measure reliability of information. 
For example, in order to define the reliability in a study analysing websites, Martin-
Facklam et al. used two criteria: citation of scientific sources and absence of financial 
interest.(45) 
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Completeness is not only the capacity of being complete, but also balanced and 
updated.(39) To support decision making, healthcare professionals need appropriate 
information in suitable format and in the correct amount.(23) Since up-to-date medical 
knowledge is paramount to high quality and effective physician performance, the 
update of the information is a topic that has generated concern among 
researchers.(26) As already mentioned, in a continuously changing practice it is 
impossible for healthcare professionals to stay updated, even within limited 
pharmacotherapeutic topics.(34) Trifiro et al. have highlighted the need of more 
homogeneous information sources and regular updates on the basis of current 
evidence from the literature.(46)  
If the information about a drug is not updated, the information that healthcare 
professionals receive may be information from early studies and not from real practice. 
When a new drug is granted a marketing authorisation, clinical trials are the primary 
source of information and manufacturers’ recommendations for the use of drugs are 
usually selected during phase one, at early stages of the pre-release research 
period.(47) These phase one studies are usually brief, limited in time and involving 
selected populations. These studies ensure in general that a medicine is effective and 
does not cause unacceptable harm.(5) However, the use of data from phase-one 
studies in clinical care is controversial. Bates highlighted the inapplicability of pre-
release data to patients in healthcare visits.(48)  One of the reasons of this 
inapplicability may be the lack of knowledge about the performance of new medicines 
in frail patients with multiple illnesses, who are not included in pre-marketing studies.(5) 
Other authors also argue that manufacturers’ dosing recommendations are usually 
based on these phase one studies. Scarce information about dosing fails to determine 
dose-concentration-response relationships, and this may lead to undesired adverse 
effects or lack of individualisation in dosing.(47)  
After a medicine is authorised, the phase four (post-release phase) begins. This phase 
often involves millions of patients for several years and is very informative. New uses, 
new adverse effects and true risks of drugs are discovered during phase four. Also 
lower doses, maybe with fewer adverse events are proven effective. This new 
information is not always incorporated into information sources and physicians still use 
doses of medications based on pre-release studies, which may lead to otherwise 
preventable dose-related adverse effects.(47) Regarding adverse events, studies show 
that only half of newly discovered serious adverse events are detected and 
documented in the Physicians’ Desk Reference within seven years after drug 
approval.(49) 
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Applicability is the capacity of being useful in the specific decision-making process, that 
is, successfully answering the question that motivated the information search.(39) The 
applicability derives from the information being a contextual concept, that is, the 
information itself should not be considered in isolation, but related to its context.(50) 
Furthermore, the applicability of the information in a specific context has been defined 
as a ‘knowledge generator’. Probst et al. remark that information is used to designate 
isolated pieces of meaningful data that, when integrated within a context, constitute 
knowledge.(51) 
Other key concepts, such as readability, comprehensibility or clinical relevance have 
also been described.(52)  According to Aronson et al. these three characteristics 
should be favoured over other characteristics of the information such as 
compactness.(52) According to Curley, the best sources of information are those that 
provide highly relevant and valid information but do not require a lot of effort to use.(53) 
Molloy et al. consider that to prescribe safely, appropriately and effectively, physicians 
should consistently receive critically appraised, evidence-based, comprehensive and 
up-to-date information.(38) Berland et al. defined the quality of the information by 
analysing the coverage of topics, accuracy of the information and absence of 
conflicting information.(54)  
Shaughnessy et al. assessed health information sources according to their usefulness, 
and defined the concept with the following equation:(40) 
Usefulness of medical information = relevance x validity / work 
Relevance is based on “the frequency of your exposure to the problem being 
addressed and the type of evidence presented”.(40) These authors divide evidence 
between disease-oriented evidence and patient-oriented evidence. Patient-oriented 
evidence is described using mortality, morbidity and quality of life information as well as 
effects on clinical events. Disease-oriented evidence is described through 
pathophysiology, pharmacology and aetiology information.(40) Shaughnessy et al. 
define “work” as the effort to access the information source. 
Internet as a source of information has attracted researchers analysing medicines 
information and many of them have aimed at analysing its characteristics and quality. 
Therefore, due to the amount of information present in Internet and the huge number of 
authors aiming at analysing the quality of this information, Eysenbach has defined a 
new research discipline and methodology: information epidemiology or ‘infodemiology’. 
This discipline studies the determinants and distribution of health information and 
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misinformation, identifying areas where there is a knowledge transfer gap between best 
evidence and practice, as well as markers for high quality medicines information on the 
web.(55) 
Eysenbach et al. have defined valid quality criteria on websites as “features that predict 
effective health communication in terms of improving knowledge or changing health 
behaviour, or which is associated with a measurable effect on health outcomes”.(55) 
These criteria that are used to evaluate health information on the web are divided into: 
Technical criteria (how the information is presented or the meta-information which is 
provided), Design (quality of presentation of the information), Readability (reading level 
of a document), Accuracy (degree of concordance of the information with the best 
evidence or with generally accepted medical practice) and Completeness 
(comprehensiveness, coverage or scope).(56) 
Regulatory agencies have also tried to define the characteristics that ensure the quality 
of health information on the Internet. The Food and Drug Administration (FDA) also 
names some of the most important questions to consider when evaluating internet 
health information: who runs the website, aim of the website, sources of information 
and evidence provided, updating and review of the content, use of the information 
collected from visitors of the webpage and accuracy of e-mails received and chat 
rooms.(57)  
The European Federation of Pharmaceutical Industries and Associations (EFPIA) sets 
out the principles of evaluating company-sponsored websites containing medicines 
information for health professionals, patients or the general public. These principles 
are: giving the sponsor’s identity; informing about the content of sites (what information 
is included on the website); providing general information on the company; providing 
balanced and accurate information; stating that the information is for healthcare 
professionals and complying with national regulations and industry codes of practice; 
providing balanced and accurate patient information which is consistent with the 
Summary of Product Characteristic (SmPC), providing copies of the SmPC and patient 
leaflet on the webpage; offering e-mail enquiries; providing links including the identity of 
the linked site; providing a scientific review of accuracy of the information on the site 
and complying with the regulation on privacy of personal information.(58) 
Silberg et al. established four basic criteria to assess the quality of information on 
Internet:(59) 
 Authorship: identifying the source of the information and determining its 
trustworthiness and qualification 
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 Attribution: evaluation of the references cited by the authors 
 Disclosure: identifying potential conflicts of interest or bias 
 Currency: update 
The Health on the Net (HON) Foundation has established 8 principles, known as the 
HON Code, used as criteria to evaluate the quality of web sites containing health 
information. These 8 principles are: authority (provide qualifications of authors), 
complementarity (information to support, not replace), confidentiality (respect the 
privacy of site users), attribution (cite sources and dates of the information), justifiability 
(justify claims and provide balanced and objective claims), transparency (accessibility, 
provide valid contact details), financial disclosure (provide details of funding), 
advertising (clearly distinguish advertising from editorial content).(60) 
Although disclosure of the authors’ names is a frequent criterion to define quality of 
medicines information on the Internet, according to other authors it is not a predictor of 
the site’s reliability, perhaps because government organizations, drug companies and 
other organizations do not usually provide names of the authors on their websites.(54) 
Nähri et al. developed the DARTS tool to assess medicines information on the Web. 
This tool helps find reliable and quality information on the Internet by assessing the 
following criteria:(61) 
 Date: when the information was updated 
 Author: disclosure of authors and their qualifications 
 References: validity of the sources of the content 
 Type: purpose of the site, who it is aimed at 
 Sponsor: if the site is sponsored and a possible conflict of interest 
According to Eysenbach, apart from the main criteria to define the quality of information 
on the Web, there are other criteria which are valid because they create context, such 
as ‘disclosure of the target audience, scope and purpose of the site’ (help users to filter 
inapplicable information), ‘links and references’ (help users to verify the information 
provided) and ‘authorship credentials’ (help users to decide if a site is trustworthy). (55)  
Taking this into consideration, Eysenbach defined the main characteristics to assess in 
a website using the mnemonic ‘CREDIBLE’:  
 Current and frequently updated 
 References cited 
 Explicit purpose and intentions of the site 
 Disclosure of developers and sponsors 
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 Interest disclosed and not influencing objectivity 
 Balanced content: listing advantages and disadvantages 
 Labelled with metadata 
 Evidence level indicated 
These systems were designed to analyse information on the Internet. Additionally, 
other systems have been developed aiming at assessing the quality of other specific 
sources of information. For example, to assess the quality of clinical guidelines the 
AGREE rating scale was created by an international group of guideline experts 
(Appraisal Guideline Research and Evaluation Europe, AGREE Collaboration). This 
instrument provides an appraisal of the predicted validity of a guideline, which is the 
likelihood that it will achieve its intended outcome. It evaluates the process of practice 
guideline development and the quality of reporting. The AGREE instrument was 
created in 2003 and refined in 2009 (AGREE II) and it currently includes 23 items 
divided into six categories. Each item should be scored with a four-point Likert scale. 
The categories and items are:(62) 
 Scope and purpose: 
o Description of the objectives of the guideline 
o Description of health questions covered in the guideline 
o Description of population to which the guideline applies 
 Stakeholder involvement 
o The guideline development group includes individuals from all relevant 
professional groups 
o Views and preferences of the target population have been sought 
o Definitions of target users of the guideline 
 Rigour of development 
o Systematic methods were used to search for evidence 
o Description of criteria for selecting evidence 
o Descriptions of methods for formulating recommendations 
o Recommendations were formulated considering health benefits, side 
effects and risks 
o Recommendations are linked to supporting evidence 
o Guideline review by external experts prior to publication 
o Updating procedure is provided 
 Clarity and presentation 
o Recommendations are specific and unambiguous 
o Different management options are clearly provided 
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o Key recommendations are easily identifiable 
 Applicability 
o Guideline provides tools/advice to put recommendations into practice 
o Description of facilitators/barriers to application of the guideline 
o Considerations of potential implications of application of the guideline 
o Presentation of monitoring/auditing criteria 
 Editorial independence 
o There is no influence of the funding body over the content of the 
guideline 
o Competing interest of developers have been recorded and addressed 
Additionally, the AGREE II included in 2009 two final overall assessment items that 
require the appraiser to make overall judgments of the practice guideline and consider 
how they rated the 23 items. These two items include rating the overall quality of the 
guideline and stating if one would recommend the guideline for use.(62) 
Classification of information sources  
Information sources may be classified into different categories according to aspects, 
such as the producer of the information or their level of evidence. Depending on the 
producer of the information, information sources may be defined as primary, secondary 
or tertiary sources. 
Primary, secondary and tertiary sources 
The most common classification of information sources is distinguishing between 
primary, secondary and tertiary sources. 
Primary sources refer to original scientific research or clinical studies. This original 
information is obtained by carrying out specific experimental designs and statistical 
analyses, such as randomised control trials, epidemiological studies such as case-
control studies and individual investigations such as case reports.  
These primary information sources have been described as the “building blocks” of 
biomedical information and are the most current source of information.(13) Primary 
sources of information are the basis of evidence-based healthcare practice. Some of 
the advantages of primary sources are that they provide original and unique 
information, in which the reader knows how the information was obtained (information 
about methods is given), they are peer-reviewed and allow a critical review of the 
results of the study.(63) 
 15
However, scientific articles in journals do not alter prescribing habits easily.(47) This 
may be because extracting the information from primary sources to formulate a 
statement and use it in clinical care is not so obvious. Specific skills are necessary to 
critically evaluate primary literature and to understand how to interpret and apply this 
information to individual patient care.(21) Assessing the type of studies, the journal 
which publishes them, their limitations, and relevancy to the question we are looking at, 
are some of the skills needed to perform an assessment of the information found in 
primary sources.(21) 
Although primary sources are considered the gold standard by some authors, they 
have also been criticised by others. Some of their disadvantages are their format, 
length, and the skills and time needed to interpret them.(63) Primary literature may also 
be biased.(64, 65) There is a known bias toward the publication of positive results. Not 
only are positive results more likely to be published, but studies that are not positive 
are often published in a way that expresses a positive outcome.(64, 66). There is not 
only a publication bias, but also peer reviewers having relationships with the industry 
may provide biased reviews in primary sources.(67) Other authors have also studied 
the prevalence of ghost authorship in primary sources, which is providing academic 
authorship to articles written by pharmaceutical company employees or third 
companies working for the pharmaceutical industry.(68) (Please refer to ghost-writing 
in section: ‘Information from the industry’ in this Introduction) 
Secondary sources of information connect the person looking for information with 
primary sources, providing efficient access to primary literature. The role of secondary 
sources is to index and provide abstracts of primary literature.  
Databases such as Pubmed (www.pubmed.com) are examples of secondary sources. 
Pubmed is a very popular database, freely available on the Internet. It provides access 
to the citations and abstracts of thousands of biomedical journals and provides links to 
the selected articles, sometimes allowing the article to be downloaded at no cost to the 
user. 
Some of the advantages of secondary sources are that they include extensive 
information and provide access to original articles. On the other hand, they generally 
only provide summaries of articles and they do not include every journal, only those 
which are indexed.(63) 
Professionals performing searches also need some skills to retrieve information 
successfully. One of the main limitations is that, often, when using broad search terms, 
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secondary sources display a vast number of citations, which have to be individually 
reviewed, and this can be a very time-consuming activity. Different databases also 
have different systems for searching and specific techniques need to be learnt in order 
to perform an optimal search. According to Iwanowicz, another limitation of secondary 
sources is that quality assurance is not a major concern in this kind of sources.(21) 
Tertiary sources are the media that summarise, integrate and evaluate original 
research reports.(13) Textbooks, medicines compendia, computer databases or review 
articles are some of the available tertiary sources. 
Review articles are published in primary sources of information, but as they do not 
provide original research, they are classified as tertiary literature. The advantage of 
tertiary literature sources is that they are convenient and easy to use, their information 
is usually comprehensive and easily accessible.(21)  
These sources offer reliable information, based, at least in part, on a review of the 
primary literature. Additionally, many textbooks and most review articles undergo a 
peer-review process prior to publication to ensure that the content is accurate and 
complete. However, this does not mean that such resources are free of limitations. 
Textbooks can be published without peer review and authored by individuals who are 
less than well-qualified to write on the matter. Information may appear accurate and 
credible but, if poorly referenced, may not be reliable. 
The main limitation of tertiary sources of information is that they become easily 
outdated due to the gap between writing and publishing. The content often lags behind 
by one to two years due to publishing delays.(21) Nevertheless, tertiary sources in 
electronic format should overcome this limitation. 
Official information sources 
Other classification system, according to the producer of the information is 
distinguishing between official and non-official information sources. Although this 
classification system may not be as popular as the previously mentioned classification, 
for our study it is more relevant. An information source is official when it is either 
produced or approved by regulatory agencies. 
A new drug cannot be marketed without approval from regulatory agencies. This 
approval depends on the new drug meeting the criteria of detailed regulations whose 
purpose is to guarantee the safety and efficacy of pharmaceuticals.  
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Regulatory agencies do not rely on published literature for their decisions, since they 
perform independent reviews of the raw data submitted by manufacturers from pivotal 
randomised clinical trials and summaries of other relevant studies.(44) Regulatory 
agency reviews have been described as ‘the most complete and accurate syntheses of 
clinical trial data available’.(44) 
In the European Union (EU) during the authorisation process manufacturers propose 
the labelling of the product and its summary of product characteristics, which have to 
be approved following the specific regulations addressing their content and format. The 
labelling includes both the ‘label’, defined as ‘a display of any written, printed or graphic 
matter on the immediate container of the drug” (69); and any written, printed or graphic 
material that accompanies the drug, including patient leaflets, containers and wrappers. 
The officially approved product information in the European Union consists of the 
Package Insert, the Summary of Product Characteristics and the European Public 
Assessment Report (EPAR). For more information about these information sources 
please refer to the section ‘Medicines information sources for healthcare professionals’ 
in this Introduction. 
In the United States (US) the labelling of a drug must also be approved by the Food 
and Drug Administration. There is an important difference between the European Union 
and the US concerning labelling. In the EU, prescription drug labelling is mainly 
addressed to patients whereas in the US it is primarily aimed at physicians.(70) In the 
US patients usually receive prescription drugs from a pharmacist in a container 
specifying at least the name and address of the dispenser, prescription serial number 
and date, name of prescriber, and when stated by the physician: name of patient, 
instructions for use and precautions.(70) Patient leaflets are only required when the risk 
of serious adverse effects makes it essential for patients to have complete 
instructions.(70) For example, patient leaflets are required for oral contraceptives, or 
intrauterine devices. In the European Union patient leaflets are compulsory for all drugs 
on the market. 
In the US, additional safety information may be added before receiving FDA approval. 
This safety information includes new information on warnings, precautions, adverse 
reactions, overdose, drug abuse or dependence, as well as adding information on 
dosing or administration for a safer use or deleting false or misleading information 
about the effectiveness of a medicine. Although the FDA considers the communication 
of risks and benefits through its product labelling as ‘the cornerstone of risk 
management efforts for prescription drugs’ (71), some authors claim that there are no 
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specific measures to ensure that a minimum amount of risk information is included in 
the labelling.(72) Minor information changes may also be made without FDA approval 
(for example, change in the size of the package or minor editorial changes).(70) 
According to Willy et al. regulations are reasonably flexible regarding the appropriate 
wording and placement of safety related information.(72) In the European Union any 
changes at any time in the information provided have to be approved by the competent 
authorities. 
Some authors argue that the information provided by regulatory authorities is not 
enough. In 1987 Herxheimer already suggested that regulatory agencies should 
publish assessment of medicines describing which medicines offer important, modest, 
little or no therapeutic advantages compared to existing treatments for the same 
indication.(73) Other authors claim that comprehensive reviews carried out by 
regulatory agencies should be more easily accessible to facilitate an accurate 
assessment of clinical research.(44) 
Evidence 
Medicines information sources may also be categorised according to their level of 
evidence. 
The practice of evidence-based medicine is defined as the explicit application of the 
best currently available evidence in making decisions about the care of individual 
patients. To provide evidence-based care, health professionals recognise the need of 
up-to-date knowledge.(23) Evidence-based medicine is valuable to the extent that the 
evidence is complete and unbiased.(64)  
Practice of evidence-based medicine implies integrating the best available clinical 
evidence from scientific research to the individual clinical skills.(63) The best available 
clinical evidence is the evidence coming from patient clinical research, based on the 
accuracy and precision of diagnostic tests and prognostic markers and the efficacy and 
safety of preventing, therapeutic and rehabilitating regimes.(63) 
Practice of evidence-based medicine is a process in which patient care generates the 
need for clinically relevant information, and it is based on the following principles:(63) 
- Clinical decisions should be based on the best available scientific evidence 
- The clinical problem determines which evidence should be used 
- To find, identify and evaluate the best evidence, basic knowledge on information 
seeking, clinical epidemiology and biostatistics is needed. 
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- Conclusions obtained from evidence are useful only if they are applicable in 
healthcare 
These principles lead to four steps in clinical practice:(63) 
- Formulate a precise question: needs of information should be turned into a simple 
and specific question in order to facilitate finding an answer. This step is crucial in 
evidence based medicine, and the ‘PICO question’ is a system developed to help 
professionals form an appropriate question. To formulate a question following PICO, 
professionals should include the following information in the question:(74) 
 Patient: describe the characteristics of the patient/group of patients 
 Intervention: the action that the health professional is considering (e.g. to 
treat an illness) 
 Comparison: other action that could be taken instead (e.g. not to treat) 
 Outcome: what the expected outcome is 
- Find the best scientific evidence: evidence is found through the appropriate search to 
answer the previous question. This process includes selecting the information 
source and the design of a search strategy.   
- Critically assess the evidence found: it includes the analysis of published studies, 
evaluations of results and determining its clinical applicability. 
- Apply results of the evidence found: make a clinical decision considering the clinical 
circumstances. 
A model to organise evidence-based information sources and rank them according to 
the level of evidence has been developed, which is represented in Figure 01-01.(75) 
 
 Systems 
   Summaries 
   Synopses 
 Syntheses
  Studies 
Fig.01-01. Levels of organization of evidence from healthcare 
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In this organization system the definitions of levels are: (75) 
 systems are “decision support services that match information from individual 
patients with the best evidence from research that applies” 
 summaries “integrate best available evidence from the lower layers (drawing 
on syntheses -systematic reviews- as much as possible) to provide a full range 
of evidence concerning management options for a given health problem” 
 synopses are “succinct descriptions of an individual study or a systematic 
review” 
 syntheses are systematic reviews, such as e.g. Cochrane reviews 
 studies are the original articles (primary sources) 
The lower layers (synopses, syntheses, and original studies) most often examine only 
one aspect of management, such as a specific drug or drug class, and healthcare 
professionals are the ones who should do their own critical appraisal and integration of 
the information.(75) 
Studies are also categorised in different levels of evidence, which are shown in Figure 
01-02: (76) 
Fig 01-02. Levels of organization of evidence from studies 
Meta-analysis
Systematic review 
Randomised  Controlled Trial  
Cohort studies  
Case Control studies  
Case Series/Case Reports  
Animal research/Laboratory studies  
 
Systematic reviews and meta-analysis have the highest level of scientific evidence. 
However, some authors claim that as they are based on the published literature, which 
is biased,(64) they are not reliable.(44) According to Dwan et al. the study publication 
bias leads to overestimation of efficacy, it is a threat to the validity of meta-analysis, 
and can make the readily available evidence unreliable for decision making.(65) 
Ely et al. argue that although physicians are urged to practice evidence-based 
medicine and advised to evaluate the results of original research, due to the lack of 
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time they are more likely to search readily available sources of information.(24) The 
obstacles to finding an answer related to the available evidence arise either because 
the evidence found does not address the question or provides incomplete information 
about it; or because the available evidence is not synthesised or interpreted.(24) 
Therefore Ely et al. consider that in order to provide evidence-based information at 
point of care, quickly accessible summaries would be more useful.(24) Other authors 
also state that although there is general access to updated primary evidence (e.g. 
through ‘Pubmed’), the traditional methods of seeking information in printed sources or 
consulting colleagues are still the most popular among physicians.(25) 
Medicines information sources for healthcare professionals 
Analysing the characteristics of medicines information sources available for healthcare 
professionals is essential for this research. Healthcare professionals have a huge 
choice of information sources about medicines, and the decision of which source 
should be selected may be based not only on personal preferences, but also on 
characteristics of the sources such as accessibility, completeness and usefulness.(21) 
The main medicines information sources used by healthcare professionals and their 
characteristics are described below. 
Summaries of Product Characteristics (SmPCs) 
As previously mentioned, SmPCs are official information sources in the European 
Union. The Directive 2001/83/CE and regulation (EC)726/2004 require that for a 
medicine to be granted a marketing authorisation, a Summary of Product 
Characteristics must be included in the application. Once the authorisation is approved, 
the marketing authorisation holder is informed by the competent authorities of the 
approved SmPC. The SmPC forms “an intrinsic and integral part of the marketing 
authorisation”.(77)  
The SmPC may be defined as ‘the basis of information for healthcare professionals on 
how to use the medicinal product safely and effectively’ (77), or ‘the agreed statement 
of known facts about a given pharmaceutical compound at a particular point in 
time’.(78) Its aim is not to give general advice to treat medical conditions but to specify 
the use of a medicinal product, administration and effects, among others. 
The SmPC defines an agreed position of the medicinal product between regulators and 
manufacturer, as agreed during the product assessment process. Not only is its first 
version approved, but every subsequent modification should also be approved by the 
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competent authority. The data submitted by the marketing authorisation holder and 
reviewed by the regulatory agency exceeds the published data in the scientific 
literature.(78) 
All SmPCs have a common structure, which is described in the ‘Guideline on 
Summaries of Products Characteristics’.(77) Authorities provide all the information and 
advice on how the information should be presented. Headings are common for all 
SmPCs and are: 
1. Name of the medicinal product: including invented name, name of the active 
substance, the strength and pharmaceutical form 
2. Qualitative and quantitative composition: full details of the composition including 
the active substance and excipients. 
3. Pharmaceutical Form: using a full standard term of the Pharmacopoeia 
Europea. 
4. Clinical Particulars: 
a. Therapeutic indications: definition of the target disease or condition, 
distinguishing between treatment, prevention and diagnostic indications. 
b. Posology and method of administration: dosage and route of 
administration including any special precautions related to the 
manipulation or administration of the product. 
c. Contraindications: situations under which the medicinal product should 
not be given for safety reasons. 
d. Special warnings and precautions for use: derived from the safety 
information of the product. 
e. Interactions: information on the potential for clinically relevant 
interactions based on pharmacodynamic properties of the product and in 
vivo pharmacokinetic studies. 
f. Fertility, Pregnancy and Lactation: recommendations for use in 
pregnant, lactating women or in women with child-bearing potential. 
g. Ability to drive and use machines: information about effects of the 
product on the ability to drive and use machines. 
h. Undesirable effects: all adverse reactions from clinical trials, post-
authorisation safety studies and spontaneous reporting. 
i. Overdose: acute symptoms, signs and potential sequelae of different 
dose levels of the product. 
5. Pharmacological properties:  
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a. Pharmacodynamic properties: brief description of pharmacotherapeutic 
group, ATC code, mechanism of action, pharmacodynamic effects, 
clinical efficacy and safety. 
b. Pharmacokinetic properties: pharmacokinetic values relevant for the 
dose, strength and pharmaceutical formulation marketed. 
c. Preclinical safety data: safety profile of the product. 
6. Pharmaceutical particulars: 
a. List of excipients: expressed qualitatively. 
b. Incompatibilities: physical and chemical incompatibilities of the product 
with others with which it is likely to be mixed or co-administered. 
c. Shelf-life: as package and after dilution, reconstitution or first opening. 
d. Special precautions for storage: storage warnings. 
e. Nature and contents of container: components of the immediate 
container according to the European Pharmacopoeia. 
f. Special precautions for disposal: instruction for disposal of the product. 
7. Marketing authorisation holder: name and address at least. 
8. Marketing Authorisation number(s): numbers included in the community 
register. 
9. Date of first authorisation/renewal of authorisation 
10. Date of revision of the text 
11. Dosimetry: internal radiation dosimetry 
12. Instructions for preparation of pharmaceuticals 
Since they are official, SmPCs are considered reliable information sources. 
Nevertheless, SmPCs may also contain errors or discrepancies. Fusier et al. analysed 
SmPCs and encountered a problem in 2.7% of SmPCs. Main errors in categories of 
information with impact on the patient were related to indications/dose, 
contraindications/precautions and interactions.(7) A study in 2008 comparing 
information on management of overdose between SmPCs and a specific toxicity 
database showed that there were minor discrepancies in 11% of drugs and major 
discrepancies in 80%. Only 9% of drugs agreed in both sources.(79) 
It is critical that SmPCs are reviewed and amended regularly as new information about 
the medicinal product is being published.(78) As previously explained, SmPCs are 
submitted to the regulatory authorities when only limited data about the drug are 
available. In order to develop a comprehensive picture of clinical safety, medicinal 
products should be closely monitored, especially during the first years of 
commercialisation.  
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Surveillance of marketed medicines is a shared responsibility of the Regulatory 
Authorities and Marketing Authorisation Holders.(80) The Marketing Authorisation 
Holder is required to submit periodic update safety reports, which ‘report all the 
relevant new safety information from appropriate sources; relate these data to patient 
exposure; summarise the market authorisation status in different countries and any 
significant variations related to safety; create periodically the opportunity for an overall 
safety re-evaluation; and indicate whether changes should be made to product 
information in order to optimise the use of the product’.(80) In the European Union, 
Council Directive 93/39/EEC and Council Regulation 2309/93 require reports with a 
periodicity of six months for two years, annually for the three following years and then 
every five years, at the time of renewal of registration.  
Despite this requirement for updates, the lack of current information is one of the 
reasons why SmPCs are mostly criticised.(79) Arguing that SmPCs are not sufficiently 
updated, Wall et al. claim that their information should reflect current practices and 
periodic updates should be better encouraged.(79) In contrast, other authors consider 
that SmPCs are the best source to aid prescribing decisions, due to the fact that they 
are updated more regularly than other sources such as clinical guidelines.(78)  
Another limitation of SmPCs is that healthcare professionals are not always fully aware 
of the content of SmPCs or how to access them.(78) In a recent study, Bastholm 
showed that few physicians had knowledge of the information in the SmPC. (42) 
Package leaflet 
Package leaflets are official information sources. Although in the European Union they 
are not intended to be used by healthcare professionals, it is worth analysing some of 
their characteristics.  
In the European Union, the package leaflet is always included in the package of every 
medicine and it is aimed at informing the patient. Although the primary and main source 
of information about medicines for patients is healthcare professionals such as 
physicians and pharmacists, the package leaflet supplements this information.(81) 
Patients are currently actively involved in clinical decisions about their treatments. 
Patients have a right and an increasing expectation, to having access to good quality 
and objective information about medicines.  Patients cannot express informed 
preferences unless they are given sufficient and appropriate information about all 
relevant treatment and management options and information about the potential 
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benefits and harms of each. Information to patients should be objective, 
comprehensive, readable, accurate and up-to-date.(81) 
Package leaflets provide information on how to use medicines safely and effectively 
and they are usually the only source of information when the patient actually takes the 
medicine. This is particularly critical for over-the-counter medicines where there may be 
less direct involvement by a health professional.(81) 
The information in package leaflets should be in accordance with the SmPC and its 
content and structure is also strongly regulated. Regulatory agencies approve package 
leaflets when issuing a marketing authorisation and any modifications and updates also 
need approval. The package leaflet is a highly accessible medicines information source 
for patients and its information is useful as a reference to be consulted by patients.(82)  
As the final reader will be a lay person, extensive scientific information is not needed. 
In fact, providing comprehensive scientific information might negatively influence the 
readability of the material. However, it is important that the information included is 
legible and written in concise and easily understandable terms.(83)  
In 2002 a report from the G10 medicines group to the European Commission 
highlighted that package inserts frequently do not meet the needs of patients and 
recommended a greater flexibility in the way information for each medicine is presented 
taking account of the views of regulators, users and all stakeholders, and ensuring that 
citizens have access to harmonised, authorised and clear information which takes 
account of different levels of health literacy.(81) 
Patient package leaflets have been criticised for being inconsistent (84), difficult to 
understand (85), and lacking essential information.(86) 
In the United States, the package leaflet or package insert is aimed at informing the 
physician and serving as a reference for key information.(70) As it is intended for 
healthcare professionals, it includes references to scientific evidence to support its 
claims.(70) 
European Public Assessment Report (EPAR) 
The summary of the European Public Assessment Report, EPAR, is an official 
medicines information source. Its purpose is to explain how the Committee for 
Medicinal Products for Human Use (CHMP) in the European Medicines Agency (EMA) 
assessed the studies performed to arrive at their recommendations on how to use the 
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medicine. It is prepared at the end of every centralised evaluation process to provide a 
summary of the grounds for the opinion in favour of a marketing authorisation. 
The EPAR takes its information from the assessment of the documentation submitted 
by the applicant and the scientific discussions undertaken by the CHMP during the 
evaluation process. Commercially confidential information is deleted before the EMA 
publishes the EPARs. The EPARs are also updated throughout the life cycle of the 
product to reflect changes to the original terms and conditions of the marketing 
authorisation. 
The EPAR abstracts were originally intended to provide information understandable to 
the general public. However, since their introduction, the EPARs have become 
increasingly technical and complex and therefore less understandable for lay people.  
Drug information centres 
In 1962 the University of Kentucky was the first to establish a drug information centre, 
which was aimed at providing patient-specific medicines information. This was the first 
step to integrating the pharmacist into the patient care team by providing their expertise 
and knowledge on drug therapies.  
The increasing availability of medicines information and the challenges of analysing, 
interpreting and communicating it, led to a growing need for qualified specialists who 
supported rational therapeutic selections to improve patient care.  
During the 1970s and 1980s the number of drug information centres grew as the 
clinical role of the pharmacist in patient care was accepted, and the need for quick 
access to current information became a common concern of healthcare professionals 
and the ability of drug information specialists was perceived as useful to correctly 
interpret conflicting therapeutic information.(87) 
The main objective of drug information centres is to promote rational drug therapy.(88) 
The strength of a drug information service is the pharmacists’ ability to link the 
provision of critically appraised information with clinical interpretation.(33) Although all 
pharmacists are providers of medicines information, drug information specialists are 
trained specifically to retrieve, evaluate and communicate information efficiently aiming 
to develop evidence-based recommendations and assist in patient care decisions.(37) 
The quality of information activities in drug information centres has traditionally been 
assessed by the establishment of internal quality criteria and protocols.(34) In general, 
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physicians consider that the information provided by drug information centres is of high 
quality and of significant clinical impact.(88) According to McEntee, 95% of enquirers of 
a drug information centre considered the advice useful, and 99% were satisfied with 
how the service was provided.(33) General practitioners use drug information centres 
more often than specialists. This may be explained by the fact that general practitioners 
usually work alone or with a few colleagues, which may increase the need for 
support.(88) 
Many of the enquirers of a drug information service seek advice to choose an 
appropriate treatment in the right dose. In a study carried out by McEntee et al. half of 
the participants wanted to confirm the appropriateness of the current or proposed 
therapy and 45% used the information to make changes to therapy. Enquiries about 
adverse effects and medicine interactions are also common and 25% used the advice 
to identify, manage or avoid an adverse effect or drug interaction. However, few used 
the information to produce guidelines, inform decisions for formularies or funding 
medicines, or make cost improvements.(33) 
The quality of the information provided by drug information centres has also been 
analysed. For example, a study showed that regarding safety in pregnancy, advice 
from a compendium and from drug information centres differs in almost 50% of cases. 
In this case, advice from the selected compendium was significantly more restrictive 
than that from drug information centres. (89) The authors explain this difference in the 
intention of drug information centres to provide advice leading to rational 
pharmacotherapy for the individual patient. (89).  
Internet 
The internet has become an important communication medium providing quick and 
cheap access to health information for healthcare professionals and patients. It is 
important to clarify that internet is not a source of information itself, but a channel, 
through which users can access primary, secondary and tertiary sources alike.  
Due to the impact of new technologies on the process of seeking and retrieving health 
information, analysing the quality of information on the Internet is a major issue. 
Information in internet is varied, and although one of the positive characteristics of the 
information retrieved through internet is its accessibility, its quality and reliability remain 
a concern.  
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It is a medium in which anyone with a computer can be simultaneously author, editor 
and publisher, and can act anonymously in any of these roles. Some authors consider 
Internet as a risky channel that escapes any regulatory control.(90) Much of the health 
information on the Internet has been described as discordant with information provided 
by evidence-based sources.(91) Moreover, even for professionals, it is not always easy 
to know if the information on the Internet is credible.(92) 
According to Berland et al., when seeking information on the Internet, search engines 
are only moderately efficient in locating information about a particular topic.(54) In their 
study, only 20% of links provided by English-language search engines and 12.5% of 
links provided by Spanish search engines led to a website with relevant content. As far 
as the quality of the content is concerned, only half of the topics considered important 
by experts about a clinical topic were covered more than minimally. 
Nevertheless, in a study in 2005, Bennett et al. found that most physicians (59%) use 
the Internet regularly to access clinical information daily or weekly, as well as using it 
for personal purposes and e-mail.(35) More recent studies show that these data are 
likely to have increased these last years. However, other authors point out that Internet 
is rarely used as an information source during patient visits.(93) This may be because 
prescribers need instantly available electronic medicines information, which interact 
with electronic health records and decision support systems, and this is not available 
yet.(43) However, most healthcare professionals choose electronic formats such as 
intranets and Internet as preferred formats of information.(23) (For more information on 
the use of Internet by healthcare professionals please refer to Chapter 3: ‘Assessment 
of medicines information sources used by healthcare professionals and researchers in 
the World’).  
The main barriers found to seeking information using Internet were navigation or 
search difficulties, the overwhelming amount of information found and difficulty in 
finding specific information.(35) 
The methods used to analyse the quality of the information found on the Internet are 
thoroughly analysed in this Introduction, section ‘Characteristics of information and 
analysis of its quality’. 
Medicines Compendia or Reference books 
A compendium is a source containing a wide spectrum of information on prescribing 
and pharmacology, including among others, indications, side effects and costs of the 
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prescription of medications available in the country. It is used by prescribers, nurses 
and pharmacists as a general reference book on medicines. Compendia are widely 
used written references for all healthcare professionals. Synonyms of compendia are 
medicine/drug reference books or formularies.  
The word Formulary comes from the Indo-European root ‘merbh’, meaning ‘to shine’ 
(as in ‘morpho’, a genus of butterflies with shiny blue wings). Because everything that 
shines is easy to see, ‘merbh’ also meant to appear or take shape. The Greek ‘morph’ 
transformed into the Latin ‘forma’ (appearance) and its diminutive ‘formula’ (shape). 
Formula was defined in 1706 by John Kersey in the edition of the Edward Phillips’ 
dictionary ‘The New World of English Words’ as a “Physician’s prescription or bill 
appointing medicines to be prepared by an Apothecary”. Consequently, a formula 
describes how a medicinal product should be prepared and a formulary lists such 
formulae and describes the formulations.(94) 
Although studies argue that the provision of information to prescribing in the form of 
books of reference information is ‘no longer fit for purpose’ (43), some authors have 
stated that it is vital that physicians, nurses and pharmacists have at their immediate 
disposal up-to-date drug reference books.(49) Some studies point out that primary care 
practitioners do not use online information resources as much as print resources (95), 
and Internet might be mainly used to search for specific patient problems or the latest 
research.(93) According to Bennett et al. when searching information about new 
therapeutic options and management of complex cases most physicians consult 
colleagues and printed sources.(93) Analysing several studies, Dawes concluded that, 
physicians use primarily printed materials as information sources, with utilization 
ranging from 50 to 80%.(96) 
The content of compendia has been subject of several assessments, concluding that 
the information contained in compendia is not homogeneous. Comparing different 
compendia has shown important discrepancies among them regarding areas such as 
interactions (97-102), off-label indications (103), or hepatotoxicity.(104) 
Some studies about compendia argue that the information provided is inaccurate (98), 
inconsistent (97), lacks transparency (103), is limited (47), cites little current evidence 
(103), lacks systematic methods to review or update evidence (103), lacks standard 
terminology (98), lacks clinical guidance (98), is outdated, misleading and even 
dangerous.(105) Some authors discuss how respected compendia listing indications, 
which are in fact not approved by authorities, may give these indications a somewhat 
formal status.(70) 
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In the United States the Physicians’ Desk Reference (PDR) is the leading drug 
reference book among physicians.(47) The PDR is a compilation of the official package 
leaflets and it is published every year. It was initially conceived as a promotional device 
and the pharmaceutical industry pays to have each package leaflet included in the 
PDR. However, currently many medicines are only available in generic form, and their 
manufacturers may discard listing their medicines in the PDR or restrict the size of the 
entry because of the fee.(106) From 82% to 90% of physicians consider the PDR as 
their single most useful reference, and the average physician consults it around 8 times 
every week.(107) Not only physicians, but also residents, nurses and other healthcare 
professionals rely heavily on the PDR. Even consumers buy the PDR for use at 
home.(47)  
Some of the advantages of the PDR are its easy-to-use format, its handy indexes and 
a state-of-the-art pill identification, as well as 500,000 units being freely distributed to 
physicians’ offices in the US.(47) In contrast, studies show that its information is often 
not comprehensive enough, outdated or inconsistent.(47, 49) Other authors suggest 
that in general it lacks basic clinical pharmacology information.(108) 
In the US due to the lack of an official medicines information source produced by the 
FDA, some compendia are considered authoritative sources for determining medically 
accepted indications. According to Abernethy et al. the FDA is not equipped or 
authorised to provide the up-to-date, rigorous and comprehensive review expected 
from the compendia.(103) These specific compendia are used in oncology, where a 
great part of anticancer drug prescriptions are written for off-label indications. In 
oncology patients, the Centres for Medicare and Medicaid Services limit coverage of 
these drugs to the indications listed in specific compendia. These ‘official’ or ‘standard’ 
compendia are approved by the Federal Centres for Medicare and Medicaid and are: 
 American Hospital Formulary Service-Drug Information (AHFS-DI) 
 National Comprehensive Cancer Network (NCCN) Drugs and Biologics 
Compendium 
 Thomson Micromedex DrugDex 
 Clinical Pharmacology  
One of the best known compendia worldwide is the British National Formulary (BNF). 
The BNF is an independent professional publication, which is highly respected and so 
widely used by healthcare professionals in the United Kingdom that in a recent study 
100% of professionals who work with medicines reported using it.(109) It has been 
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translated into several languages for use outside the United Kingdom and has an 
appendix for medicine interactions.   
In 1939 the British Health Minister appointed a committee to prepare a wartime 
formulary to contain a “selection of medications sufficient in range to meet ordinary 
requirements of therapeutics” and the first edition of the BNF was published in 
1949.(110) After the end of the war, it was the Royal Pharmaceutical Society and the 
British Medical Association that wanted to continue the publication of a formulary for 
general use. In 2010 its 60th issue was published. Since September 2005 there is also 
a BNF for children (paediatric formulary). However, some authors argue that it does not 
give clear information or practical advice to healthcare professionals (111), it is difficult 
to read and understand (52), or has inconsistent categorisation of medicines.(52) 
Cantrill analysed physicians prescribing outside the recommendations given in the BNF 
and demonstrated that the circumstances under which prescriptions of general 
practitioners do not conform to the BNF are: difficulty in applying the guidance of the 
BNF, not being aware of it or not believing that the guidance was based on sound 
evidence.(112) 
Clinical guidelines 
Clinical practice guidelines are “systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific clinical 
circumstances”.(113) They are developed throughout the world to improve the quality 
of healthcare. With the growth of evidence-based medicine in the 1990s, there has 
been a movement towards scientific rigor in healthcare decisions. Clinical guidelines 
are usually based on research evidence and consensus views of experts on a specific 
topic.(114) This research evidence to produce guidelines is usually based on the use of 
systematic reviews and meta-analyses.(115) (Please refer to the section ‘evidence’ in 
this Introduction) 
Recommendations in guidelines should be accompanied by a statement on the 
strength of the evidence, which reflects “the extent to which confidence in an estimate 
of the effect is adequate to support recommendations”.(116). When making clinical 
decisions, healthcare professionals weigh up benefits and disadvantages of alternative 
strategies and, after reaching a conclusion, they will be influenced by their confidence 
in these estimates.(116) A categorisation of the quality of the evidence of 
recommendations indicates whether the evidence is high quality (the desirable effects 
clearly outweigh the undesirable effects) or there is a close or uncertain balance.(116) 
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The most used system of defining the quality of evidence is the GRADE system 
(Grading of Recommendations Assessment, Development and Evaluation). The 
GRADE system classifies quality of evidence into four levels: (117) 
 High quality: further research is very unlikely to change the confidence in the 
estimate of effect 
 Moderate quality: further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
 Low quality: further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
 Very low quality: any estimate of effect is very uncertain. 
The quality of the evidence is used in guidelines to determine the strength of the 
recommendation, together with other three factors: balance between desirable and 
undesirable effects, values and preferences, and costs.(118) 
This GRADE system is widely used: organizations such as the World Health 
Organization, the American College of Physicians and the Cochrane Collaboration 
have adopted GRADE. However, some authors claim that the rating of the quality of 
the evidence is inconsistent among guidelines.(116) 
Other methods have been developed to analyse the quality of guidelines such as the 
AGREE method (for a more in-depth description, please refer to the section 
‘Characteristics of the information and analysis of its quality’ in this Introduction). 
Managers in healthcare systems are aware of the need to ensure the quality of care 
and guidelines help managers to differentiate these practices that constitute quality of 
care.(116) Although clinical practice guidelines have been playing an increasing role in 
clinical and decision-making in the last few years (113), most physicians do not adopt 
guidelines into their prescribing habits.(47) 
As shown by Grilli et al. guidelines developed by different groups on the same clinical 
scenario have sometimes resulted in conflicting clinical recommendations.(119) 
Authors such as Pencharz et al. point out that while guidelines contain similar 
recommendations in areas where there is strong evidence, they make either no 
recommendations or disagree on therapies for which the evidence is not so clear.(113) 
Other authors suggest that cultural factors play an important role in the production of 
guidelines, both in the selection of literature and in formulation of recommendations. 
These cultural factors may be habits, patients’ expectations and the structure of the 
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healthcare system.(120) The same evidence was found to be used for opposite 
conclusions.(120) Other studies analysing quality of guidelines conclude that while 
rigour of development is moderate among most guidelines, many are difficult to apply, 
few are reviewed externally and most do not consider the national or local care 
systems or cultural or socioeconomic issues.(121)  
Information from the pharmaceutical industry 
The pharmaceutical industry plays a key role in the development, manufacturing and 
distribution of medicines. In some countries it is also the main funder of continuing 
medical education and research. The pharmaceutical sector is highly profitable and 
companies are under pressure to continuously expand product sales. In 1993 the 
World Health Organization already described that there was “an inherent conflict of 
interest between the legitimate business goals of manufacturers and the social, 
medical and economic needs of providers and the public to select and use drugs in the 
most rational way”.(122) 
The percentage of total sales revenues which is spent on marketing is almost twice as 
much as that spent on research and development.(123) This expense, however, is an 
investment, as increasing promotion is mostly associated with increasing sales.(124) 
Pharmaceutical companies see how funding doctors increases requests from hospitals 
for their marketed products to be included in hospital formularies.(124)) 
WHO defines drug promotion as: "all informational and persuasive activities by 
manufacturers and distributors, the effect of which is to induce the prescription, supply, 
purchase and/or use of medicinal drugs”.(125) By definition the aim of promotion is to 
stimulate product sales.  
Already in 1985 WHO developed a set of Ethical Criteria for Medicinal Drug Promotion. 
These criteria were adopted by the 1988 World Health Assembly and were the result of 
a consensus discussion involving health workers, drug regulatory agencies, consumers 
and the industry.  
The WHO Ethical Criteria state that promotion of medicines should:(125) 
 Be consistent with national health policies  
 Contain reliable claims, without misleading or unverifiable statements  
 Be accurate, truthful, informative, balanced, up-to-date, and in good taste. 
 Contain no omissions which could lead to health risks  
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 Not be designed so as to disguise its real nature, for example as educational or 
scientific activities.  
When a pharmaceutical product is granted a marketing authorisation, it is accompanied 
by the approved product information. This officially approved product information – in 
the European Union Package Insert, Summary of Product Characteristics and 
European Public Assessment Report – should serve as a basis to develop the 
information provided by the pharmaceutical industry. To be consistent with the officially 
approved information means strictly sticking to the indications approved and conditions 
of use. Although it is forbidden that pharmaceutical companies promote a medicine for 
unapproved indications, these ‘off-label’ indications appear commonly in medical 
literature.(70) 
According to Campbell, 94% of physicians have some type of relationship with the 
pharmaceutical industry and most of these relationships involved receiving food in the 
workplace, drug samples, reimbursement for professional meetings or continuing 
medical education or direct payment for consulting, giving lectures, or enrolling patients 
in clinical trials.(126) Many healthcare professionals believe that they are not 
influenced by pharmaceutical promotion, but, on the other hand, they also believe that 
their colleagues are affected by it.(127) In fact, studies show that physicians are more 
influenced by promotion than they realise.(124)  Most physicians believe that receiving 
gifts from the industry is acceptable and that their prescribing is not influenced by those 
gifts.(124) Physicians’ opinions on the usefulness of information from drug companies 
vary, but most believe that such information is useful, although biased.(124) 
Promotion is often used as a source of medicines information. The profile of physician 
relying more on information provided by the industry is an older physician, seeing more 
patients, generalist rather than specialist, with less access to peer support and a more 
positive attitude to the use of drugs.(124) Promotion is also a very common source of 
information for new medicines, in which physicians have less expertise.(124) 
Pharmaceutical companies often use other influence techniques in their promotional 
activities. Review of advertisements and other promotional information sources shows 
that there is a consistent trend to exaggerate benefits of drugs while not mentioning or 
underestimating harmful effects.(124) This information may then be misleading for 
healthcare professionals. There are also other ways of providing misleading 
information, such as inclusion of flawed information (exaggerated, inaccurate, 
ambiguous or oversimplified), omission of relevant information or distraction with 
irrelevant information.(8)  
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Advertisements in journals 
It is almost impossible for physicians today to read a medical journal and not find a new 
medication promising to change the course of a disease.(48) Although pharmaceutical 
companies spend only a small percentage of marketing expenses on advertisements in 
scientific journals (8), they are successful in increasing sales.(128) Some authors claim 
that physicians using journal advertisements as an information source prescribe less 
appropriately.(129) 
Journal advertisements should contain at least the information described in the WHO 
Ethical criteria (125), which is name of medicine and manufacturer, indications, key 
beneficial and harmful effects, and references to scientific evidence. Nevertheless, 
although all these criteria are included, the advertisement may not promote the most 
appropriate use.(8)  Data, graphics, images and other elements should be carefully 
evaluated to critically appraise advertisements.(8)  
Many studies show that reviews by journal editors do not provide effective control in 
drug advertisements, and these advertisements often do not meet the regulations and 
guidelines of the countries where they are published.(124) 
Ghost writing 
Another form of medicine promotion by the pharmaceutical industry is ghost writing. 
Ghost writing consists of publishing research articles with academic authors but written 
by pharmaceutical company employees or third companies working for the 
pharmaceutical industry. To control ghost writing, most scientific journals have 
strengthened guidelines for authorship. However, according to Wislar et al. 21% of 
articles published in major scientific journals in 2008 had either honorary or ghost 
authorship.(130) Other studies show that research often does not disclose funding from 
the industry.(124) 
Additionally, most journals publish company-sponsored supplements, which are mainly 
extra journal issues consisting of reports of sponsored symposia. In these cases 
pharmaceutical companies, paying to publish the report, have a large degree of control 
over the content.(8) 
Research funded by pharmaceutical companies shows more likely results favourable to 
the product being studied than research funded from other sources. There is an 
association between the opinions of investigators about products and their source of 
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funding but causality has not been established.(124) Funding not only influences 
results of research but also the topics studied.(124) 
Pharmaceutical sales representatives 
In general, most of sales representatives’ time is spent in direct contact with practising 
healthcare professionals. This form of promotion, which is also called ‘detailing’, 
represents a high percentage of the budget that pharmaceutical companies spend on 
marketing. In 2004, it was estimated that there were 90,000 sales representatives in 
the United States, spending more than US$ 10 billion on promotion, which may 
account for more than a quarter of the total marketing expenditure.(8) 
Evidence shows that information provided by sales representatives is often incomplete 
and biased.(131, 132) The information is not balanced, underestimating potential risks 
and harmful effects of the medicine and highlighting its benefits. Little information is 
given about interactions, adverse effects or contraindications.(131, 132) Although 
opinions vary, most physicians also recognise that information provided by sales 
representatives is biased.(124) 
 According to Caudill et al. the frequency of use of information provided by sales 
representatives is associated with increased primary care physician prescribing 
costs.(133) Other authors have also shown that physicians relying more on promotional 
information prescribe less appropriately, prescribe more often or prescribe new drugs 
more quickly.(124) Studies show that guidelines and regulations controlling 
pharmaceutical sales representatives’ promotion activities are not effective.(124) 
Pharmaceutical company drug information centres 
Pharmaceutical company drug information centres were established to provide medical 
information about company products in response to a request either from healthcare 
professionals or from patients. These centres provide information from published 
sources, but sometimes also from unpublished resources, such as data from internal 
stability studies or details of study methods. Because these data may have legal, 
regulatory or medical implications, pharmaceutical companies have specific policies 
regarding the use of this unpublished information and the provision of this information 
through pharmaceutical company drug information centres. In a study carried out by 
Cudny et al. 20% of specialists in pharmaceutical company drug information centres 
failed to reference the American package insert when answering questions on drug 
safety. Even when they use the package insert as a source, company drug information 
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centres may provide inaccurate or outdated information. Additionally, resources used to 
answer safety questions are those which are usually already available in a community 
pharmacy.(134) In another study in the European Union, Fernandez-Llimos et al. found 
that when asking pharmaceutical company drug information centres for more 
information than that included in the SmPC for new medicines, nearly 47% of 
pharmaceutical companies did not send any information, 18% sent a minimal reply and 
9% sent unacceptable information. Only 27% returned additional information.(135) 
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Justification of the research 
Medicines information for healthcare professionals is paramount in clinical practice. A 
thorough knowledge of different aspects of medicines information for healthcare 
professionals will allow the assessment of its quality and thus improve its usefulness, 
optimising clinical care. 
There is a wide range of medicines information sources designed for healthcare 
professionals, each with different properties regarding characteristics such as 
accessibility, reliability, completeness or applicability. With the aim of assessing 
medicines information sources to optimise clinical care, research should be conducted 
using a practical approach. Consequently, to focus on medicines information sources 
used in clinical practice, the assessment of preferences of healthcare professionals 
concerning medicines information sources should be the cornerstone of this study. 
Once identified the most commonly used medicines information sources, factors 
impacting on their quality should be evaluated.  
Accessibility to medicines information sources is one of the main characteristics and 
barriers to the use of medicines information sources.(39, 40) The analysis of availability 
of highly regarded medicines information sources should be one of the main 
characteristics to be evaluated. Furthermore, completeness of medicines information 
sources is a major need of healthcare professionals for decision making.(23) Although 
the general concept of completeness may appear as subjective, completeness may be 
addressed from a practical perspective, focusing on specific areas relevant in clinical 
practice. Clinical pharmacology information and information about safety have been 
considered key in this study to support decision making of healthcare professionals.  
Finally, in order to provide healthcare professionals with medicines information sources 
adapted to their real needs, a description of the content of the ideal source of 
information for healthcare professionals is a challenging goal that should allow us not 
only to design more applicable new information sources, but also to assess and 
improve the already existing information sources.  
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Research objectives 
General objective: The general objective of this study is the assessment of the 
characteristics of medicines information sources designed for healthcare professionals.  
Specific objectives: 
In addressing the general objective, the research was divided into five specific 
objectives. The specific objectives for this research were as follows: 
Objective 1: to assess the preferences regarding medicines information sources 
among healthcare practitioners and researchers from the entire World. 
Objective 2: to evaluate which countries publish their own drug compendia and assess 
what factors are associated with drug compendia publishing in the world. 
Objective 3: to assess the clinical pharmacology information provided in the 
Summaries of Product Characteristics (SmPCs) of European drugs compared to their 
package inserts. 
Objective 4: to assess completeness of drug information related to safety in European 
SmPCs regarding fertility and use of medicines in pregnancy and lactation.  
Objective 5: to design a universal tool to evaluate the content of drug information 
sources for healthcare professionals. 
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Background 
The healthcare environment is increasingly demanding for healthcare professionals. 
The huge amount of treatments available, expanding indications and complexity of 
treatment regimens, poly-pharmacy and elderly patients are some of the reasons that 
challenge healthcare professionals today.(1) Moreover, the continuously changing 
scenario, in which good prescribing today may not necessarily be so in a year, makes 
the provision of appropriate information of vital importance in clinical care.(1) 
As mentioned in the Chapter one: Introduction (section ‘Medicines information for 
healthcare professionals), although professionals receive a range of information 
resources on a daily basis (such as scientific and professional journals, newsletters, e-
mail alerts and discussion lists, among others) only a small number of professionals 
are satisfied with this provision of information.(2) Seeking information is a frequent 
routine for healthcare professionals, and according to Jackson et al., 79% of 
professionals perform searches for information, female professionals being more likely 
than males to perform searches (85% versus 75%).(2) Loza et al. found that 83% of 
community pharmacists consulted medicines information sources regularly.(3) 
Professionals need to be able to access information in response to information needs 
as they arise (4), and searches for information are often performed in the presence of 
the patient.(5, 6) According to Bastholm et al. it is essential for physicians to have 
concise medicines information sources available at point of care in order to ensure the 
right medicine is prescribed to the right patient in the correct dose.(7)  
Several authors have tried to evaluate which information resources are preferred by 
healthcare professionals (for more information please refer to chapter 1, Introduction, 
section ‘Medicines information for healthcare professionals’). However, most of these 
studies concentrate on specific professionals, mainly physicians.  
Results of studies are controversial. In the last few years, studies showed that the two 
information sources mostly used by physicians are textbooks, followed by 
colleagues.(8) Physicians want to know that the information they are using is 
documented by experts, up-to-date, structured and short.(7) 
The use of electronic sources is variable among studies. The use of computer 
searches was reported by only 13% physicians (8), and according to Andrews et al., 
40% of practitioners never or almost never perform literature searches from online 
sources.(6) In contrast, other authors have highlighted the general use of online 
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evidence in clinical practice (9), and according to more recent studies, Internet 
searches may be the preferred source of retrieving information.(2) According to 
Jackson et al., healthcare professionals most frequently use the Internet to perform 
searches, followed by informal networks and library and written resources.(2). Other 
recent studies consider that professionals mainly use compendia such as the British 
National Formulary (BNF) to aid decisions at point of care, and digital resources are 
used for review, education and continuing professional development.(10) 
In conclusion, although some authors argue that the provision of information to 
prescribing in the form of books of reference information is ‘no longer fit for purpose’ 
(1), others show that practitioners do not use online information resources as much as 
print resources.(6) Internet may also be used to search for specific patient problems or 
the latest research, but some authors report that few physicians use the Internet during 
patient visits. For information about new therapeutic options and management of 
complex cases, most physicians consult colleagues and printed sources.(11) 
Some authors have considered that the transition from printed text to electronic 
resources may lead to a blurring of the line between information and 
misinformation.(12) Ideally, electronic drug information, instantly available and 
interfacing with the electronic health record and decision support systems may be the 
solution for prescribers, provided that an authoritative, standardized, validated and 
regularly updated system is developed.(1) Prescribers need instantly available 
electronic drug information, capable of interfacing with electronic health records and 
decision support systems, but this kind of information systems are not available yet.(1) 
Although the computerization of healthcare has increased enormously in the last few 
decades, integrated information support systems are not standardized yet.(7) When 
asked about the preferred information format for future information delivery, most 
healthcare professionals choose electronic formats such as intranets and information 
delivered through the Internet.(2) 
Primary care physicians and their information-seeking behaviours have been 
thoroughly analysed, maybe because general practitioners prescribe 98% of medicines 
in primary care.(13) Primary care physicians have limited access to colleagues 
compared to specialists (14), and this may be one of the reasons why primary care 
physicians prefer journals as a source of information, followed by meetings and 
websites.(14) Other authors have also stated that, in comparison to specialists, general 
practitioners have a reduced preference for electronic formats, and they prefer 
personal collections of written materials.(2) According to McGettigan et al., general 
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practitioners choose compendia as their preferred source, followed by journal articles, 
clinical meetings and colleagues. However, for the latest ‘new’ drugs prescribed, 
general practitioners receive information through pharmaceutical representatives and 
hospital recommendations.(15) 
In a study with paediatricians, Kim et al. suggested that the resources mostly used by 
these physicians are specialists and generalist colleagues, followed by medicines 
compendia and specialty textbooks.(16) Generalist colleagues were, in general, 
contacted for confirmation of findings and discussion of diagnostic and management 
decisions, and contact was usually face-to-face. Paediatric textbooks were mostly 
selected when seeking drug dosing, information about cardiology, dermatology, 
genetics, infectious diseases and disease-specific protocols. For information about 
medicines (dosing, adverse reactions, packaging information, new treatments, etc), 
drug compendia were selected. Guidelines were used for disease management and 
continuing education.(16) To access guidelines and other information, professional 
organization and federal health Websites were also selected.(16) 
In a study in community pharmacies, Loza et al. identified printed resources as the 
most used source of information. Among printed texts, medicines compendia were the 
preferred source of information. (3) According to Zehnder et al., medicines compendia 
are also the preferred source of information for community pharmacies, followed by 
information provided by manufacturers, journals and textbooks. The use of Internet was 
variable among pharmacists.(17) More recent studies show that community 
pharmacists most frequently seek information on drug interactions in their electronic 
drug management systems, however most pharmacists are not satisfied about the 
information present in these systems.(18) 
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Objective 
The aim of this study was to assess preferences regarding medicines information 
sources among healthcare practitioners and researchers from the entire World. 
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Methods 
In order to serve as a basis to establish the perceived importance of different 
medicines information sources for healthcare professionals, an exploratory study was 
performed by means of a global survey. 
Sample 
In order to define the list of countries in the world, an up-to-date list of the independent 
ones was selected from the US Department of State (Bureau of Intelligence and 
Research) webpage (19), and from the Central Intelligence Agency webpage (“CIA: 
The World Factbook”).(20) Countries or independent states refer to “a people politically 
organized into a sovereign state with a definite territory recognized as independent by 
the United States”.(19) This list comprised 193 countries.  
To avoid potential influence in the response rate from the two authors of the study, data 
from their countries of origin and current affiliation were obtained from the researchers 
themselves.  Excluding these two countries (Spain and Portugal) resulted in a pool of 
191 countries. 
To perform a global web-based survey, a pool of e-mail addresses of potential 
participants was gathered. To find potential participants within a broad spectrum of 
healthcare professionals, two main approaches were made: the first aiming to identify 
healthcare researchers publishing articles, and a second approach to find healthcare 
practitioners from different fields of work. 
To find healthcare researchers who have published a research article affiliated to a 
specific country, the webpage ‘www.pubmed.com’ was used. The search was based on 
retrieving between 50 and 250 medicine-related articles which contained the e-mail of 
at least one of the authors and were published in that country in the last few years. 
Results showing the name of the country in the Affiliation field, because it was 
coincident with one of the surnames of the authors were rejected (e.g. Monaco as a 
surname). To perform the search a series of Medical Subject Headings (MeSH) terms 
was used. The purpose of this filtering process was to obtain the highest amount of 
addresses in countries with few research articles. On the other hand, for developed 
countries with extensive research activity, the aim was to find researchers working in 
fields related to medicines information, which presumably will be more interested in 
answering the questionnaire. The following MeSH terms were used: 
 [Health care category] + [human]: the most general term 
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 [Health care category] 
 [Health services] 
 [Community health services] 
 [Pharmaceutical services] + [ambulatory care] 
 [Drug information services]: the most specific term 
The MeSH was selected in order to obtain less than 250 results between the years 
2005-2007. If there were more than 250 results, the next MeSH term was selected. For 
those countries with more than 250 results when using the term [Drug information 
services], which is the most specific one, only the 250 most recent results were 
retrieved. 
In the second approach the webpage ‘www.google.com’ was used to select healthcare 
practitioners from the 191 countries listed. The purpose was to find at least ten e-mail 
addresses in every country, trying to cover a broad spectrum of areas of work in the 
healthcare field. Individual searches were performed per country using the following 
categories: 
- Medical associations: general associations of physicians in a country, trying not to 
limit to a specific medical specialty, when possible. 
- Pharmaceutical associations: general associations of pharmacists. 
- WHO: World Health Organization representatives in a country, whose presence is 
especially important in underdeveloped and developing countries. 
- Ministry of Health: e-mail addresses from the Ministry of Health, or any related to 
Governmental Health Institutions, preferably in the medicines area. 
- Regulatory Agencies: Agencies that control medicines in a country, being responsible 
for its safety and efficiency, and intervening in its authorization, commercialization and 
post-commercialization use. 
- Hospital: Email addresses of physicians and services in a hospital, mainly in those 
areas where a greater contact with patients is present: in this case family medicine 
physicians and internal medicine physicians. When it was not possible, other 
professionals such as dermatologists, cardiologists, pharmacologists, etc. were used. 
- Hospital Pharmacists: pharmacists working at a hospital pharmacy. 
- Red Cross/Crescent: Country representatives of the Red Cross or Red Crescent. 
- University: Medicine Faculty: Professors or Associates devoted preferably to the fields 
of Family Medicine, Community Medicine or Internal Medicine.  
- University: Pharmacy Faculty: Professors or Associates devoted preferably to 
Pharmacy Practice. 
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- Practitioner Physicians: Physicians currently working (not in hospitals) and preferably 
those with most daily contact with patients, such us in General Medicine or Family 
Medicine.  
- Practitioner Pharmacists: Pharmacists working in Community Pharmacies.  
- Others: any other health professional considered relevant during the development of 
the study.  
Study design 
A webpage with all the information for the study was created. Information about the aim 
of the study, the involved researchers and the methodology to answer the 
questionnaire were displayed in the webpage.  
The questionnaire, which could be accessed and answered online, consisted of three 
questions, in which participants had to select the country they were working in, their 
area of work (presented in Table 03-01) and their preferred source of medicines 
information (displayed in Table 03-02). Questions were numbered and check boxes 
were provided to answer the questions.  
Table 03-01. Questionnaire: areas of work of participants  
Public institution 
University 
Education (others) 
Hospital 
Pharmacy 
Pharmaceutical industry 
Non-governmental organization 
Ambulatory clinic 
Others 
 
Table 03-02. Questionnaire: first-choice medicines information sources of participants  
Internet search engines 
Information given by manufacturers 
Medicines reference books 
Scientific journals 
Summaries of product characteristics 
Patient leaflets 
Congresses 
Informal contacts with colleagues 
Formal meetings at workplace 
 
From August 2007 to April 2008, e-mails were sent individually to each country. E-
mails contained an invitation to participate in the study and a link to the webpage with 
the questionnaire. Invalid e-mail addresses from returned e-mails were deleted. 
Participants with valid e-mail addresses were contacted three times, allowing at least 
three weeks between each e-mail.  
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Data analysis 
Descriptive statistics were performed using central tendency and dispersion measures. 
All the analysis was done using the SPSS v-16, with statistical significance defined as 
p<0.05. 
Covariates representing socio-economic aspects of the country, such as population, 
income, Gross Domestic Product (GDP), or Human Development Index (HDI), were 
collected from the US Department of State (Bureau of Intelligence and Research) 
webpage (19), the World Bank (21), and the World Health Organization databases.(22) 
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Results 
E-mail gathering and sending process 
For the 191 countries 18,985 e-mail addresses were gathered, with an average of 99.4 
e-mail addresses per country (SD=118.3) in a distribution with skewness=5.6 and 
median=67.0. The average number of e-mail addresses was not homogeneous 
throughout the different continents (Kruskal-Wallis test p<0.001). Table 03-03 presents 
the average number of e-mail addresses per country grouped by continent. 
Table 03-03 Average number of e-mail addresses per country grouped by continent 
 Mean (SD) Skewness 
Africa 65.2 (56.6) 1.6 
America 111.3 (213.6) 5.1 
Asia 115.8 (101.4) 1.2 
Europe 132.6 (78.1) 0.6 
Oceania 44.8 (62.5) 2.1 
 
After sending the first invitation to participate in the study, 4103 e-mails were 
undelivered, representing 21.7% of the initially sent e-mails. These e-mails were 
considered invalid, and thus deleted. The remaining 14882 e-mail addresses were 
considered as correctly received, resulting in an average of 77.9 (SD=106.7) delivered 
e-mails per country, in a distribution with skewness=6.4 and median=43.0. The 
average number of delivered e-mail addresses was not homogeneous throughout the 
different continents either (Kruskal-Wallis test p<0.001). Table 03-04 presents the 
average number of delivered e-mail addresses grouped by continent. 
Table 03-04 Average number of delivered e-mail addresses per country grouped by continent
 Mean (SD) Skewness 
Africa 47.0 (45.8) 1.6 
America 89.0 (199.3) 5.3 
Asia 85.9 (84.5) 1.6 
Europe 112.5 (69.4) 0.6 
Oceania 37.1 (59.4) 2.1 
 
The rate of success in the e-mail gathering process, measured as the percentage of e-
mails delivered, was 72.6% (SD=15.8). This rate of success was not homogeneously 
distributed by continent (Kruskal-Wallis test p<0.001), with Africa=65.5% (SD=17.9), 
America=72.1% (SD=12.6), Asia=70.4% (SD=14.5), Europe=84.1% (SD=8.6) and 
Oceania=73.3% (SD=18.2).  
Response rate 
The global response rate per country was 2.9% (SD=3.6); median=1.9.  
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Fig 03-01. Distribution of response rate per country 
 
 
This response rate per country was not homogeneously distributed among continents 
(Kruskal-Wallis p<0.001), with Africa=1.4% (SD=2.4), America=3.7% (SD=3.9), 
Asia=2.4% (SD=2.9), Europe=5.3% (SD=4.1), and Oceania 0.8% (SD=2.2) 
Table 03-05 presents the statistical association of the response rate per country with 
the main categorical variables in the analysis. 
Table 03-05. Association of response rate per country with categorical covariates. 
 % Response rate (SD) p 
OECD (n=191) 
Y 
N 
 
4.9 (2.8) 
2.6 (3.6) 
<0.001* 
World Bank income classification (n=188) 
High 
Upper middle 
Lower middle 
Low 
 
3.7 (2.9) 
3.7 (4.6) 
2.7 (3.4) 
1.5 (2.7) 
0.001** 
WHO regional office (n=189) 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
1.3 (2.5) 
3.7 (3.9) 
2.3 (2.0) 
5.0 (4.3) 
2.5 (2.8) 
1.1 (2.0) 
<0.001** 
English as official language (n=191) 
Y 
N 
 
2.0 (2.9) 
3.2 (3.8) 
0.024* 
Spanish as official language (n=191) 
Y 
N 
 
5.0 (4.2) 
2.6 (3.4) 
0.011* 
French as official language (n=191) 
Y 
N 
 
1.3 (2.5) 
3.2 (3.7) 
0.001* 
Arabic as official language (n=191) 
Y 
N 
 
2.2 (1.9) 
3.0 (3.7) 
0.978* 
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Table 03-05. Association of response rate per country with categorical covariates. 
 % Response rate (SD) p 
Portuguese as official language (n=191) 
Y 
N 
 
1.1.(1.9) 
2.9 (3.6) 
0.156* 
*Mann-Whitney test 
** Kruskal-Wallis test 
OECD: Organisation for Economic Cooperation and Development, WHO= World Health Organisation 
 
Table 03-06 presents correlations of response rate per country with the main 
continuous variables 
Table 03-06. Correlations of response rate per country with continuous variables 
Variable Pearson coefficient p-value* 
Population - 0.538 
GDP per capita 0.16 0.025 
Physicians per 1000 inh. - 0.559 
Pharmacists per 1000 inh. - 0.341 
% of GDP as Health expenditure 0.20 0.007 
% of GDP as private health expenditure 0.16 0.042 
Human Development Index (HDI) 0.31 <0.001 
Healthy Life Expectancy at birth (HALE) 0.32 <0.001 
* Pearson correlation 
 
Analysis of responding countries 
A valid answer was obtained from 107 countries out of the 191 (a response rate of 
56.5%). These respondent countries comprised a population of 5,678,190,154 
inhabitants, representing 88.29% of the 6,431,274,883 inhabitants populating the 191 
countries (subtracting 51,003,712 inhabitants in Spain and Portugal from the 
6,482,278,595 world population). 
The percentage of responding countries was not equally distributed among continents 
(p<0.001):  
 Africa 35.8% 
 America 60.0% 
 Asia 63.8% 
 Europe 83.3% 
 Oceania 14.3%  
Differences between respondents and non-respondent countries regarding quantitative 
covariates are presented in table 03-07: 
Table 03-07. Characteristics of respondents and non-respondent countries regarding quantitative 
covariates. 
Mean (SD) Total Respondents p No Yes 
Population  
(n=191) 
33814344 
(9256244) 
48472764 
(186641156) 
22306800 
(41860014) 0.687* 
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Table 03-07. Characteristics of respondents and non-respondent countries regarding quantitative 
covariates. 
Mean (SD) Total Respondents p No Yes 
GDP per capita 
(n=190) 
10176 
(11475) 6384 (9625) 13117 (11963) <0.001* 
Physicians per 1000 inh 
(n=187) 1.70 (3.64) 1.59 (5.33) 1.78 (1.33) <0.001* 
Pharmacists per 1000 inh 
(n=150) 0.37 (0.45) 0.26 (0.38) 0.43 (0.48) 0.002* 
% GDP as health expenditure 
(n=172) 3.57 (2.00) 3.12 (1.54) 3.88 (2.21) 0.075* 
% GDP as private health 
expenditure 
(n=173) 
2.53 (1.33) 2.27 (1.37) 2.70 (1.28) 0.014* 
HDI 
(n=173) 0.72 (0.17) 0.65 (0.16) 0.77 (0.16) <0.001* 
HALE 
(n=185) 57.17 (11.15) 52.09 (10.66) 61.05 (9.94) <0.001* 
* Mann-Whitney test 
SD=standard deviation; GDP=gross domestic product; inh=inhabitants; HDI=Human Development Index. 
 
Differences between respondents and non-respondent countries regarding categorical 
covariates are presented in table 03-08: 
Table 03-08. Characteristics of respondents and non-respondent countries regarding categorical 
covariates. 
 
Respondents Num (%) 
p No
(n=84) 
Yes 
(n=107) 
OECD (n=191) 
Y 
N 
 
2 (8.0%) 
82 (49.4%) 
 
23 (92.0%) 
84 (50.6%) 
<0.001* 
World Bank income classification (n=188) 
High 
Upper middle 
Lower middle 
Low 
 
10 (20.8%) 
18 (40.9%) 
27 (50.9%) 
26 (60.5%) 
 
38 (79.2%) 
26 (59.1%) 
26 (49.1%) 
17 (39.5%) 
0.001* 
WHO regional office (n=189) 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
32 (69.6%) 
14 (40.0%) 
5 (23.8%) 
11 (21.6%) 
5 (45.5%) 
16 (64.0%) 
 
14 (30.4%) 
21 (60.0%) 
16 (76.2%) 
40 (78.4%) 
6 (54.5%) 
9 (36.0%) 
<0.001* 
English as official language (n=191) 
Y 
N 
 
32 (56.1%) 
52 (38.8%) 
 
25 (43.9%) 
82 (61.2%) 
0.027* 
Spanish as official language (n=191) 
Y 
N 
 
5 (26.3%) 
79 (45.9%) 
 
14 (73.7%) 
93 (54.1%) 
0.102* 
French as official language (n=191) 
Y 
N 
 
22 (75.9%) 
62 (38.3%) 
 
7 (24.1%) 
100 (61.7%) 
<0.001* 
Arabic as official language (n=191) 
Y 
N 
 
6 (26.1%) 
78 (46.4%) 
 
17 (73.9%) 
90 (56.6%) 
0.065* 
Portuguese as official language (n=191) 
Y 
N 
 
5 (71.4%) 
79 (42.9%) 
 
2 (28.6%) 
105 (57.1%) 
0.136* 
*Chi-Square test 
OECD: Organisation for Economic Cooperation and Development, WHO= World Health Organisation 
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Use of medicines information sources 
Table 03-09 shows the overall distribution of preferred information sources. 
Table 03-09 Distribution of preferred information sources
 Frequency Percent 
Internet 197 31,3 
Manufacturers 35 5,6 
Reference books 236 37,5 
Journals 94 14,9 
SmPCs 46 7,3 
Patient leaflets 3 0.5 
Congresses 9 1,4 
Informal contacts 4 0.6 
Formal meetings 6 1,0 
Total 630 100,0 
 
Due to the low percentage of respondents choosing patient leaflets, congresses, 
informal contacts and formal meetings as preferred information sources, these 
information sources were grouped into ‘others’, resulting in 3.5% when combined. 
Table 03-10 presents the differences found among the categorical covariates between 
respondents reporting using Internet as preferred information source and those not 
considering Internet their preferred information source. 
Table 03-10. Characteristics of respondents selecting Internet/not selecting Internet as preferred 
information source regarding categorical covariates. 
 Internet as preferred information source p 
No Yes
Continent 
Africa 
America 
Asia 
Europe 
Oceania 
 
42 (72.4%) 
105 (71.4%) 
73 (60.3%) 
196 (69%) 
17 (85%) 
 
16 (27.6%) 
42 (28.6%) 
48 (39.7%) 
88 (31%) 
3 (15%) 
0.120* 
OECD 
N 
Y 
 
251 (66.2%) 
182 (72.5%) 
 
128 (33.8%) 
69 (27.5%) 
0.096* 
World Bank income classification 
High 
Upper middle 
Lower middle 
Low 
 
219 (70%) 
116 (69%) 
75 (65.2%) 
23 (67.6%) 
 
94 (30%) 
52 (31%) 
40 (34.8%) 
11 (32.4%) 
0.823* 
WHO regional office 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
35 (74.5%) 
105 (71.4%) 
25 (61%) 
212 (69.1%) 
25 (64.1%) 
30 (62.5%) 
 
12 (25.5%) 
42 (28.6%) 
16 (39%) 
95 (30.9%) 
14 (35.9%) 
18 (37.5%) 
0.664* 
English as official language 
N 
Y 
 
296 (68.5%) 
137 (69.2%) 
 
136 (31.5%) 
61 (30.8%) 
0.866* 
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Table 03-10. Characteristics of respondents selecting Internet/not selecting Internet as preferred 
information source regarding categorical covariates. 
 Internet as preferred information source p 
No Yes
Spanish as official language 
N 
Y 
 
373 (67.8%) 
60 (75%) 
 
177 (32.2%) 
20 (25%) 
0.195* 
French as official language 
N 
Y 
 
397 (68%) 
36 (78.3%) 
 
187 (32%) 
10 (21.7%) 
0.148* 
Arabic as official language 
N 
Y 
 
414 (69.2%) 
19 (59.4%) 
 
184(30.8%) 
13 (40.6%) 
0.241* 
Portuguese as official language 
N 
Y 
 
430 (69.1%) 
3 (37.5%) 
 
192 (30.9%) 
5 (62.5%) 
0.055* 
Working area 
Public institution 
Education 
Hospital 
Non-governmental 
University 
Pharmacy 
Industry 
Ambulatory care 
Others 
 
57 (59.4%) 
7 (87.5%) 
116 (66.3%) 
19 (73.1%) 
171 (71.5%) 
18 (78.3%) 
5 (71.4%) 
22 (66.7%) 
18 (78.3%) 
 
39 (40.6%) 
1 (12.5%) 
59 (33.7%) 
7 (26.9%) 
68 (28.5%) 
5 (21.7%) 
2 (28.6%) 
11 (33.3%) 
5 (21.7%) 
0.355* 
*Chi-square test 
 
Table 03-11 presents the differences found among the quantitative covariates of the 
countries of origin of respondents reporting use of Internet as their preferred 
information source and those not considering Internet their preferred information 
source. 
Table 03-11. Characteristics of countries of respondents selecting Internet/not selecting Internet 
as preferred information source regarding quantitative covariates. 
 Internet as preferred information source p Mean  (SD) No Yes
Population 
 
88,569,334 
(201,000,000) 
86,248,089 
(215,300,000) 0.115* 
Healthy life expectancy (HALE) at 
birth (years) 64.31 (8.54) 63.99 (8.13) 0.212* 
GDP per capita 18652.42 (13536.58) 17281.73 (13107.71) 0.341* 
Physicians per 1000 inh 
 
2.21 
(1.24) 
2.09 
(1.22) 0.357* 
Pharmacists per 1000 inh 
 
0.51 
(0.41) 
0.48 
(0.42) 0.306* 
% GDP as health expend 
 
4.81 
(2.21) 
4.62 
(2.25) 0.311* 
% GDP as private health expend 
 
3.04 
(1.93) 
2.95 
(1.97) 0.337* 
HDI 
 
0.83 
(0.14) 
0.83 
(0.14) 0.360* 
*Chi-square test 
 
Table 03-12 presents the differences found among the categorical covariates between 
respondents reporting using information from the industry as their preferred information 
source and those not considering the industry their preferred information source. 
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Table 03-12. Characteristics of respondents selecting/not selecting the pharmaceutical industry as 
preferred information source regarding categorical covariates. 
 Industry as preferred information 
source 
p 
No Yes
Continent 
Africa 
America 
Asia 
Europe 
Oceania 
 
53 (91.4%) 
145 (98.6%) 
114 (94.2%) 
265 (93.3%) 
18 (90%) 
 
5 (8.6%) 
2 (1.4%) 
7 (5.8%) 
19 (6.7%) 
2 (10%) 
0.115* 
OECD 
N 
Y 
 
359 (94.7%) 
236 (94%) 
 
20 (5.3%) 
15 (6%) 
0.708* 
World Bank income classification 
High 
Upper middle 
Lower middle 
Low 
 
292 (93.3%) 
162 (96.4%) 
109 (94.8%) 
32 (94.1%) 
 
21 (6.7%) 
6 (3.6%) 
6 (5.2%) 
2 (5.9%) 
0.555* 
WHO regional office 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
42 (89.4%) 
145 (98.6%) 
40 (97.6%) 
287 (93.5%) 
39 (100%) 
42 (87.5%) 
 
5 (10.6%) 
2 (1.4%) 
1 (2.4%) 
20 (6.5%) 
0 
6 (12.5%) 
<0.001* 
English as official language 
N 
Y 
 
407 (94.2%) 
188 (94.9%) 
 
25 (5.8%) 
10 (5.1%) 
0.708* 
Spanish as official language 
N 
Y 
 
517 (94%) 
78 (97.5%) 
 
33 (6%) 
2 (2.5%) 
0.202* 
French as official language 
N 
Y 
 
550 (94.2%) 
45 (97.8%) 
 
34 (5.8%) 
1 (2.2%) 
0.298* 
Arabic as official language 
N 
Y 
 
563 (94.1%) 
32 (100%) 
 
35 (5.9%) 
0 
0.159* 
Portuguese as official language 
N 
Y 
 
587 (94.4%) 
8 (100%) 
 
35 (5.6%) 
0 
0.490* 
Working area 
Public institution 
Education 
Hospital 
Non-governmental 
University 
Pharmacy 
Industry 
Ambulatory care 
Others 
 
91 (94.8%) 
8 (100%) 
162 (92.6%) 
26 (100%) 
227 (95%) 
21 (91.3%) 
7 (100%) 
32 (97%) 
21 (91.3%) 
 
5 (5.2) 
0 
13 (7.4%) 
0 
12 (5%) 
2 (8.7%) 
0 
1 (3%) 
2 (8.7%) 
0.758* 
*Chi-square test 
 
Table 03-13 presents the differences found among the quantitative covariates of the 
countries of origin of respondents reporting using the industry as their preferred 
information source and those not considering the industry their preferred information 
source. 
 
 
 65
Table 03-13. Characteristics of countries of respondents selecting/not selecting the 
pharmaceutical industry as preferred information source regarding quantitative covariates. 
 
Industry as preferred information 
source p 
No Yes 
Population Mean  (SD) 91,059,027 (210,700,000) 
33,179,255 
(43,910,000) 
0.047* Median 22,303,552 10,235,455 
Skewness 4,260 1,424 
Kurtosis 19,029 0,648 
Healthy life expectancy 
(HALE) at birth (years)  Mean (SD) 64,25 (8.29) 63.47 (10.44) 0.874* 
GDP per capita Mean  (SD) 18200.84 (13487.46) 
18614.29 
(12160.40) 0.790* 
Physicians per 1000 inh. Mean  (SD) 2.15 (1.22) 2.46 (1.39) 0.204* 
Pharmacists per 1000 inh. Mean  (SD) 0.50 (0.41) 0.48 (0.42) 0.779* 
% GDP as health expend Mean  (SD) 4.77 (2.23) 4.48 (2.05) 0.278* 
% GDP as private health 
expend Mean  (SD) 3.05 (1.98) 2.45 (1.02) 0.275* 
HDI Mean  (SD) 0.83 (0.14) 0.83 (0.16) 0.922* 
* Chi-square test 
 
Table 03-14 presents the differences found among the categorical covariates between 
respondents reporting using reference books as their preferred information source and 
those not considering reference books their preferred information source. 
Table 03-14. Characteristics of respondents selecting/not selecting reference books as 
preferred information source regarding categorical covariates. 
 Reference books as preferred 
information source 
p 
No Yes
Continent 
Africa 
America 
Asia 
Europe 
Oceania 
 
36 (62.1%) 
85 (57.8%) 
78 (64.5%) 
185 (65.1%) 
10 (50%) 
 
22 (37.9%) 
62 (42.2%) 
43 (35.5%) 
99 (34.9%) 
10 (50%) 
0.440* 
OECD 
N 
Y 
 
253 (66.8%) 
141 (56.2%) 
 
126 (33.2%) 
110 (43.8%) 
0.007* 
World Bank income classification 
High 
Upper middle 
Lower middle 
Low 
 
187 (59.7%) 
107 (63.7%) 
78 (67.8%) 
22 (64.7%) 
 
126 (40.3%) 
61 (36.3%) 
37 (32.2%) 
12 (35.3%) 
0.461* 
WHO regional office 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
27 (57.4%) 
85 (57.8%) 
26 (63.4%) 
198 (64.5%) 
25 (64.1%) 
32 (66.7%) 
 
20 (42.6%) 
62 (42.2%) 
15 (36.6%) 
109 (35.5%) 
14 (35.9%) 
16 (33.3%) 
0.755* 
English as official language 
N 
Y 
 
285 (66%) 
109 (55.1%) 
 
147 (34%) 
89 (44.9%) 
0.009* 
Spanish as official language 
N 
Y 
 
341 (62%) 
53 (66.2%) 
 
209 (38%) 
27 (33.8%) 
0.463* 
French as official language 
N 
Y 
 
368 (63%) 
26 (56.5%) 
 
216 (37%) 
20 (43.5%) 
0.381* 
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Table 03-14. Characteristics of respondents selecting/not selecting reference books as 
preferred information source regarding categorical covariates. 
 Reference books as preferred 
information source 
p 
No Yes
Arabic as official language 
N 
Y 
 
373 (62.4%) 
21 (65.6%) 
 
225 (37.6%) 
11 (34.4%) 
0.711* 
Portuguese as official language 
N 
Y 
 
386 (62.1%) 
8 (100%) 
 
236 (37.9%) 
0 
0.028* 
Working area 
Public institution 
Education 
Hospital 
Non-governmental 
University 
Pharmacy 
Industry 
Ambulatory care 
Others 
 
62 (64.6%) 
5 (62.5%) 
113 (64.6%) 
15 (57.7%) 
146 (61.1%) 
15 (65.2%) 
5 (71.4%) 
19 (57.6%) 
14 (60.9%) 
 
34 (35.4%) 
3 (37.5%) 
62 (35.4%) 
11 (42.3%) 
93 (38.9%) 
8 (34.8%) 
2 (28.6%) 
14 (42.4%) 
9 (39.1%) 
0.990* 
*Chi-square test 
 
Table 03-15 presents the differences found among the quantitative covariates of the 
countries of origin of respondents reporting using reference books as their preferred 
information source and those not considering reference books their preferred 
information source. 
Table 03-15 Characteristics of countries of respondents selecting/not selecting reference books 
as preferred information source regarding quantitative covariates. 
 
Reference books as preferred 
information source p 
No Yes 
Population 
Mean  (SD) 81,586,355 (206,700,000) 
98,289,709 
(203,200,000) 
0.006* Median 19,954,373 24,385,858 
Skewness 4.62 4.03 
Kurtosis 22.08 17.85 
Healthy life expectancy 
(HALE) at birth (years) Mean  (SD) 64 (8.15) 64.56 (8.82) 0.058* 
GDP per capita 
Mean  (SD) 16902.54 (12555.66) 
20429.66 
(14483.78) 
0.010* Median 12100.00 19350.00 
Skewness 0.55 0.14 
Kurtosis -1.02 -1.53 
Physicians per 1000 inh Mean  (SD) 2.18 (1.27) 2.16 (1.18) 0.932* 
Pharmacists per 1000 inh Mean  (SD) 0.49 (0.42) 0.52 (0.39) 0.086* 
% GDP as health expenditure 
Mean  (SD) 4.57 (2.20) 5.07 (2.22) 
0.005* Median 4.30 5.90 Skewness -0.057 -0.517 
Kurtosis -1.345 -1.065 
% GDP as private health 
expend Mean  (SD) 2.86 (1.73) 3.28(2.22) 0.147 
HDI 
Mean  (SD) 0.827 (0.86) 0.841 (0.93) 
0.008 Median 0.855 0.926 Skewness -1.383 -1.435 
Kurtosis 1.611 1.238 
* Chi-square test 
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Table 03-16 presents the differences found among the categorical covariates between 
respondents reporting using scientific journals as their preferred information source and 
those not considering scientific journals their preferred information source. 
Table 03-16. Characteristics of respondents selecting/not selecting scientific journals as 
preferred information source regarding categorical covariates. 
 Scientific journals as preferred 
information source 
p 
No Yes
Continent 
Africa 
America 
Asia 
Europe 
Oceania 
 
49 (84.5%) 
113 (76.9%) 
105 (86.8%) 
252 (88.7%) 
17 (85%) 
 
9 (15.5%) 
34 (23.1%) 
16 (13.2%) 
32 (11.3%) 
3 (15%) 
0.026* 
OECD 
N 
Y 
 
310 (81.8%) 
226 (90%) 
 
69 (18.2%) 
25 (10%) 
0.004* 
World Bank income classification 
High 
Upper middle 
Lower middle 
Low 
 
280 (89.5%) 
133 (79.2%) 
95 (82.6%) 
28 (82.4%) 
 
33 (10.5%) 
35 (20.8%) 
20 (17.4%) 
6 (17.6%) 
0.018* 
WHO regional office 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
42 (89.4%) 
113 (76.9%) 
105 (86.8%) 
272 (88.6%) 
31 (79.5%) 
44 (91.7%) 
 
5 (10.6%) 
34 (23.1%) 
16 (13.2%) 
35 (11.4%) 
8 (20.5%) 
4 (8.3%) 
0.021* 
English as official language 
N 
Y 
 
356 (82.4%) 
180 (90.0%) 
 
76 (17.6%) 
18 (9.1%) 
0.005* 
Spanish as official language 
N 
Y 
 
481 (87.5%) 
55 (68.8%) 
 
69 (12.5%) 
25 (31.2%) 
0.000* 
French as official language 
N 
Y 
 
500 (85.6%) 
36 (78.3%) 
 
84 (14.4%) 
10 (21.7%) 
0.178* 
Arabic as official language 
N 
Y 
 
511 (85.5%) 
25 (78.1%) 
 
87 (14.5%) 
7 (21.9%) 
0.257* 
Portuguese as official language 
N 
Y 
 
530 (85.2%) 
6 (75%) 
 
92 (14.8%) 
2 (25%) 
0.421* 
Working area 
Public institution 
Education 
Hospital 
Non-governmental 
University 
Pharmacy 
Industry 
Ambulatory care 
Others 
 
92 (95.8%) 
6 (75%) 
150 (85.7%) 
22 (84.6%) 
194 (81.2%) 
19 (82.6%) 
5 (71.4%) 
29 (87.9%) 
19 (82.6%) 
 
4 (4.2%) 
2 (25%) 
25 (14.3%) 
4 (15.4%) 
45 (18.8%) 
4 (17.4%) 
2 (28.6%) 
4 (12.1%) 
4 (17.4%) 
0.088* 
*Chi-square test 
 
Table 03-17 presents the differences found among the quantitative covariates of the 
countries of origin of respondents reporting using scientific journals as their preferred 
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information source and those not considering scientific journals their preferred 
information source. 
Table 03-17. Characteristics of countries of respondents selecting/not selecting scientific journals 
as preferred information source regarding quantitative covariates. 
 
Scientific journals as preferred information 
source p 
No Yes 
Population Mean  (SD) 86,061,949.72 (202,100,000) 
98,002,023.22 
(224,100,000) 0.308* 
Healthy life expectancy 
(HALE) at birth (years) 
Mean  (SD) 64.36 (8.62) 63.36 (7.06) 
0.021* Median 66 64 Skewness -1.619 -0.998 
Kurtosis 2.516 0.794 
GDP per capita 
Mean  (SD) 18925.00 (13571.76) 14225.53 (11722.36) 
0.003* Median 16100.00 10000.00 Skewness 0.308 1.002 
Kurtosis -1.333 -0.251 
Physicians per 1000 inh Mean  (SD) 2.19 (1.22) 2.06 (1.30) 0.161* 
Pharmacists per 1000 inh Mean  (SD) 0.50 (0.40) 0.48 (0.47) 0.216* 
% GDP as health 
expenditure 
Mean  (SD) 4.86 (2.23) 4.13 (2.08) 
0.003* Median 5.70 3.70 Skewness -0.292 0.114 
Kurtosis -1.266 -1.332 
% GDP as private health 
expenditure 
Mean  (SD) 2.98 (1.98) 3.18 (1.71) 
0.028* Median 2.40 2.81 Skewness 1.684 1.463 
Kurtosis 2.378 2.754 
HDI 
Mean  (SD) 0.84 (0.14) 0.81 (0.13) 
0.002* Median 0.87 0.82 Skewness -1.477 -0.937 
Kurtosis 1.629 0.342 
* Chi-square test 
 
Table 03-18 presents the differences found among the categorical covariates between 
respondents reporting using SmPCs as their preferred information source and those 
not considering SmPCs their preferred information source. 
Table 03-18. Characteristics of respondents selecting/not selecting SmPCs as preferred 
information source regarding categorical covariates. 
 SmPCs as preferred information 
source 
p 
No Yes
Continent 
Africa 
America 
Asia 
Europe 
Oceania 
 
56 (96.6%) 
143 (97.3%) 
117 (96.7%) 
249 (87.7%) 
19 (95%) 
 
2 (3.4%) 
4 (2.7%) 
4 (3.3%) 
35 (12.3%) 
1 (5%) 
0.001* 
OECD 
N 
Y 
 
358 (94.5%) 
226 (90%) 
 
21 (5.5%) 
25 (10%) 
0.037* 
World Bank income classification 
High 
Upper middle 
Lower middle 
Low 
 
284 (90.7%) 
158 (94%) 
109 (94.8%) 
33 (97.1%) 
 
29 (9.3%) 
10 (6%) 
6 (5.2%) 
1 (2.9%) 
0.269* 
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Table 03-18. Characteristics of respondents selecting/not selecting SmPCs as preferred 
information source regarding categorical covariates. 
 SmPCs as preferred information 
source 
p 
No Yes
WHO regional office 
AFRO 
AMRO 
EMRO 
EURO 
SEARO 
WPRO 
 
46 (97.9%) 
143 (97.3%) 
40 (97.6%) 
272 (88.6%) 
37 (94.9%) 
45 (93.8%) 
 
1 (2.1%) 
4 (2.7%) 
1 (2.4%) 
35 (11.4%) 
2 (5.1%) 
3 (6.2%) 
0.014* 
English as official language 
N 
Y 
 
400 (92.6%) 
184 (92.9%) 
 
32 (7.4%) 
14 (7.1%) 
0.88* 
Spanish as official language 
N 
Y 
 
508 (92.4%) 
76 (95%) 
 
42 (7.6%) 
4 (5%) 
0.397* 
French as official language 
N 
Y 
 
541 (92.6%) 
43 (93.5%) 
 
43 (7.4%) 
3 (6.5%) 
0.833* 
Arabic as official language 
N 
Y 
 
553 (92.5%) 
31 (96.9%) 
 
45 (7.5%) 
1 (3.1%) 
0.351* 
Portuguese as official language 
N 
Y 
 
576 (92.6%) 
8 (100%) 
 
46 (7.4%) 
0 
0.424 
Working area 
Public institution 
Education 
Hospital 
Non-governmental 
University 
Pharmacy 
Industry 
Ambulatory care 
Others 
 
85 (88.5%) 
7 (87.5%) 
165 (94.3%) 
23 (88.5%) 
226 (94.6%) 
20 (87%) 
6 (85.7%) 
31 (93.9%) 
21 (91.3%) 
 
11 (11.5%) 
1 (12.5%) 
10 (5.7%) 
3 (11.5%) 
13 (5.4%) 
3 (13%) 
1 (14.3%) 
2 (6.1%) 
2 (8.7%) 
0.526* 
*Chi-square test 
 
Table 03-19 presents the differences found among the quantitative covariates of the 
countries of origin of respondents reporting using SmPCs as their preferred information 
source and those not considering SmPCs their preferred information source. 
Table 03-19.  Characteristics of countries of respondents selecting/not selecting SmPCs as 
preferred information source regarding quantitative covariates. 
 SmPCs as preferred information source p No Yes 
Population 
Mean  (SD) 88,621,563 (202,000,000) 
77,965,267 
(247,300,000) 
0.027* Median 22,303,552 9,815,933 
Skewness 4.369 4,507 
Kurtosis 20,398 19,914 
Healthy life expectancy 
(HALE) at birth (years) 
Mean  (SD) 63.99 (8.53) 66.96 (6.10) 
0.017* Median 66 70 Skewness -1.528 -1.529 
Kurtosis 2.241 3.10 
GDP per capita Mean  (SD) 18007.19 (13508.82) 
20973.91 
(11853.65) 0.261* 
Physicians per 1000 inh 
Mean  (SD) 2.14 (1.24) 2.54 (1.13) 
0.028* Median 2.30 2.86 Skewness 0.042 -0.537 
Kurtosis -0.895 -0.484 
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Table 03-19.  Characteristics of countries of respondents selecting/not selecting SmPCs as 
preferred information source regarding quantitative covariates. 
 SmPCs as preferred information source p No Yes 
Pharmacists per 1000 inh Mean  (SD) 0.49 (0.41) 0.58 (0.40) 0.181* 
% GDP as health expenditure 
Mean  (SD) 4.69 (2.21) 5.52 (2.23) 
0.005* Median 4.80 6.50 Skewness -0.194 -0.666 
Kurtosis -1.318 -0.858 
% GDP as private health 
expenditure 
Mean  (SD) 3.08 (1.97) 2.16 (1.12) 
0.001* Median 2.70 1.70 Skewness 1.605 1.19 
Kurtosis 2.152 0.696 
HDI 
Mean  (SD) 0.83 (0.14) 0.88 (0.10) 
0.042* Median 0.86 0.94 Skewness -1.359 -1.545 
Kurtosis 1.282 2.295 
* Chi-square test 
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Discussion 
Method used 
When aiming at an extensive population, the method to reach potential participants is a 
major challenge. Due to limitations in time, costs and volume of participation requests, 
the use of a web-based survey was considered the best option. Some advantages of 
web-based surveys are easy access, instant distribution, rapid return of answers and 
reduced costs.(23, 24) Additionally, using Internet allows researchers to provide 
information of results to participants in a timely manner.(24) When compared to 
traditional postal surveys, answered online questionnaires present fewer incomplete 
questions, but more address errors are found when collecting e-mail addresses than 
with postal addresses and fax numbers.(25) As far as response rates are concerned, 
postal, telephone and mixed-mode surveys (postal mail and web surveys) provide 
higher levels of response than web surveys. However, postal, telephone or mixed-
mode surveys may not be feasible at a global level. 
Some survey researchers have warned that the population online may not be 
representative of the general population, as access to the Internet is not universal.(23, 
26) Couper et al. identified three main limitations of e-Health surveys: drawing through 
the Internet a representative sample of the general population, people’s restrictions to 
access the Internet and the potential non-response bias.(27) The non-response bias 
refers to the bias that may exist in the data because respondents to the survey are 
different from those who did not respond regarding important characteristics. (28) We 
should bear in mind that e-Health surveys address general population. However, we 
surveyed healthcare professionals and researchers, and the non-response bias should 
not be of relevance due to the high level of education they all have. 
In general, previous research on surveys addressed specific population groups, 
physicians being the most frequent group. Although highly educated professionals 
should have theoretically higher response rates than less educated participants (29), 
surveys to physicians have been characterized by low response rates.(26) VanGeest et 
al. identified several reasons for non-response among physicians: lack of time, 
perception of unclear or low value of the study and concerns about the confidentiality of 
the results.(26) On the other hand, financial incentives have been seen to improve 
physicians’ response to surveys (26, 30), whereas other non-monetary incentives were 
much less effective.(26) Personalization and sponsorship of studies by health 
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organizations seem to improve participation among physicians, and the number of 
times physicians are contacted is also directly related to participation rates.(26) 
Despite the above mentioned limitations of online surveying, e-mail was the only 
feasible data collection tool for this study and therefore, it was selected as contacting 
method for the 18,985 potential participants. Consequently, the use of a web-based 
survey was preferred among all other options. 
Response rate 
The global response rate of 2.9% may appear as a low response rate; however, it 
should be considered that the study was performed at a global level and comprised 
14,882 potential participants. Literature about response rates for multiple-country 
studies is sparse, as very little research focuses on cross-cultural reaction to 
surveys.(31)  Although there are studies analysing the effect on response rates of 
every possible aspect of surveys (number of questions, format, colour or length of the 
questionnaire, author-related or topic-related aspects, etc), they are all performed in a 
domestic setting, and scientific literature about international settings is extremely 
scarce.(31)  
Performing a global survey presents some disadvantages that clearly reduce the 
response rate. Some of the known fundamental problems of cross-cultural research 
are: definition of cultures, identification of whether a phenomenon is culturally specific 
or universal, cultural bias of researchers when designing and conducting the study, 
determination of equivalent and identical aspects of the study across cultures and 
identification of threats to interpretation caused by cultural aspects.(32) Another aspect 
influencing negative response rates is the geographical and/or cultural distance of the 
sender of the survey. Foreign surveys have been seen to generate lower response 
rates than domestic surveys.(32) Other characteristics such as personalization of the 
survey or incentives, which increase response rates, are not feasible in such extensive 
populations.(31)  
Analysing the figures, this overall 2.9% response rate covered 56.5% of countries and 
comprised 88.3% of the world population. Although the individual response rate was 
low, the analysis may be considered representative of the world population at a country 
level. 
A further analyse of the characteristics of countries answering the questionnaire should 
be of interest. There were differences in participation rates among countries, Europe 
being the most participative continent, followed by America and Asia and being Africa 
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and Oceania the least participative continents. Previous research has shown that 
response rates to mail surveys in the US are higher than those in European countries 
for questionnaires sent from the US.(31) Conversely, our study shows that while the 
response rate in Europe as a continent is 5.3%, response rates in the US are 4.02% 
Not only were there differences per continent, but also other demographic and 
socioeconomic variables were associated with different response rates. When 
analysing development indicators, results showed that members of the ‘Organisation 
for Economic Co-operation and Development’ (OECD), with higher Gross Domestic 
product (GDP) per capita, higher percentage of GDP as health expenditure and higher 
Human Development Index (HDI), and higher Healthy Life Expectancy at birth (HALE) 
were significantly associated with a higher response rate. Conversely, countries 
classified by the World Bank as low income countries, were the countries with a smaller 
response rate.  
Developing countries often lack the resources to participate in costly research projects, 
and the use of Internet may not be so extended as in developed countries, a fact that is 
also seen in the difference in the number of e-mail addresses found for each country 
and continent. However, for those healthcare professionals with a valid e-mail address, 
participation in the study was easy, simple and free, and resource limitation could not 
explain the low response rates. The only resource limitation was that an Internet 
connection was needed to retrieve the questionnaire. However, as potential 
participants were contacted by e-mail, we may assume that all accepting participants 
had Internet access available. Other authors have previously pointed out that 
healthcare professionals in developing countries are rarely involved in the promotion of 
rational drug use.(33)  
Having information about health issues in developing countries is essential to plan the 
improvement of the healthcare sector. In fact, deficits in health information have been 
seen as an important barrier for the development of countries and the implementation 
of health programmes and policies.(34)  One of the potential reasons for the low 
response rate in these countries may be cultural differences. As previously explained, 
the higher the cultural distance, the lower the response rate.(31)  
As far as languages are concerned, countries with Spanish or French as official 
language and countries in which English is not the official language are associated with 
a higher response rate. The language of the survey was expected to influence the 
response rates in different countries, so that apparently non-native English speakers 
might have declined their participation. However, results showed an opposite trend. 
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The fact that Europe was the continent with the highest response rate, where from 44 
countries in Europe only four (Iceland, Ireland, Malta and United Kingdom) have 
English as their official language, may be one of the reasons for these results. Spanish 
is also related to a high response rate, because it is the main language in Latin 
America, and America was also one of the continents with a high response rate.  
Regarding categorical covariates, there were also significant differences per World 
Bank Income classification of the country and membership of OECD (please refer to 
Table 03-08). Only 12% of countries classified as having a ‘high income’ did not 
answer the questionnaire. The participation rate of countries increased with higher 
World Bank income classification. 
Analysis of results 
Our results showed that drug reference books, also called medicines compendia, are 
the leading information source among healthcare professionals, followed by information 
on the Internet and scientific journals. These results are in agreement with previous 
studies, which have selected reference books as the preferred source of information 
among different healthcare professionals in different settings and countries.(8, 35-37) 
When analysing each information source separately, there was a relationship between 
using the information from the pharmaceutical industry and the WHO regional office to 
which the country belongs. Although, in general, the pharmaceutical industry does not 
appear to be very popular as information source, countries belonging to the WPRO 
(Western Pacific Region) and AFRO (Africa) WHO offices seemed to use the 
information from the pharmaceutical industry significantly more than countries from the 
EURO (Europe), EMRO (Eastern Mediterranean), AMRO (America) and SEARO 
(South East Asia) WHO offices. The association between the covariate population and 
using the pharmaceutical industry as an information source was also statistically 
significant. Countries using the industry as their information source had less population 
than those not using the industry. Nevertheless, considering the high standard 
deviation, as well as the values of skewness and kurtosis, this may occur due to the 
influence of countries with a massive population, such as China or Russia. 
As far as drug reference books are concerned, which were in general the preferred 
information source, there was a statistically significant association between selecting 
reference books and being a member of the OECD, having English as an official 
language, and having Portuguese as an official language. Members of the OECD used 
reference books more often (43.8%) than non-members (33.2%). Possible 
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explanations are that countries that edit the most well-known reference books (BNF, 
VIDAL; PDR; Martindale, etc) are all members of the OECD. Moreover, as not every 
country has its own reference book, some countries not members of the OECD may 
not have their own reference books. Also countries with English as an official language 
used reference books more often (44.9%) than those which do not have English as an 
official language (34%). This makes sense, because the availability of reference books 
in English is very high, and English speaking countries have at their disposal a variety 
of reference books, and even if they do not publish their own compendia, foreign 
compendia written in English can be used. Although there are other compendia written 
in languages such as French, Spanish or Portuguese, the number is not so high and 
their accessibility may be lower. For countries with Portuguese as an official language, 
none of the respondents chose reference books as their preferred information source, 
however, we should be cautious with these results because only eight responses were 
analysed. 
Other covariates such as population, GDP per capita, percentage of GDP as health 
expenditure and HDI were also significantly associated with selecting reference books. 
Countries selecting reference books had a higher population, a higher GDP and health 
expenditure (expressed as percentage of the GDP) and higher HDI. Those countries 
spending more on health services have their own reference books adapted to the 
needs and medications of the country, thus reference books would be more easily 
available and, in consequence, would be used more frequently by healthcare 
professionals. 
The use of Internet as the preferred medicines information source ranked second at a 
global level, after drug reference books. None of the analysed covariates presented a 
significant association with the selection of Internet. This finding indicates that the 
selection of Internet is homogeneously preferred around the world, regardless of 
development, income or socioeconomic indicators in the countries. 
The use of scientific journals was associated with the continent, OECD membership, 
World Bank income classification, WHO regional office and English and Spanish as the 
official languages. The preference for scientific journals was higher in America, 
followed by Africa, Oceania, Asia and lastly Europe. Scientific journals were more 
selected by non-members of the OECD and by upper middle income countries. 
Surprisingly high income countries selected scientific journals less often than lower 
middle and low income countries. Countries with English as their official language used 
fewer scientific journals and Spanish countries used more. Countries selecting 
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scientific journals as their preferred information source had a fewer HALE at birth, GDP 
per capita, a lower percentage of GDP as health expenditure (public and private), as 
well as a lower HDI. Scientific journals may not be the best option for searching for 
medicines information in daily clinical practice. The selection of scientific journals in 
some developing countries may be associated with their limited access to other 
sources of information, such as drug compendia. Currently, the Health Inter-network 
Access to Research Initiative (HINARI), which is a WHO initiative, promotes access to 
scientific information by providing free (or low cost) online access to major science 
journals.(38) Although controversial, this initiative may facilitate access to scientific 
journals in developing countries.(39) 
The use of SmPCs was associated with the covariates continent, OECD, and WHO 
regional office. It is evident that SmPCs, as official information sources in the European 
Union intended for healthcare professionals, are mostly used in Europe. The small 
percentage of use of SmPCs in other continents may be attributed to European 
expatriates or healthcare professionals who have somehow been related to Europe in 
their studies or professional living. The use of SmPCs in Europe accounted for 12.3%. 
Although some authors consider that healthcare professionals are not aware of the 
content of SmPCs or even do not know how to access them (7, 40), our study showed 
that SmPCs are the third preferred medicines information source among healthcare 
professionals in Europe. Drug reference books and information on Internet ranked 
respectively, first and second as preferred medicines information sources.  
Members of the OECD used more SmPCs because all European countries belong to 
the OECD. As expected, the WHO regional office EURO is the one with a greater use 
of SmPCs as the preferred information source. Countries using SmPCs were less 
populated, had a higher HALE at birth, had more physicians per 1000 inhabitants, had 
a higher percentage of GDP as health expenditure, but a lower percentage of GDP as 
private health expenditure, and had a higher HDI. These characteristics reflect in 
general the characteristics of European countries. In the European Union public 
funding dominates the healthcare sector in most countries, ranging from 56.2% of 
public funding in Bulgaria to more than 80% of public funding in countries such as the 
Netherlands, Denmark, Luxembourg or Sweden. Private insurances generally 
represent a small share of healthcare financing among member states (their relative 
share is only greater than 10% in France and Bulgaria).(41) 
Lastly, we should notice that the area of work was not significantly associated with the 
preference of any of the information sources listed. Our study included a vast range of 
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healthcare professionals and researchers from different areas (practitioners versus 
researchers; pharmacists versus physicians; hospital versus community settings). 
Remarkably, this whole set of healthcare professionals did not present differences in 
their preference when selecting medicines information sources. This may indicate that 
creating a good quality medicines information source would be beneficial for all 
healthcare professionals, regardless of their area of work. 
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Conclusions 
At a global level, drug reference books or medicines compendia were the leading 
medicines information source among healthcare professionals. 
There were different patterns of preferences associated to socio-demographic 
indicators:  
 Drug reference books were preferred in highly developed countries and high 
income countries, as represented by OECD membership, Gross Domestic 
Product per capita, Human Development Index and health expenditure. 
 Internet was the second preferred medicines information source, with a 
homogeneous distribution, not associated with any socio-demographic 
indicator. 
 As expected, the preference for Summaries of Product Characteristics was 
linked to Europe; however, this official source remained as the third option 
when selecting medicines information sources in this continent, after drug 
compendia and Internet. 
No association was found between area of work and the medicines information source 
selected.   
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Background 
Whenever drug therapy is considered during pregnancy, both potential teratogenic 
risks of treatment and the potential risks of no treatment for the mother have to be 
carefully weighed.(1) A teratogenic exposure can be defined as ‘one that may produce 
a permanent abnormality of structure or function in an organism exposed during 
embryonic or foetal life’.(2) According to the European Medicines Agency a teratogen is 
an “environmental factor which can cause congenital abnormalities”, congenital 
abnormalities (also known as structural birth defect, congenital malformation, or foetal 
defect) being: “a consequence of error of morphogenesis, i.e. structural-morphological 
defect, grossly or microscopically present at birth whether detected at birth or not”.(3) 
The use of drugs in pregnant women is a well-studied subject. Several studies have 
concluded that more than 80% of women use at least one drug during pregnancy (1, 
4). The most widely used drugs are vitamins, iron preparations, analgesics, 
dermatological and gynaecological preparations, antiemetics and antacids, but also 
drugs such as nervous system drugs, respiratory drugs and cardiovascular drugs are 
used.(4, 5) If folic acid, iron preparations and vitamins are excluded, 69.2% of pregnant 
women still use at least one drug.(1) In a study from Schirm et al. more than half of 
pregnant women used between one and three different kinds of drugs and 16% used 
five of more different types. In addition, drug use increased with trimester, 45.3% of 
women used drugs in the first trimester, 57.1% in the second and 70.3% in the third 
trimester.(1)   
A study among Danish women pointed out that of all prescriptions during pregnancy, 
40.9% of prescriptions were for drugs classified as safe by the Swedish classification 
system (systems of classification are further explained in this chapter, section 
‘Classification of medicinal product according to their risk during pregnancy’), 26% as 
potentially harmful and for 28.7% the risk was unknown.(6) It should be noted that the 
category ‘potentially harmful’ does not necessarily mean that the drugs with such 
classification are not safe. A suspicion of potential adverse effects is enough to classify 
a drug under this category.(1) On the other hand, studies showed that the proportion of 
women using potentially harmful drugs is lower during pregnancy than before 
pregnancy.(1) 
Major congenital anomalies occur in approximately 2-4% of all pregnancies, of which 
20-25% anomalies have a genetic origin and around 10% have an exogenous and 
potentially preventable cause (such as drug teratogenicity, maternal diabetes or alcohol 
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abuse). The aetiology of the remaining 70-75% is unknown.(7) Although teratogenic 
effects of drugs cause approximately 1% of birth defects, many health professionals 
and patients tend to overestimate them.(7) 
Clinicians often have to determine the risk of inadvertent exposure of a pregnant 
woman to a medicinal product or decide whether a treatment is appropriate during 
pregnancy.(8) One of the main concerns of researchers and healthcare professionals is 
the lack of information for clinical practice about the use of medicines during 
pregnancy.(9) Pregnant women are frequently considered a ‘special population’ and 
thus excluded from clinical trials. The effects of drugs during pregnancy are largely 
unknown prior to post-marketing experience (10), and drug safety information is based 
on animal studies of variable validity in humans.(11) Teratology testing in rodents and 
rabbits is usually required before a new medicinal product is placed on the market, but 
in these preclinical studies both false positives and false negatives occur.(2) 
Although the opportunities to collect toxicity data before a drug is placed on the market 
are very limited, such data can be obtained afterwards.(2) Safety data during clinical 
use should help improve the information available on teratogenicity for healthcare 
professionals. As explained in the ‘Introduction’ section, Regulatory Authorities and 
Marketing Authorisation Holders share responsibility for surveillance of marketed 
drugs. Both of them record information on drug safety from different sources, and 
procedures have been developed to ensure timely detection and mutual exchange of 
safety data.  
Classification of medicinal products according to their risk during pregnancy 
According to their known or suspected adverse effects on the unborn child, different 
classification systems have been developed. These classification systems place drugs 
in risk groups to provide guidance for healthcare professionals in the decision of 
whether to use a drug during pregnancy.  
The most well-known systems include the FDA classification, Swedish classification, 
Australian classification and Teratogen Information System (TERIS) risk ratings. These 
systems use almost the same codes (A, B, C, D and X) but with different meanings. 
The FDA category B, for example might be similar to the Australian and Swedish 
category C. Although the aim of these systems is to categorise drugs to help clinicians 
in their decision-making, some authors have pointed out differences in the 
categorisation of the same drug across the systems. For drugs falling into a specific 
risk group, Addis et al. showed that only 26% of the drugs present in the FDA, Swedish 
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and Australian systems were placed in the same risk category.(12) These differences 
are a source of confusion for healthcare professionals (1), and the usefulness and 
reliability of these classification systems is a matter for debate.(12)  
Some authors consider that a possible solution to the ambiguity of the classification 
systems and difficulties in the evaluation of teratogenic risk by healthcare professionals 
should be the use of narrative statements that describe, summarise and interpret the 
available evidence about risks. These narrative statements should replace the existent 
rating of drugs to provide estimates of teratogenic risks.(13, 14) 
Table 06-01 and 06-02 summarise the FDA, Australian and Swedish classification of 
drugs:(15, 16) 
Table 06-01. FDA categories for drug use in pregnancy
Category Interpretation 
      A Adequate, well-controlled studies in pregnant women have not shown an increased risk of 
foetal abnormalities to the foetus in any trimester of pregnancy. 
      B Animal studies have revealed no evidence of harm to the foetus, however, there are no 
adequate and well-controlled studies in pregnant women. 
OR 
Animal studies have shown an adverse effect, but adequate and well-controlled studies in 
pregnant women have failed to demonstrate a risk to the foetus in any trimester. 
      C Animal studies have shown an adverse effect and there are no adequate and well-controlled 
studies in pregnant women. 
OR 
No animal studies have been conducted and there are no adequate and well-controlled 
studies in pregnant women. 
      D Adequate well-controlled or observational studies in pregnant women have demonstrated a 
risk to the foetus.  
However, the benefits of therapy may outweigh the potential risk. For example, the drug 
may be acceptable if needed in a life-threatening situation or serious disease for which safer 
drugs cannot be used or are ineffective. 
      X Adequate well-controlled or observational studies in animals or pregnant women have 
demonstrated positive evidence of foetal abnormalities or risks.  
The use of the product is contraindicated in women who are or may become pregnant. 
 
Table 06-02. Australian and Swedish categories for drug use in pregnancy
Category Interpretation 
A Drugs which have been taken by a large number of pregnant women and women of 
childbearing age without any proven increase in the frequency of malformations or other 
direct or indirect harmful effects on the foetus having been observed. 
B1 Drugs which have been taken by only a limited number of pregnant women and women 
of childbearing age, without an increase in the frequency of malformation or other direct 
or indirect harmful effects on the human foetus having been observed. 
Studies in animals have not shown evidence of an increased occurrence of foetal 
damage. 
B2 Drugs which have been taken by only a limited number of pregnant women and women 
of childbearing age, without an increase in the frequency of malformation or other direct 
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Table 06-02. Australian and Swedish categories for drug use in pregnancy
or indirect harmful effects on the human foetus having been observed. 
Studies in animals are inadequate or may be lacking, but available data show no 
evidence of an increased occurrence of foetal damage. 
B3 Drugs which have been taken by only a limited number of pregnant women and women 
of childbearing age, without an increase in the frequency of malformation or other direct 
or indirect harmful effects on the human foetus having been observed. 
Studies in animals have shown evidence of an increased occurrence of foetal damage, 
the significance of which is considered uncertain in humans. 
C Drugs which, owing to their pharmacological effects, have caused or may be suspected 
of causing, harmful effects on the human foetus or neonate without causing 
malformations. These effects may be reversible. Accompanying texts should be 
consulted for further details. 
D Drugs which have caused, are suspected to have caused or may be expected to cause, 
an increased incidence of human foetal malformations or irreversible damage. These 
drugs may also have adverse pharmacological effects. Accompanying texts should be 
consulted for further details. 
X 
-only in the 
Australian 
classification- 
Drugs which have such a high risk of causing permanent damage to the foetus that they 
should not be used in pregnancy or when there is a possibility of pregnancy. 
 
The FDA is currently using the classification previously described. Nevertheless, the 
FDA has proposed the amendment of labelling regulations concerning drug use during 
pregnancy. The agency proposed a requirement that labelling should include a 
summary of the risks of using a drug during pregnancy and lactation and a discussion 
of the data supporting that summary. The labelling would also include relevant clinical 
information to help healthcare providers to make prescribing decisions and counsel 
women about the use of drugs during pregnancy and/or lactation. This proposal would 
eliminate the current pregnancy categories A, B, C, D, and X.(17) At the moment, the 
Final Rule is in the writing and clearance process. This process requires identification 
and consideration of all issues that were raised in the public comments since the 
amendment proposal. 
European Union Regulations 
In the European Union, regulatory authorities have specific rules regulating the 
provision of safety information. In the European Union, safety information in SmPCs is 
included in two main sections: ‘Contraindications’ (section 4.3) and ‘Special Warnings 
and Precautions for Use’ (section 4.4). In section 4.6, specific information about the 
use of the drug in pregnancy, lactation and women of child-bearing potential and its 
influence on fertility is given (for more information about sections in SmPCs please 
refer to chapter one, Introduction, ‘Summaries of Product Characteristics’ section). 
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Fertility is defined as “the actual reproductive performance of an individual, a couple, a 
group, or a population, and thus the failure to reproduce defines infertility”.(18) 
The European Union highlights the importance of marketing authorisation holders 
providing recommendations for use of drugs during pregnancy and lactation and for 
women of child-bearing potential and reasons to support these recommendations in 
SmPCs.(19) SmPCs do not use any of the previously mentioned systems of drug 
classification. Instead, narrative statements are included in the appropriate section. The 
European Commission Guideline on Summary of Product Characteristics set the 
principles of the content and structure of the information that should be included in this 
section.(19) 
Because all information cannot be evaluated simultaneously and in order to set 
priorities, in most European countries, systems for a rapid transmission of information 
have been developed which usually focus on reporting adverse reactions that are both 
serious and unexpected.(20) Additionally, the Marketing Authorisation Holder is 
required to submit update safety reports periodically. These reports should contain all 
reports of drug safety events related to the medicinal product including those coming 
from clinical trials, reported spontaneously during clinical use or published in scientific 
literature.(21) This monitoring leads to periodical safety changes in the Summaries of 
Product Characteristics. As reviewed in the Introduction section, the European Union 
requires the Marketing Authorisation Holder to submit reports with a periodicity of six 
months for two years, annually for the three following years and then every five years, 
at the time of renewal of registration of the medicinal product.(20) 
The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) brings together the regulatory 
authorities and pharmaceutical industry of Europe, Japan and the US to discuss 
scientific and technical aspects of drug registration. ICH's mission is ‘to achieve greater 
harmonisation to ensure that safe, effective, and high quality medicines are developed 
and registered in the most resource-efficient manner’.  
The situation of the submission of periodic update safety reports is different in the three 
ICH regions (Europe, United States and Japan). The U.S regulations require quarterly 
reports during the first three years, and then annual reports are required. Some authors 
consider that the collection of information of safety after a drug is approved by the FDA 
is a passive process which is notoriously inefficient and often misleading in the 
identification of teratogenic effects.(2) In Japan, the authorities require a survey on a 
cohort of a few thousand patients established by a certain number of identified 
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institutions during the six years following authorisation. Systematic information on this 
cohort must be reported annually. Regarding other marketing experience, non-serious 
adverse reactions, but both mild in severity and unlabelled must be reported every six 
months for three years and annually thereafter.(20) 
In 2008 the ‘Guideline on risk assessment of medicinal products on human 
reproduction and lactation: from data to labelling’ was published in the European Union 
in order to describe the process of assessment of non-clinical and human data, and 
integrate these assessments for the labelling of the medicinal product. Decision 
schemes are provided to determine whether or not a contraindication during pregnancy 
should be settled in the labelling and examples of standardized texts are given for 
recommendations on use during pregnancy and lactation.(18) 
The main recommendations proposed by the guideline regarding use of medicines 
during pregnancy are: (18) 
 [brand] is contraindicated during pregnancy/during (trimester) of pregnancy 
 [brand] should not be used during pregnancy/during (trimester) of pregnancy 
unless the clinical condition of the woman requires treatment with [active 
substance] 
 [brand] is not recommended during pregnancy/during (trimester) of pregnancy 
 As a precautionary measure, it is preferable to avoid the use of [brand] during 
pregnancy/during (trimester) of pregnancy 
 The use of [brand] may be considered during pregnancy/during (trimester) of 
pregnancy, if necessary 
 [brand] can be used during pregnancy/during (trimester) of pregnancy if 
clinically needed 
 [brand] can be used during pregnancy 
These recommendations are suggested in the guideline, taking into account the 
information provided from animal and human data. 
The main recommendations proposed by the guideline regarding use of medicines 
during breastfeeding are: (18) 
 [brand] is contraindicated during breast-feeding (see section 4.3) (or) should not 
be used during breast-feeding (or) breast-feeding should be discontinued during 
treatment with [brand] (or) a decision must be made whether to discontinue 
breast-feeding or to discontinue/abstain from [brand] therapy taking into 
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account the benefit of breast feeding for the child and the benefit of therapy for 
the woman. 
 [brand] can be used during breast-feeding 
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Objective 
To assess completeness of drug information related to safety in European SmPCs 
regarding fertility and use of medicines in pregnancy and lactation. 
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Methods 
Summaries of product characteristics of medicinal products granted a marketing 
authorisation through a centralised procedure in the European Union were retrieved 
from the webpage of the European Medicines Agency (www.ema.europa.eu).  
From all the retrieved SmPCs those medicinal products which, according to their 
indications are not intended to be used in pregnant women, were excluded. Due to the 
fact that information in SmPCs is intended to describe the use of the medicinal product 
for the indications included in the SmPCs, section 04 ‘Therapeutic Indications’ of the 
SmPCs was used to determine which drugs should be excluded from the analysis. Five 
groups of indications were used as exclusion criteria: drugs for use in postmenopausal 
women, drugs for paediatric use, drugs for male patients, drugs indicated for 
contraception, and drugs indicated for assisted reproduction techniques.  
For the analysis, all relevant information about the medicinal product included in 
section 4.6 (Fertility, pregnancy and lactation) was assessed and included in an ad hoc 
created form. When general information about drug class effects was given, it was 
considered relevant for the specific medicinal product. 
Design of the database 
In order to analyse the information from section 4.6 (Fertility, pregnancy and lactation) 
on SmPCs an ad-hoc form was created in a Microsoft Access® database. The design 
of the database was made taking into consideration scientific literature on the use of 
drugs during pregnancy and European Union regulations on the provision of safety 
information. According to the EU regulations for the assessment of medicines related to 
their use during pregnancy, lactation and in women of child-bearing potential, 
knowledge from non-clinical studies, clinical studies, post-marketing surveillance and 
knowledge about drugs within the same class should be taken into account.(19) The 
form was piloted until the best structure to collect all the relevant information was 
agreed. The database consisted of 15 close-ended questions, and two open-ended 
questions: 
Table 06-03. Questions and answers in the designed database
Questions Answers
1. Is the drug included in the analysis?  Yes 
 No: post-menopause 
 No: paediatrics 
 No: men 
 No: contraceptive 
 No: assisted reproduction 
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Table 06-03. Questions and answers in the designed database
Preclinical studies 
2. Does the SmPC provide information about the existence of 
studies in animals for the medicinal product? 
 Yes, there is information and 
there are animal studies 
 Yes: there is information and 
there are not animal studies 
 There is no information on this 
subject 
3. Does the SmPC provide information about results of animal 
studies for the medicinal product? 
 Yes, there is information  
 No, there is no information on this 
subject 
 Not applicable 
Clinical trials 
4. Does the SmPC provide information about the existence of 
clinical trials in pregnant women for the medicinal product? 
 Yes, there is information and 
there are clinical trials 
 Yes: there is information and 
there are not clinical trials 
 Unclear origin of information 
 There is no information on this 
subject 
Post marketing surveillance 
5. Does the SmPC provide information about the existence of 
clinical experience in pregnant women for the medicinal product? 
 Yes, there is information and 
there is clinical experience 
 Yes: there is information and 
there is not clinical experience 
 Unclear origin of information 
 There is no information on this 
subject 
6. Does the SmPC quantify the existing clinical experience for the 
medicinal product? 
 Yes, it quantifies the clinical 
experience 
 No, there is no information on this 
subject 
 Not applicable 
Knowledge about the drug 
7. Does the SmPC provide information about the drug crossing the 
human placental barrier? 
 Yes, there is information and it 
crosses the placental barrier 
 Yes: there is information and it 
does not cross the barrier 
 It is not known whether it crosses 
or not 
 There is no information on this 
subject 
8. Does the SmPC provide information about the effect of the drug 
on human fertility? 
 Yes, there is information and it 
affects fertility 
 Yes: there is information and it 
does not affect fertility 
 The SmPC indicates that it is not 
known 
 No, there is no information on this 
subject 
9. Does the SmPC provide information about the need of 
contraception in women of child-bearing potential taking the 
medicinal product? 
 Yes, there is information and 
women should use contraceptive 
measures 
 Yes: there is information and 
contraceptive measures are not 
needed 
 No, there is no information on this 
subject 
10. Does the SmPC indicate how long contraceptive measures 
should last? 
 Yes, it specifies how long 
contraceptive measures should 
be taken 
 No, there is no information on this 
subject 
 Not applicable 
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Table 06-03. Questions and answers in the designed database
11. Does the SmPC provide information about the excretion of the 
medicinal product in human milk? 
 Yes, there is information and the 
drug is excreted in human milk 
 Yes, there is information and the 
drug is not excreted in human 
milk 
 The SmPC indicates that it is not 
known 
 No, there is no information on this 
subject 
12. Does the SmPC provide information about the adverse 
reactions (ADRs) of the medicinal product in lactating neonates? 
 Yes, it provides information about 
ADRs 
 No, there is no information on this 
subject 
 The SmPC indicates that it is not 
known 
 Not applicable 
13. Does the SmPC provide information obtained from clinical trials 
or clinical experience regarding the potential ADRs of the medicinal 
drug in embryo, foetus, neonates or in pregnant women? 
 Yes, it provides information about 
ADRs 
 No, there is no information on this 
subject 
 Not applicable 
14. Does the SmPC provide a recommendation for managing the 
exposure of a pregnant woman to the medicinal product? 
 Yes, a clear recommendation is 
given 
 No, there is no information on this 
subject 
 Not applicable 
Recommendations of use of the medicinal product regarding pregnancy and breastfeeding 
15. Does the SmPC include a conclusive recommendation about 
the use of the medicinal product in pregnant women? 
 Yes, a conclusive 
recommendation is given 
 No, an ambiguous 
recommendation is given 
16. Is the use of the medicinal product during pregnancy somehow 
restricted? 
 Yes, there is a restriction to the 
use of the medicinal product 
during pregnancy 
 No, there is no restriction to its 
use 
17. Does the SmPC include a conclusive recommendation about 
the use of the medicinal product during breastfeeding? 
 Yes, a conclusive 
recommendation is given 
 No, an ambiguous 
recommendation is given 
18. Is the use of the medicinal product during breastfeeding 
somehow restricted? 
 Yes, there is a restriction to the 
use of the medicinal product 
during breastfeeding 
 No, there is no restriction to its 
use 
 
Analysis of SmPCs 
Information about the above mentioned fields was retrieved from SmPCs using a 
systematic and previously defined guideline. Only specific information items were 
sought, using the European regulations on the content and structure of SmPCs as a 
model.(19) No deductions or interpretations were made and explicit information items 
were sought. 
To minimise errors of interpretation and due to the potential lack of homogeneity of 
SmPCs, a reference manual was created including the guidelines to fill out the form. 
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Due to the potential use of different terms across the SmPCs, a dictionary of terms was 
produced prior to the assessment. The terms ‘human studies’, ‘assessment’ or ‘trials’ 
were used as synonymous to clinical trials. Clinical experience was assimilated to 
‘epidemiological use’, ‘epidemiological evidence’ or ‘experience’. If expressions such as 
‘clinical data’, ‘limited data’ or ‘clinical data on exposure’ appear, both clinical trials and 
clinical experience were defined as ‘unclear origin’.  
In order to define whether the recommendation about the use of the medicinal product 
during breastfeeding or pregnancy was conclusive, a list extracting the expressions 
found in SmPCs was created and they were categorised as follows: 
Conclusive expressions: 
 Contraindicated 
 Must not be used 
 Should not be used 
 Not recommended 
 No restrictions to the use 
Non-conclusive expressions: 
 Should not be used, unless… (clearly necessary, the benefits outweigh the 
risks, or other ambiguous expressions) 
 Should be used only if… (ambiguous expression) 
 It is preferable to 
 Use with caution 
For drugs which are a combination of several active substances, information may be 
given separately for each active substance. In these cases if any of the active 
substances are known to be excreted into human milk, the whole drug was considered 
to be excreted into human milk. Furthermore, if for any of the active substances there 
are no animal studies, clinical trials or experience; it was considered that there are no 
animal studies, trials or experience for the drug. If the combination drug mentions the 
effects of at least one of the substances in nursing neonates, it was considered that it 
provided information about ADRs. In case information was given for several active 
substances, the most restricted information was selected to complete the form. 
If for any of the questions (very) limited data are mentioned, we considered that data 
on the topic exist. However, if SmPC states ‘there are limited or no data’ or ‘insufficient’ 
we considered that data on the subject were lacking.  
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Data extraction was performed independently by two researchers (T.M.S. and B.A.) 
who strictly followed the reference manual. When discrepancies existed, 
disagreements were adjudicated by a third reviewer (F.F-L).  
Data analysis 
To avoid potential effects of low component prevalence on Kappa results, inter-rater 
agreement was evaluated using a prevalence-adjusted bias-adjusted kappa (PABAK) 
(22), by using the WinPepi version 11.25 software. The PABAK was used as an index, 
because it allows the adjustment of Kappa for differences in prevalence of the 
variables.(22, 23) As standards for strength of agreement for the PABAK coefficient, 
we assumed: PABAK≤0=poor, 0.01–0.20=slight, 0.21–0.40=fair, 0.41–0.60=moderate, 
0.61–0.80=substantial, and 0.81–1=almost perfect.(23)  
After reconciliation of discrepancies between raters, a descriptive analysis with 
frequencies of categorical/ordinal variables, as well as central tendency/dispersion 
measures for the discrete variables, was performed. Normality for the latter was 
assessed using the Kolmogorov–Smirnov test. For non-normally distributed variables, 
non-parametric tests were used to explore the association with categorical variables 
(Mann-Whitney test). Association between categorical variables was evaluated through 
chi-square tests. Statistical analyses were performed using the SPSS version 16 
software package. 
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Results 
Analysis of SmPCs 
A total of 582 SmPCs were retrieved from the EMA website on 29th April 2011, from 
which 59 (10.1%) were orphan medicines. The average number of days since the 
authorisation date was 2083.5 days (SD=1595.0), approximately 5.7 years old. The 
average number of days since publication/last update was 266.9 days (SD=273.3). The 
Kolmogorov–Smirnov test revealed that both authorization and last update dates were 
not normally distributed (p<0.001). 
Table 06-04 presents the results of the application of exclusion criteria by the two 
raters: 
Table 06-04. Results of application of exclusion criteria by two independent raters 
Exclusion criteria 
T.M.S B.A. 
n % n % 
No: post-menopause 12 2.1 13 2.2 
No: men 11 1.9 11 1.9 
No: contraceptive 3 0.5 1 0.2 
No: assisted reproduction programmes 7 1.2 7 1.2 
No: paediatrics 14 2.4 11 1.9 
Included 535 91.9 539 92.6 
 
Table 06-05 presents inter-rater agreement coefficients, expressed as PABAK 
(Prevalence-Adjusted Bias-Adjusted Kappa) and percentage of agreement. Out of the 
18 variables evaluated, 14 (77.8%) presented an ‘almost perfect’ agreement, three 
(16.7%) presented a ‘substantial’ agreement, and one (5.6%) presented a ‘moderate’ 
agreement. 
Table 06-05. Inter-rater agreement
Name PABAK % Agreement 
1. Included in the analysis 0.99 98.8 
2. Existence animal studies 0.90 92.8 
3. Results animal studies 0.90 92.3 
4. Existence clinical trials 0.70 75.6 
5. Existence clinical experience 0.60 67.9 
6. Quantifies clinical experience 0.86 89.3 
7. Crosses placental barrier 0.94 95.0 
8. Information about influence on human fertility 0.91 92.6 
9. Information about need for contraceptive measures 0.66 69.0 
10. Information on duration of contraception 0.91 93.3 
11. Excretion in human milk 0.91 92.8 
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Table 06-05. Inter-rater agreement
12. ADRs nursing neonates 0.73 78.7 
13. ADRs embryo, foetus, neonates or  pregnant women 0.84 88.1 
14. Information on management of exposure 0.86 89.5 
15. Conclusive recommendation use in pregnancy 0.86 90.9 
16. Restrictions to use during pregnancy 0.98 98.5 
17. Conclusive recommendation use in breastfeeding 0.96 97.1 
18. Restrictions to use during breastfeeding 0.98 98.6 
 
After the third-rater reconciliation of discrepancies, 534 SmPCs were included for the 
analysis, the remaining 48 being excluded for the reason presented in Table 06-06. 
Table 06-06. Results of application of exclusion criteria 
Exclusion criteria n % 
No:postmenopause 12 2.1 
No:men 11 1.9 
No:contraceptive 2 0.3 
No:assisted reproduction programmes 9 1.5 
No:paediatrics 14 2.4 
Included 534 91.8 
 
No statistical difference was found (Mann-Whitney p=0.128) between the average 
number of days since the authorisation date of the SmPCs ‘included’ (2051.1 days, 
SD=1576.6) and the SmPCs ‘not included’ (2443.6 days, SD=1764.5). Likewise, no 
statistical difference was found (Mann-Whitney p=0.462) between the number of days 
since publication/last update of the ‘included’ SmPCs (268.6 days, SD=275.3) and 
those ‘not included’ (248.6 days, SD=251.8). No statistical association was found (chi-
square p=0.152) with regard to the percentage of orphan drugs between the SmPCs 
‘included’ (10.7%) and the SmPCs ‘not included’ (4.2%). 
Information content in SmPCs 
Regarding information about animal studies, from the 534 analysed SmPCs, 14.6% 
(78/534) did not include any information about the existence of animal studies for the 
medicinal product; 76.4% of SmPCs (408/534) included the information and stated that 
animal studies had been carried out with the drug, and 9% of SmPCs (48/534) included 
the information and stated that no animal studies had been carried out with the 
medicinal product. From the 408 SmPCs which state that there are animal studies, 
99.5% SmPCs (406/408) provide information about the results of the animal studies 
and 0.5% (2/408) do not indicate the results of the studies. 
 119
Regarding information about clinical trials, from the 534 analysed SmPCs, 28.7% 
(153/534) did not provide any information; 1.5% (8/534) informed about the existence 
of clinical trials in pregnant women; 67.2% (359/534) provided information on the 
subject and stated that no clinical trials had been carried out in pregnant women and in 
2.6% (14/534) the information was not clear. 
As far as clinical experience is concerned, from the 534 analysed SmPCs, 13.1% 
(70/534) did not provide any information; 16.7% (89/534) informed of the existence of 
clinical experience in pregnant women; 67.6% (361/534) provided information on the 
subject and stated that there was no clinical experience in pregnant women and in 
2.6% (14/534) the information was not clear. From the 89 SmPCs stating that there is 
clinical experience, 37.1% SmPCs (33/89) quantify this clinical experience and 62.9% 
(56/89) do not quantify it.  
Making an overall assessment of these last variables, from the 408 SmPCs stating that 
there are animal studies, 347 SmPCs indicate that there are no clinical trials and there 
is no clinical experience or do not provide any information about trials and experience. 
This means that in 65.0% of all the analysed SmPCs, the only information provided is 
that from preclinical studies. 
No statistical difference (Mann-Whitney p=0.185) was found between the days since 
marketing authorisation in the 89 SmPCs that inform about the existence of clinical 
experience of the medicinal product (mean=2284.9 days; SD=1874.6), and in the 361 
SmPCs stating that there is no clinical experience (mean=1885.3 days; SD=1476.0).  
In order to analyse the information about ADRs obtained from clinical trials or clinical 
experience (item number 13 in the questionnaire), the 106 SmPCs that stated that 
there were clinical trials and/or clinical experience of the drug during pregnancy were 
further analysed. From those 106 SmPCs, 85.8% SmPCs (91/106) provided 
information about potential ADRs in embryo, foetus, neonates or in pregnant women, 
and 14.2% (15/105) did not mention any ADRs. 
Regarding information about the drug crossing the placental barrier, from the 534 
analysed SmPCs, 89.3% (477/534) did not include any information about the drug 
crossing (or not) the placental barrier. 8.6% of SmPCs (46/534) included the 
information and stated that the drug crossed the placental barrier; 1.3% of SmPCs 
(7/534) included the information and stated that the drug did not cross the placental 
barrier and 0.7% (4/534) stated that it was not known whether the drug crossed the 
placental barrier or not. No statistical difference (Mann-Whitney p=0.574) was found 
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between the days since marketing authorisation in the 53 SmPCs that provide 
information about the drug crossing (or not) the placental barrier (mean=2130.7 days; 
SD=1580.0), and in the four SmPCs stating that this information is not known 
(mean=2339.3 days; SD=1797.4).  
Regarding the effect of the drug on human fertility, from the 534 analysed SmPCs, 79% 
SmPCs (422/534) did not provide any information on the subject. 2.2% SmPCs 
(12/534) provide information and state that the drug affects fertility, 1.1% (6/534) 
provide information and state that the drug does not affect fertility and 17.6% (94/534) 
state that this fact is not known. No statistical difference (Mann-Whitney p=0.412) was 
found between the days since marketing authorisation in the 18 SmPCs that provide 
information about the influence (or not) of the medicinal product in human fertility 
(mean=1640.6 days; SD=1691.0), and in the 94 SmPCs stating that this information is 
not known (mean=1802.9 days; SD=1453.3).  
Out of the 112 SmPCs providing any information on human fertility, there is no 
statistical difference (Chi-square p=0.656) in the prevalence of SmPCs reporting not 
knowing whether the drug affects human fertility between orphan drugs (80.0%) and 
non-orphan drugs (84.5%).  
About the use of the drug in women with child-bearing potential, from the 534 analysed 
SmPCs, 70.6% SmPCs (377/534) do not provide any information on this matter. 29.4% 
SmPCs (157/534) provided information and stated that women of child-bearing 
potential using the medicinal product should use contraceptive measures. None of the 
SmPCs provided information to state that there was no need to take contraceptive 
measures. From the 157 which indicated that contraceptive measures were needed, 
79% SmPCs (124/157) clearly indicated how long these contraceptive measures 
should last and 21% (33/157) did not provide information on the subject. 
As far as the excretion of the medicinal product in human milk is concerned, from the 
534 analysed SmPCs, 21.5% SmPCs (115/534) do not provide any information on this 
matter. 16.5% SmPCs (88/534) provided information and indicated that the drug is 
excreted in human milk, 0.6% SmPCs (3/534) provided information and indicated that 
the drug is not excreted in human milk, and 61.4% (328/534) indicated that this fact is 
not known. From the 88 SmPCs which indicated that the medicinal product was 
excreted in human milk, 88.6% (78/88) did not provide information about the ADRs in 
lactating neonates, 9.1% (8/88) provided information about potential ADRs in lactating 
neonates and 2.3% (2/88) indicated that there is no known information about ADRs in 
lactating neonates. No statistical difference (Mann-Whitney p=0.613) was found 
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between the days since marketing authorisation in the 91 SmPCs that provide 
information about excretion (or not) of the medicinal product in human milk 
(mean=1953.2 days; SD=1456.3), and in the 328 SmPCs stating that this information is 
not known (mean=2076.1 days; SD=1571.8). Out of the 419 SmPCs providing any 
information on the excretion of the medicinal product in human milk, statistical 
difference appears (Chi-square p=0.013) in the prevalence of SmPCs reporting not 
knowing whether the drug is excreted into human milk between orphan drugs (91.1%) 
and non-orphan drugs (76.3%) appears.  
Regarding management of pregnancies exposed to the medicinal product, from the 
534 analysed SmPCs, 87.3% SmPCs (448/534) do not provide any information on how 
pregnant women exposed to the drug should be managed and 12.7% SmPCs (65/534) 
gave a clear recommendation on how to manage this exposure. 
Recommendations for use 
Finally, analysing the recommendations given about the use of the drug during 
pregnancy, from the 534 analysed SmPCs, 94.6% SmPCs (505/534) restricted the use 
of the drug to some extent, 3.7% SmPCs (20/534) did not restrict the use of the 
medicinal product in pregnant women and 1.7% (9/534) did not provide a 
recommendation on the use of the drug during pregnancy. From the 505 SmPCs that 
restrict the use of the drug during pregnancy 89.7% (453/505) do not provide 
information about the drug crossing or not the placental barrier; 13.1% (66/505) do not 
provide information about the existence of studies in animals; 26.9% SmPCs (136/505) 
do not provide any information about the existence of clinical trials in pregnant women; 
and 12.3% SmPCs (62/505) do not provide any information about the existence of 
clinical experience in pregnant women. 
From the 525 SmPCs which provide a recommendation, 43% (226/525) included a 
conclusive recommendation about the use of the medicinal product in pregnant women 
and 57% (299/525) provided an ambiguous recommendation. From those 299 SmPCs 
which provide an ambiguous recommendation, 91.6% (274/299) lack information about 
the drug crossing the placental barrier; 9.4% (28/299) lack information about the 
existence of studies in animals; 21.4% SmPCs (64/299) do not provide any information 
about the existence of clinical trials in pregnant women; and 10.7% SmPCs (32/299) do 
not provide any information about the existence of clinical experience in pregnant 
women. 
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When analysing the recommendations given about the use of the drug during 
breastfeeding, from the 534 analysed SmPCs, 92.1% SmPCs (492/534) restricted the 
use of the drug to some extent, 6.7% SmPCs (36/534) did not restrict the use of the 
medicinal product in breastfeeding women and 1.1% (6/534) did not provide a 
recommendation on the use of the drug during breastfeeding. From the 492 SmPCs 
that restrict the use of the drug during breastfeeding 16.9% (83/492) do not provide 
information about the drug being excreted into human milk. 
From the 528 SmPCs which provide a recommendation, 83.5% (441/528) included a 
conclusive recommendation about the use of the medicinal product in pregnant women 
and 16.5% (87/525) provided an ambiguous recommendation. From those 87 SmPCs 
which provide an ambiguous recommendation, 26.4% (23/87) lack information about 
the drug being excreted into human milk. 
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Discussion 
Analysis of SmPCs 
Access to SmPCs through the European Medicines Agency website was complete. 
SmPCs retrieved from in the EMA website correspond to medicines authorised through 
a centralised procedure. The centralised procedure came into operation in 1995, and 
allows a medicinal product to be granted a marketing authorisation throughout the EU, 
as well as in Iceland, Liechtenstein and Norway. In our analysis, the average SmPC 
was approximately 5.7 years old, which suggests that the centralised procedure has 
been increasingly popular in recent years. These data agree with those published by 
the European Medicines Agency.(24) Since the centralised procedure has been in 
force since 1995, we should expect that medicinal products would be, in general, more 
recent than those authorised through the national authorities. 
Applying to a marketing authorisation through a centralised procedure is optional for 
any medicine as long as it is a significant therapeutic, scientific or technical innovation, 
or if its authorisation would be in the interest of public or animal health. For some 
medicinal products, it is compulsory to apply through the centralised procedure. These 
are the following: (25) 
 human medicines containing a new active substance which was not authorised 
in the Community before 20 May 2004 for the treatment of HIV/AIDS, cancer, 
diabetes, neurodegenerative diseases, auto-immune and other immune 
dysfunctions, and viral diseases 
 veterinary medicines for use as growth or yield enhancers 
 medicines manufactured using biotechnology processes 
 advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or 
tissue-engineered medicines 
 officially designated 'orphan medicines'  
Not only is the authorisation date more recent, but also the last update of the average 
SmPC (220 days) was much more recent than the updates seen in SmPCs (3 years) in 
our study presented in Chapter 5 (‘Clinical Pharmacology Information in Summaries of 
Product Characteristics and Package Inserts’). In this study, most of the analysed 
SmPCs belonged to medicinal products authorised by national regulatory authorities. 
When reviewing the method selected to analyse the SmPCs, after the production of the 
guidelines to help in the process of assessment, according to the PABAK values, we 
can consider it was successful. Nearly 95% of the variables achieved an ‘almost 
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perfect’ or ‘substantial’ agreement. This is coincident with the high values of the 
percentages of agreement among researchers, which ranged from 67.9 to 98.8%. 
Information content in SmPCs 
When analysing the content of SmPCs, we should highlight that it is not the purpose of 
the SmPC to give general advice, but specific aspects related to use of the medicinal 
product and its effects related to the treatment should be mentioned.(19) According to 
European regulations, “information on the risks following exposure to the medicinal 
product before and during pregnancy, and during lactation should be provided as well 
as recommendations on the management of risk in clinical practice”.(18) According to 
the European Commission Guideline on SmPCs, which sets the principles to present 
the information in SmPCs regarding content and structure, “in the overall assessment, 
all available knowledge should be taken into account, including clinical studies and 
post-marketing surveillance, pharmacological activity, results from non-clinical studies, 
and knowledge about compounds within the same class”.(19) According to this 
regulation, all of the mentioned sources of knowledge were evaluated.  
Regarding non-clinical studies, more than 75% of SmPCs provided information and 
results of animal studies. The European Medicines Agency highlights the importance of 
non-clinical studies, specially during drug development, and the early post-marketing 
period.(18) However, although these non-clinical studies can be useful to predict 
human risk, the extent of this prediction needs ‘to be taken with caution’.(3)  
For clinical trials, only 1.5% of SmPCs stated that there were clinical trials on the use of 
the drug during pregnancy. Pregnant women have traditionally been excluded from 
biomedical research which results in a lack of knowledge about the risks and potential 
benefits of medicinal products in this population.(26) Until 1993, the US Food and Drug 
Administration had a policy of excluding all women of childbearing potential from 
participating in drug research. Today, although the FDA is still cautious about the 
inclusion of pregnant women in clinical trials, the FDA ‘Office of Women's Health’, 
actively promotes their participation.(26) Other authors also argue that pregnant 
women should be enrolled in clinical trials.(26) In the EU, clinical trials rarely include 
pregnant women (unless the product is intended specifically for use during pregnancy) 
and most clinical trials require women of childbearing age to use effective 
contraception.(3) 
Another source of clinical information is clinical experience after the medicinal product 
has been marketed. Once the medicinal product is granted a marketing authorisation, 
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pharmacovigilance programmes in pregnant women collect information on safety 
during pregnancy, aiming to provide better information for healthcare professionals. 
This information on drug exposure in pregnancy is necessary to identify agents 
potentially harmful to the foetus or establish that the foetal toxicity of a product is 
limited.(3) In 2005, the European Medicines Agency adopted its ‘Guideline on the 
Exposure to Medicinal Products during Pregnancy’. This guideline proposed active 
post-marketing surveillance for collecting data on drug use during pregnancy, not only 
for newly marketed drugs but also for established products, for which reliable data in 
animals are lacking and experience in humans was poorly documented.(26) Our study 
shows that in 2012, fewer than 17% SmPCs informed of the existence of clinical 
experience in pregnant women. The other 83% SmPCs either did not provide any 
information, stated that there was no clinical experience or their information was 
unclear. Additionally, from those in which there was clinical experience only 37% 
quantified this experience. 
According to EU regulations, the clinical data section should also “include 
comprehensive information on relevant adverse events reported in the embryo, the 
foetus, neonate, infant and pregnant woman, when appropriate”. From the SmPCs 
which provide information about clinical trials or experience, those providing the 
potential ADRs observed in the trials or post-marketing surveillance or their absence 
represented only 17% of all SmPCs. 
In conclusion, according to EU regulations the available knowledge of non-clinical 
studies, clinical studies, post-marketing surveillance, pharmacological activity, and 
knowledge about compounds within the same class should be taken into account in the 
overall assessment.(19) Considering that, according to our results, 65.0% of all the 
analysed SmPCs only include information from preclinical studies; and only 17% of all 
SmPCs describe the potential ADRs (or the lack of them) observed in clinical trials or 
clinical experience, we can conclude that the available information in SmPCs for 
healthcare professionals is scarce. 
Although no statistical difference was found, the mean ‘age’ of SmPCs informing of the 
existence of clinical experience (around 6 years) is greater than the mean ‘age’ of 
those which state that there is no clinical experience (around five years). Nevertheless, 
five years should be a reasonable amount of time to gain experience through post-
marketing surveillance. 
Another of the analysed variables was to know if the medicinal product crosses the 
placental barrier. Most medicinal products could have effects on the foetus if they can 
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cross the placenta to at least some extent. The potential to reach the foetus and 
consequently, the potential harmful effects, depends on whether the rate and extent of 
drug transfer results in sufficient concentrations within the foetus.(3) Although the 
information about crossing the placental barrier is not a requirement in the EU 
Guideline on SmPCs, we have considered that these data would be of value for the 
assessment of the medicinal product. Nearly 90% did not include any information about 
this subject and approximately 1% stated that this fact was not known. Although there 
was no statistical difference, the average ‘age’ of the SmPCs, which state that it is not 
known whether the medicinal product crosses the placental barrier or not is more than 
6 years. 
Regarding the effect of the medicine on human fertility, nearly 80% SmPCs do not 
provide any information on the matter and around 18% state that this fact is not known. 
While the Guideline on SmPcs includes a specific section for data on fertility (19), most 
SmPCs do not provide information on the matter. It is remarkable that medicines, for 
which the effect on human fertility is not known, were authorised on average about five 
years ago. This time, added to pre-authorisation research, should be time enough to 
have information on the subject. 
Information about the use of the medicinal product in women of child-bearing potential 
was also assessed. The guideline on SmPCs notes that “recommendations on the use 
of the medicinal product in women of childbearing potential should be given when 
appropriate, including the need for a pregnancy test or contraceptive measures”.(19) 
However, around 70% of SmPCs did not provide any recommendation for use in 
women of child-bearing potential. It is also remarkable that none of the analysed SmPC 
stated that there was no need to take contraceptive measures. The reason why those 
70% SmPCs did not provide any information may be because there is no need to take 
contraceptive measures or it is not known. This could be a source of confusion for 
healthcare professionals, who do not know if they can safely recommend the use of a 
medicinal product in this population. Analysing the SmPCs that did provide information, 
nearly 80% indicated how long the contraceptive measures should be taken, but there 
was still 20% in which this information was not included. 
Regarding the use of drugs in breastfeeding, information on the excretion of the 
medicinal product in human milk was evaluated. According to the EMA, there are major 
elements of risk assessment during lactation, such as the plasma concentration of the 
medicinal product in lactating infants, and the estimation of the amount of medicinal 
product received by infants via milk.(18) However, more than 20% SmPCs do not 
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include any information on the excretion of the drug in human milk, and more than 60% 
indicated that it is not known. The other major elements for risk assessment during 
lactation are “case reports of adverse effects in breastfed infants” and “follow-up of 
breastfed infants during treatment”.(18) From the SmPCs indicating that the medicinal 
product was excreted in human milk, nearly 89% did not provide any information about 
known ADRs in lactating neonates and more than 2% indicated that this information is 
not known. Although there is no statistical difference, both the SmPCs providing 
information on excretion of the drug in human milk and those which state that it is not 
known are on average more than five years old. This time should be considered 
sufficient to provide some information about the excretion of the medicinal product into 
human milk and efforts should be made to provide these data. Statistical difference 
was found between orphan drugs not knowing if the drug was excreted in milk (around 
91%) and non-orphan drugs (around 76%). It makes sense that orphan drugs, due to 
their characteristics, provide poorer information than non-orphan drugs. However, 
values found in the analysis are quite high for both categories. 
Regarding management of exposed pregnancies, the guideline on SmPCs indicates 
that “recommendations for the management of exposure during pregnancy when 
appropriate (including relevant specific monitoring such as foetal ultrasound, specific 
biological or clinical surveillance of the foetus or the neonate) should be given”.(19) Our 
study found that more than 87% SmPCs do not provide any information on how 
pregnant women exposed to the drug should be managed. This information is essential 
for the healthcare professional when dealing with a pregnant woman who has already 
used the medicinal product. Andrade et al. calculated that approximately one half of all 
pregnant women used drugs for which there was no evidence of safety during 
pregnancy in humans or which had evidence of foetal risk in animal or human 
studies.(27) 
Expressions and wording in SmPCs 
Lack of homogeneity in word-use was a constant across SmPCs. Although criteria for 
the definition of ambiguous expressions were established, some expressions present in 
SmPCs and the use of the same words with different meanings across SmPCs led to 
difficulties in interpretation during the analysis.  
For example, the existence of ‘limited’ data was used in several SmPCs with different 
meanings. Although EU regulations set as an example the sentence “there are no or a 
limited amount of data from the use of [Active substance] in pregnant women” and 
defines ‘limited amount of data’ as less than 300 pregnancy outcomes, and ‘moderate 
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amount of data’ as between 300-1000 pregnancy outcomes(18), the use of ‘limited 
data has been shown to be associated to different meanings across SmPCs. Some 
SmPCs mentioned that there are limited data available and describe ADRs derived 
from these data: e.g. “there is limited data from the use of [brand] in pregnant women. 
However, congenital malformations including ear malformations, i.e. abnormally formed 
or absent external/middle ear, have been reported in children of patients exposed to 
[brand] in combination with other immunosuppressants during pregnancy. Cases of 
spontaneous abortions have been reported in patients exposed to [brand]”. (SmPC 
number 67); other SmPCs assimilate limited data to ‘no data’, e.g. “there are no or a 
limited amount of data from the use of [brand] in pregnant women” (SmPCs numbers 
16, 59, 108); others briefly state “there is a limited amount of data from the use of 
[brand] in pregnant women” and no further information is provided, and others quantify 
‘limited experience’ as more than 800 exposed pregnant women and ‘very limited’ as 
more than 300 exposed pregnant women (SmPC number 317). 
It is also surprising, that the SmPC being the official drug information source for 
healthcare professionals in the European Union, some SmPCs state in their 
recommendations “the use of [brand] may be considered during pregnancy if this is 
thought to be necessary, taking into account official recommendations” (SmPC 
numbers 204, 391) or even just state as a recommendation: “the use of [brand] during 
pregnancy has to take into account official recommendations” (SmPC number 180). 
Other ambiguous expressions found in SmPCs may lead to confusion of the healthcare 
professional in decision-making. For example, one SmPC stated: “If it is used during 
pregnancy, the patient must be informed of the potential risk to the foetus and be 
monitored carefully. If [brand] is used at the end of pregnancy, potential adverse 
reactions should be monitored carefully in the newborn.” (SmPC number 560). 
Although information on management of exposure is relevant in clinical practice, 
healthcare professionals not receiving additional information may not know what 
parameters should be monitored according to the mentioned recommendation. 
Finally, some SmPCs make absurd recommendations for the use of the drug during 
pregnancy by stating obvious principles, such as: “can be used during pregnancy if the 
dosage recommendation in section 4.2 is respected” (SmPC number 141) or “can be 
used during pregnancy if clinically needed” (SmPC number 149). 
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Recommendations 
Analysing the recommendations given about the use of the drug during pregnancy, 
nearly 95% SmPCs restricted to some extent the use of the drug, fewer than 4% 
SmPCs did not restrict the use of the medicinal product in pregnant women and fewer 
than 2% did not provide a recommendation on the use of the drug during pregnancy. 
From the SmPCs in which the use of the drug was restricted, nearly 90% do not 
provide information about the drug crossing or not the placental barrier; around 13% do 
not provide information about the existence of studies in animals; around 27% SmPCs 
do not provide any information about the existence of clinical trials in pregnant women; 
and around 12% SmPCs do not provide any information about the existence of clinical 
experience in pregnant women. For those mentioned SmPCs, their use is restricted not 
because their potential effects on the foetus are known, but because data are not 
available. Other authors have previously argued that, although only a few drugs are 
known to cause birth defects in humans, it is the uncertainty about the safety of the 
majority that may lead to underprescribing for pregnant women.(7) This has also been 
demonstrated by our results, in which nearly 95% SmPCs are restricted.  
Other authors have stated that information to determine the risks of treatment with a 
particular medication during pregnancy is often unavailable.(2) Lo et al. examined 486 
drugs authorised between 1980 and 2000 and found that more than 90% of these 
drugs did not have a determined teratogenic risk.(2) Adam et al. reviewed prescription 
medications approved by the FDA between 2000 and 2010 and the teratogenic risk 
was undetermined in 97.7%.(28) Friedman et al. stated that published data are 
insufficient to determine teratogenicity in humans of almost half all the analysed drugs, 
and moreover, the quality of the available data for those drugs which could be rated for 
teratogenicity was only considered as ‘fair’ on average.(29) The American Teratology 
Society Public Affairs Committee, in the ‘Workshop on the Use of Data from Animal 
Developmental Toxicity Studies in Pregnancy Labels’ agreed that when evaluating 
risks of use of drugs during pregnancy, the following statements should be considered: 
(8)  
 Lack of data does not indicate lack of effect. 
 Lack of effect found in animal studies does not guarantee lack of effect in 
humans. 
 The dose and route of administration affect the likelihood of an adverse effect. 
 Effects depend on the timing of exposure during pregnancy and several agents 
may also have an influence on adverse effects (genetic factors of the patient, 
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exposure to other nutritional agents, drugs, or chemicals, including over-the-
counter medications, herbals, dietary supplements, and environmental agents). 
With regard to providing a conclusive statement on the use of the drug during 
pregnancy, according to our results 43% of SmPCs contained a conclusive statement 
and 57% provided an ambiguous recommendation. Although some of the 
recommendations considered ‘ambiguous’ in this study are proposed in the 2008 
guideline on risk assessment in human reproduction (18), it is important to identify 
which is the main objective of the SmPC. Although the SmPC is a document with legal 
value to establish limits to the responsibilities of the marketing authorisation holder, it is 
also a source of information for healthcare professionals in clinical practice. Obviously, 
a balance between the two roles of the SmPC should be found.  
Healthcare professionals are not aware of the meanings of the statements that 
recommend or discourage the use of a medicinal product during pregnancy or lactation 
that are explained in the EMA guideline.(18) This guideline should therefore reject any 
subjectivity in the statements that may lead professionals to confusion in decision-
making. 
Moreover, some SmPCs have been updated after the 2008 guideline was published, 
and do not use the proposed statements and use other more restrictive statements.  
For example, according to the guideline if “a moderate amount of data on pregnant 
women (between 300-1000 pregnancy outcomes) indicate no malformative or 
feto/neonatal toxicity + Animal studies do not indicate reproductive toxicity” the 
statement that should be used is: “the use of [brand] may be considered during 
pregnancy/during (trimester) of pregnancy, if necessary”. In one of the reviewed 
SmPCs, which states that “the moderate number (approximately 450) of prospectively 
collected pregnancies exposed to [active substance] with known outcomes, does not 
indicate unexpected effects on pregnancy outcome” and “in a developmental toxicity 
study conducted in mice …., there was no indication of maternal toxicity, embryotoxicity 
or teratogenicity”, the recommendation provided was “administration of [active 
substance] is therefore not recommended during pregnancy” (SmPC number 410). 
In SmPCs including an ambiguous recommendation, the decision is to some extent left 
to the healthcare professional. When analysing other data provided in those SmPCs, 
we found that nearly 92% lacked information about the drug crossing the placental 
barrier; around 9% lacked information about the existence of studies in animals; 21% 
SmPCs did not provide any information about the existence of clinical trials in pregnant 
women; and nearly 11% SmPCs did not provide any information about the existence of 
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clinical experience in pregnant women. Due to the lack of information, a decision is 
difficult to make under these circumstances. Other authors consider that for most drugs 
information available for healthcare professionals is inadequate to determine whether 
the benefits exceed the teratogenic risks.(1) 
Regarding breastfeeding, the use of medicines during breastfeeding was restricted in 
92.1% SmPCs and 1.1% did not provide any recommendation on the use of the drug 
during breastfeeding. From the SmPCs that restrict the use of the drug during 
breastfeeding, 16.9% do not provide information about the drug being excreted into 
human milk. This can be seen in some examples, such as “it is unknown whether 
[brand] is excreted in human milk. No effects on the breastfed newborn/infant are 
anticipated since the systemic exposure of the breast-feeding woman to [brand] is 
negligible….As a precautionary measure, the use of [brand] during lactation should be 
avoided” (SmPC number 242). 
Although the use of drugs during breastfeeding is also highly restricted, the 
recommendations included are much clearer and 83.5% of SmPCs that provided a 
recommendation included a conclusive statement about the use of the medicinal 
product in pregnant women. From those 16.5% SmPCs which provide an ambiguous 
recommendation, 26.4% lack information about the drug being excreted into human 
milk. As an example, one SmPC stated “no specific advice can be given on whether to 
use or not in lactating mothers” (SmPC number 19): 
Despite the limitations of SmPCs, their value as an official source of information is 
undeniable. Savill et al. analysed the safety information in all SmPCs for medicinal 
products authorised in the United Kingdom for the treatment of Attention Deficit 
Hyperactivity Disorder, and compared it to the safety advice and recommendations 
provided in two UK clinical guidelines (SIGN –Scottish Intercollegiate Guidelines 
Network- and NICE – National Institute for Health and Clinical Excellence - guidelines). 
Indications, contraindications, and warnings and precautions were analysed in the 
previous mentioned sources. The results of this study show lack of consistency among 
sources, which leads to confusion in healthcare professionals about the suitability of 
specific medications in individual patients. Additionally, the clinical guidelines state that 
professionals have the responsibility of knowing the information in the SmPC of any 
drug and are expected to take this information fully into account when making clinical 
decisions.(21) Savill et al. concluded that the SmPC, as an independent and current 
source of information, may be the best way of making prescribing decisions based on 
sound evidence.(21) 
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Limitations:  
This analysis was performed in the SmPCs of medicinal products granted a marketing 
authorisation through a centralised procedure. These medicinal products are a small 
percentage of all the authorised products in the European Union and the results of this 
analysis cannot be extrapolated to SmPCs of medicinal products authorised through 
national regulatory agencies. However, we should expect that national agencies also 
use the guidelines approved and published by the European Medicines Agency and 
European Commission.  
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Conclusions 
The percentage of Summaries of Product Characteristics which include information 
about the drug crossing (or not) the placental barrier (9.9%) or being excreted (or not) 
into human milk (17.1%) can be considered low. From the SmPCs reporting excretion 
of the drug into human milk, 88.6% did not provide information on the adverse 
reactions in lactating neonates. 
Although the analysed medicinal products were granted a marketing authorisation on 
average 5.7 years ago, fewer than 17% SmPCs informed of the existence of clinical 
experience in pregnant women. However, from the SmPCs that reported having carried 
out clinical trials in pregnant women or mentioned data from post-marketing 
surveillance, 85.8% provided a description of the adverse reactions obtained from 
clinical trials or clinical experience. 
Regarding fertility, 79% of SmPcs did not provide any information on the effects of the 
medicinal product on human fertility and 17.6% stated that these effects were not 
known. Information about the potential effects of the medicinal product in women of 
child bearing potential was not provided in 70.6% SmPCs. 
The information about management of exposure to the medicinal product in pregnant 
women is scarce and 12.7% SmPCs mention this information.  
A high percentage of SmPCs contain non-conclusive statements regarding the use of 
the medicinal product during pregnancy (57%) and breastfeeding (16.5%). The use of 
the medicinal product is restricted in 94.6% of SmPCs during pregnancy and 92.1% 
during breastfeeding. 
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information sources for healthcare professionals 
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Background 
Assuming that better evidence helps healthcare professionals to provide better care, a 
critical analysis of information sources would help professionals to improve patients’ 
health outcomes. 
As reviewed in the chapter one: Introduction (section ‘Characteristics of the information 
and analysis of its quality’), different criteria have been used to define the quality of 
health information. These different approaches aim to assess different characteristics 
of medicines information. To assess the quality of the information some authors have 
analysed the content itself, assessing completeness of information regarding different 
topics. Molloy et al. considered that to ensure an appropriate, safe and effective 
prescription, physicians should consistently receive critically appraised evidence-
based, comprehensive and up-to-date information.(1) Other authors, such as Berland 
et al. approached this assessment by analysing not only the coverage of topics, but 
also the accuracy of the information and absence of conflicting information.(2) In other 
studies, priority was given to how the information was presented, introducing concepts 
such as readability or comprehensibility.(3) Other authors, such as Shaughnessy et al., 
assessed health information sources according to their usefulness in the clinical 
setting.(4), Curley, et al. described the best sources of information as those that 
provide highly relevant and valid information, but do not require a lot of effort to use.(5) 
Fernandez-Llimos used other four criteria: accessibility, reliability, completeness and 
applicability.(6)  
There have been other researchers aiming to analyse the quality of the information in 
specific sources, and among them several approaches have been made to analyse the 
quality of the information on the Internet. With the advent of new technologies, the 
Internet has become an important communication medium, providing quick and cheap 
access to health information. However, Internet can also be a risky channel that 
escapes to any regulatory control (7), and even for healthcare professionals, it is not 
always easy to assess whether the information on the Internet is credible.(8) 
The Health on the Net (HON) Foundation established eight principles, known as the 
HON Code, used as criteria to evaluate the quality of web sites containing health 
information (please refer to chapter one, Introduction, ‘Characteristics of the 
information and analysis of its quality’). These eight principles are: authority, 
complementarity, confidentiality, attribution, justifiability, transparency, financial 
disclosure, and advertising.(9) 
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Eysenbach et al. divided the criteria to evaluate health information on the Internet into 
different categories: technical criteria, design, readability, accuracy, and 
completeness.(10) Using these categories, Eysenbach et al. defined the main 
characteristics to assess on a website using the mnemonic ‘CREDIBLE’: Current, 
References cited, Explicit purpose of the site, Disclosure of developers and sponsors, 
Interest disclosed, Balanced content, Labelled with metadata and Evidence level 
indicated.(11)  
The FDA raised several questions when evaluating health information on the Internet: 
who runs the website, aim of the website, sources of information and evidence 
provided, update and review of the content, how visitors use the information on the 
webpage, and accuracy of e-mails sent out to subscribers.(12) 
The European Federation of Pharmaceutical Industries and Associations (EFPIA) 
defined the principles to evaluate company-sponsored websites containing drug 
information. These principles are described in the introduction (section ‘quality of the 
information’) and aim to assess whether companies provide balanced and accurate 
information consistent with the official information present in the SmPCs.(13) 
Nähri et al. developed the DARTS tool, aiming to help identify reliable and quality 
information on the Internet by assessing date, authors, references and purpose of the 
site.(14) Silberg et al. established four basic criteria to define the quality of the 
information on the Internet: authorship, attribution, disclosure and currency.(15) 
Other systems to assess the quality of specific drug information sources have been 
developed, and clinical guidelines have also been a focus of interest. In 2003, the 
AGREE rating scale was created by an international group of guideline experts 
(Appraisal Guideline Research and Evaluation Europe, AGREE Collaboration). This 
instrument provides an appraisal of the predicted validity of a guideline, which is the 
likelihood that it will achieve its intended outcome. Not only does it evaluate the quality 
of the information, but also the process of practice guideline development. The AGREE 
instrument was refined in 2009 (AGREE II) and it currently includes 23 items divided 
into six categories.(16) (For a detailed description please refer to chapter one, 
Introduction, ‘Characteristics of the information and analysis of its quality’) 
Apart from all the mentioned approaches, some other studies have aimed at assessing 
specific aspects of drug information. These studies assessed information on specific 
topics such as: adverse drug reactions (17), drug interactions (18), overdose 
management (19, 20), and dose adjustment in renal impairment.(21) Others, selected a 
 140
group of topics like indications, side effects and precautions, and compared them 
among different printed materials.(22) Furthermore, other studies focused on a specific 
drug class, or groups of drugs with common characteristics, such as antihypertensive 
(23) or hepatotoxic drugs.(24, 25) There were also studies analysing the information 
contained in a specific source, such as electronic databases, by comparing their 
content.(26) 
Not only has drug information been analysed from different perspectives, but also the 
methodology used in these different approaches should also be considered. The most 
commonly used method to analyse the quality of drug information is based on the 
comparison of the information provided in different sources. Other methods, such as 
assessing the answers that healthcare professionals provide to specific questions 
using the analysed sources, have also been used.(26) Berland et al. assessed the 
quality of the information by analysing the coverage of topics (all the clinical elements 
describing a topic), the accuracy of the information, and the absence of conflicting 
information (existence of contradictions in the text or misleading information).(2) 
However, this is a very specific approach in which clinical topics were assessed by 
specialists in the area, and it is difficult to extrapolate to a general analysis of quality of 
information. 
Some authors created a scale, a checklist or a score chart for the evaluation. This 
method allows a deeper analysis of the information, as well as reproducibility with other 
sources, other countries and different environments and settings. This reproducibility 
also allows the comparison of studies from different authors.(27) Clauson et al. 
designed a checklist to evaluate the scope and completeness of fifteen categories of 
drug information in databases.(28) Spyker et al. created a checklist to specifically 
assess clinical pharmacology information in drug labelling.(27) Iijima et al. evaluated 
drug information in generic medicines according to nine categories of information.(29) 
Fernandez-Llimos et al. analysed drug information in product monographs provided by 
manufacturers.(30) Strang et al. created a checklist and developed a Delphi study to 
determine the information that physicians needed from pharmaceutical representatives 
to prescribe a drug appropriately.(31) 
When analysing completeness through a checklist, most authors scored the items 
using an a priori defined list of elements.(10) These checklists, created by the authors 
of the articles, are mainly based on published literature, queries addressed to drug 
information centres (28), authors’ criteria (32), FDA requirements for information (18, 
25), drug package inserts, and interview forms (29) or clinical guidelines.(10) These 
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checklists seem to be specifically designed for the purpose of each study, and were 
frequently created disregarding an international scope. Thus, they should not be 
considered universal assessment tools, applicable to different sources of information 
and targeting the needs of healthcare professionals in their daily practice. 
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Objective 
The aim of this study was to design a general tool to evaluate the content of drug 
information sources for healthcare professionals, and to analyse their completeness.  
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Methods 
Creating the initial pool of information items 
An initial pool with the different drug information topics or items that may describe a 
drug and may be included in any drug information source was created by the research 
team. To gather these items, a comprehensive literature review in Pubmed 
(www.pubmed.com), and an in-depth analysis of all aspects of information concerning 
drugs, was carried out. Scientific literature and common sources of information for 
healthcare professionals such as drug reference books, official information sources 
(SmPCs) and their regulations (which provide a detailed description of all aspects of 
the information that should be included), product monographs and web pages with 
information for healthcare professionals (official and non-official) were reviewed. In 
addition, any other item concerning drug information was included in the initial pool. 
The appraisal of the retrieved literature provided a comprehensive pool of medicines 
information topics evaluated in previous studies and/or presented in different medicines 
information sources. A clear definition for each information item in the pool was created 
or retrieved from the reviewed literature and then discussed by the research team to 
produce a glossary with all the items in the initial pool (please refer to Appendix 07-01). 
A first checklist with the pool of information items was designed. This checklist was 
structured and divided into sections according to different information categories. The 
information categories comprising the items were the following: 
 Characteristics of the medicinal product (24 items) 
 Use of the medicinal product (31 items) 
 Contraindications (6 items) 
 Adverse reactions (23 items) 
 Interactions (10 items) 
 Overdose (3 items) 
 Pharmacodynamic properties (13 items) 
 Pharmacokinetic properties (41 items) 
 Safety data (5 items) 
 Evidence (2 items) 
 Prescription data (4 items) 
In order to design an assessment tool to evaluate the content of drug information 
sources, an evaluation and refinement of this pool of items was performed using a 
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Delphi technique in three rounds. The Delphi technique is a consensus method based 
on the agreement of experts about a given issue. The essence of this method is to 
obtain quantitative estimates through the qualitative assessment of evidence.(33)  
During the rounds, the experts evaluated all items on the checklist, and every item was 
scored twice according to two questions: 
 1. ‘Do you consider the item to be a minimal set of information?’ 
This was a ‘yes/no’ question. A minimal set of information was defined as ‘the essential 
information needed for clinical practice. Items selected as a minimal set of information 
should be included in any information source, regardless of its size, i.e. abridged or 
unabridged’. 
The aim of this first question was to create a list containing all the information 
considered minimal by the panel members. This list defined the minimum and essential 
elements that any drug information source should include. 
 2. ‘How would you score the importance of that item?’ 
Participants should score every item from 0 (no importance at all) to 10 (essential, 
greatest importance). 
The aim of this second question was to evaluate the relevance of the information items 
on the checklist for healthcare professionals, in order to define a tool to assess the 
completeness of drug information sources. This tool was created only with the items 
reaching consensus and using the consensus scores that participants attributed to 
them. The tool generated allows us to measure, with a continuous variable, the 
percentage of completeness of a drug information source. It also allows us to compare 
information about completely different drugs. 
An equation to calculate completeness is presented below. In this equation the points 
obtained by the source of information in the analysis are divided by the maximum 
possible points for that source. The maximum possible points differ among drugs 
analysed, as not every item in the list is applicable to every drug (e.g. items defining 
pharmacokinetics in topical treatments or eye drops).  
 
Completeness (%) = 
Points obtained by the analysed source of information x 100 
                                                       
Total possible points 
 145
Not answering an item was also an option for the panel members. In rounds 1 and 2, 
participants were allowed to add new items which they considered to be missing in the 
checklist, and to make any comment to improve the already existing items and their 
definitions. The new items and the comments suggested by the panel members were 
included in subsequent rounds, always maintaining the anonymity of the participants 
who suggested them. 
The initial checklist was reviewed by an independent researcher who estimated the 
response time of the questionnaire (30-45 minutes).  
The questionnaire in the first round comprised 162 items (Table 07-01): 
Table 07-01. Initial questionnaire 
SECTION 1: CHARACTERISTICS OF THE MEDICINAL PRODUCT 
Items 
101. Name of the holder of the marketing authorization 
102. Address of the holder of the marketing authorization 
103. Telephone number of the holder of the marketing authorization 
104. Contact to the medical department of the holder of the marketing authorization 
105. Identification of the active substance 
106. Quantitative composition: the quantity of the active substance, expressed per  dosage unit. 
107. Excipients (qualitative description) 
108. Excipients (quantitative description) 
109. Residues that may be present from the manufacturing process (expressed qualitatively) 
110. Residues that may be present from the manufacturing process (expressed quantitatively) 
111. Pharmaceutical form 
112. Visual description of the product 
113. Colour pictures for product identification 
114. Expiry date 
115. Special precautions for storage 
116. Hygroscopicity of the active substance 
117. Shelf-life after dilution or reconstitution according to instructions given 
118. Shelf-life after first opening the container 
119. Dissolution test of the product 
120. Manufacturing process of the product 
121. Pharmacotherapeutic group (ATC code) 
122. Type of marketing authorization 
123. Marketing authorization numbers 
1 24. Date of first authorization/renewal of the authorization 
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Table 07-01. Initial questionnaire 
SECTION 2: USE OF THE MEDICINAL PRODUCT
Items 
201. Therapeutic indications 
202. Treatment algorithm 
203. Target population 
204. Instructions for correct administration/use 
205. Posology/Dosing 
206. Statement of the therapeutic window 
207.  Maximum recommended single dose 
208. Maximum recommended daily dose 
209. Maximum recommended total dose 
210. The need for dose titration or not 
211. Need for tapering off  
212. Dosage individualization based on disease/severity being treated 
213. Dosage adjustment in renal impairment 
214. Categories of renal impairment related to the dose or interval adjustment 
215. Dosage adjustment in liver disease 
216. Dosage adjustment in other concomitant diseases 
217. Dosage adjustment related to interactions 
218. Normal duration of treatment 
219. Restrictions on duration 
220. What to do if a dose is missing 
221. Implications of non-compliance, intermittent dosing 
222. Influence of food with the intake of the product 
223. Use in the paediatric population  
224. Use in the elderly  
225. Use during pregnancy 
226. Recommendations on the use of the product at different times during pregnancy in respect to 
gestation 
227. Use during lactation 
228. Influence on fertility 
229. Influence on the ability to drive and use machines 
230. Comparison of risks and benefits with drugs in the same class 
231. Comparison of risks and benefits with other drugs for the same condition 
SECTION 3: CONTRAINDICATIONS
Items 
301. Contraindications (disease) 
302. Contraindications (interactions) 
303. Contraindications (hypersensitivity reactions) 
304. Contraindications (Patient populations not studied in the clinical trials) 
305. Contraindications (Patient populations likely to experience product or class related adverse reactions 
occurring under normal conditions of use) 
306. Steps to take if the contraindicated drug is administered 
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Table 07-01. Initial questionnaire 
SECTION 4. ADVERSE REACTIONS
Items 
401. Description of ALL adverse reactions attributed to the medicinal product 
402. Description of only the MOST FREQUENT adverse reactions  
403. Serious adverse reactions to which the healthcare professional should be alert 
404. Mechanism of action of adverse reactions 
405. Circumstances under which patients are at risk of experiencing specified adverse reactions 
406. Relationship between dose and adverse reactions 
407. The action to take in case those serious adverse reactions related to the treatment appear 
408. Warning about the adverse reactions related to the excipients (even traces) 
409. Statement of the need to monitor for specific asymptomatic drug reactions (lab tests) 
410. Instructions on how frequently asymptomatic reactions should be monitored (lab tests) 
411. Instructions on how to respond to monitoring values of asymptomatic drug reactions (lab tests) 
412. Assessment of causality of adverse reactions 
413. Assessment of severity of adverse reactions 
414. Assessment of frequency of adverse reactions 
415. Inclusion of a table of adverse reactions according to a standard system organ class 
416. Information on frequencies of adverse reactions related to the clinical trials from which they stem 
417. Time of onset of adverse reactions 
418. Particular risks on initiating the treatment, such as first dose effects 
419. Particular risks associated with stopping the treatment 
420. Measures to be taken to avoid specific adverse reactions 
421. The action to take in case those serious adverse reactions related to the treatment appear 
422. Reversibility of adverse reactions 
423. Preclinical safety data 
SECTION 5: INTERACTIONS
Items 
501. Clinically relevant interactions suffered by the described medicine 
502. Clinically relevant drug interactions produced by the described medicine 
503. Interacting medicinal products are listed by drug class 
504. Interacting medicinal products are listed as specific compounds 
505. Description of the severity of the drug interaction 
506. Description of the effect of the drug interaction 
507. Food interactions 
508. Interactions with alcohol 
509. Clinical manifestations and effects on laboratory tests 
510. Effects on the results of lab tests not associated to physiological alterations (potential false positives) 
SECTION 6: OVERDOSE
Items 
601. Description of symptoms and signs of overdose of the medicinal product 
602. Management of overdose 
603. Potential sequelae of overdose 
SECTION 7: PHARMACODYNAMIC PROPERTIES
Items 
701. Description of the mechanism of action of the medicinal product 
702. Identification of the principal physiological effects 
703. Efficacy data 
704. Pharmacodynamic effects 
705. Time to onset of effect (with minimal and maximal time) 
706. Time to peak effect (with minimal and maximal time) 
707. Duration of action/effect with minimal and maximal time 
708. Graphical display visualising the mechanism of action 
709. Evidence for tachyphylaxis/tolerance and maximum dose 
710. Pro-drug: information about whether the medicinal product is a pro-drug or not 
711. Chirality 
712. Relationship between dose and effect 
713. Pharmacogenomic alterations on pharmacodynamics 
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Table 07-01. Initial questionnaire 
SECTION 8: PHARMACOKINETIC PROPERTIES
Items 
801. Absorption 
802. Bioavailability: absolute and/or relative bioavailability 
803. Systemic bioavailability for locally applied medicinal products 
804. Time to peak concentration (Tmax) 
805. Variability and modifying factors of time to peak concentration 
806. Influence of  absorption by food 
807. Graphical display of concentration trajectory and variability 
808. Pharmacokinetic model and model parameters 
809. PK/PD dose response or hysteresis loop 
810. Plasma protein binding: expressed in % 
811. Volume of distribution: in L/Kg or absolute values in L 
812. Blood-brain barrier penetration 
813. Placental barrier penetration 
814. Distribution to cerebrospinal fluid 
815. Distribution to milk 
816. Tissue concentration 
817. Plasma concentration 
818. Effective plasma concentration 
819. Toxic plasma concentration 
820. Statement of one-compartment kinetics behaviour or deviation from it 
821. Identification of the route/mechanism of metabolism 
822. Enzymes involved in metabolism 
823. Degree of metabolism 
824. Metabolites: which metabolites 
825. Activity of metabolites 
826. What is the contribution of the metabolites (if any) to the effect 
827. Pharmacokinetics of principal metabolite(s) 
828. List of factors known to increase or decrease metabolism 
829. Induction or inhibition of metabolic enzymes from the medicinal product 
830. Site of metabolism 
831. Elimination half lives 
832. Identification of factors increasing and decreasing half-life 
833. Total clearance: in L/min or L/min/Kg 
834. Inter- and/or intra-subject variability in total clearance 
835. Excretion routes of the unchanged substance 
836. Excretion routes of the metabolites 
837. Linearity/non-linearity of the pharmacokinetics of the medicinal product with respect to dose and/or 
time 
838. Variation in pharmacokinetics with respect to characteristics of patients: age, gender, smoking status, 
etc 
839. Variation in pharmacokinetics with respect to polymorphic metabolism 
840. Variation in pharmacokinetics with respect to pathological situations such as renal impairment, 
hepatic insufficiency, etc 
841. In vivo pharmacokinetic studies of the medicinal product 
SECTION 9: PRECLINICAL SAFETY DATA
Items 
901. Toxicity study (LD50) 
902. Repeated dose toxicity 
903. Genotoxicity 
904. Carcinogenic potential 
905. Toxicity to reproduction 
SECTION 10: EVIDENCE
Items 
1001. Level of evidence 
1002. Clinical trials 
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Table 07-01. Initial questionnaire 
SECTION 11: PRESCRIPTION DATA
Items 
1101. Existence of a generic drug of the same active substance 
1102. Cost of the package 
1103. Sales situation of the product 
1104. Includes patient counselling information 
 
Selecting the Delphi panel 
Dalkey identified the Delphi method as a restructuration of the communication process 
in a group of experts, so that their opinions are brought together to formulate a set of 
priorities.(34) The Delphi technique permits exploring the attitudes, needs and priorities 
of the group of experts on a specific subject.(35) The Delphi process is characterized 
by: “quasi-anonymity”, multistage iteration with controlled feedback, statistical group 
response, and use of experts. Quasi-anonymity means that participants will be known 
to the researcher and even to the other participants, but their responses will remain 
strictly anonymous.(36) This anonymity ensures that the ideas presented are unbiased 
by the identities of other participants and each opinion carries the same weight.(35) 
A suitable expert for a Delphi panel is defined as someone with relevant knowledge 
and experience in a specific field and whose opinions are respected by fellows of 
his/her field of work.(37) The commitment of participants to complete the Delphi 
questionnaires is often related to their interest and involvement with the topic being 
studied. The Delphi panel should consist of 15 to 30 participants from the same 
discipline, or five to 10 per category from different professional groups.(38) Groups of 
more than 30 experts have not been found to improve the results.(36, 39) Using a 
heterogeneous sample of experts ensures that an entire spectrum of opinions and 
views are explored.(35) 
In this study, a convenience sample of healthcare professionals from the European 
Union with relevant knowledge and experience in drug information was recruited. 
These professionals were selected according to their academic and professional 
background, including as many different European countries as possible. In order to 
provide a broad view of the needs of healthcare professionals regarding drug 
information, members of the panel of experts were also selected from different settings: 
hospitals, community pharmacies and academic and research institutions.  
An invitation to participate in the Delphi study was sent via e-mail to the group of 
selected professionals. Expressing the interest to participate was a requirement to 
 150
receive the questionnaire in Microsoft Word® format. Participants involved in the panel 
of experts were kept anonymous during the whole Delphi process. 
Establishing consensus requirements 
When using a Delphi technique, establishing the consensus criteria may be 
controversial and subject to interpretation. A universally agreed definition of consensus 
in the Delphi technique does not exist, as different specialists have established 
different consensus criteria.(36) Usually, consensus on a topic can be decided “if a 
certain percentage of the votes falls within a prescribed range”.(40) Jones and Hunter 
defined the rules to assess the agreement of participants in other consensus methods, 
such as nominal groups. However, for Delphi studies the authors suggested that 
researchers are responsible for defining their own consensus criteria.(41) McKenna 
suggested that consensus should be equated with 51% agreement amongst 
respondents.(42) Villiers et al. defined consensus as 70% of respondents agreeing with 
a statement.(39) Ulschak recommended accepting as consensus when 80% of panel 
members’ votes fall within two adjoining categories on a seven-point scale.(43) Other 
authors suggested using measures of the stability of subjects’ responses throughout 
the rounds, rather than percentages.(40) 
In the present study, consensus criteria were established by the research team based 
on a progressive filtering process, using higher consensus requirements in the first 
round, and then reducing these requirements in subsequent rounds. In the first round, 
consensus criteria were established as ≥90% agreement for the categorical question 
‘Do you consider the item a minimal set of information’ For the discrete-scoring 
question ‘How would you score the importance of the item?’, consensus was defined 
as 80% of the respondents falling within one point on either side of the modal 
response. Those responses falling at the extremes of the ten-point scale (zero or ten) 
required only 70% of responses to indicate consensus. 
In the following rounds, the items for which consensus had been achieved were 
retained and not scored again. For non-consensual items, participants received 
information about the percentage of affirmative responses to the categorical question, 
and about the median, mode, and percentage of answers scoring the mode for the 
discrete-scoring question. Additionally, each participant received information about 
his/her previous answers for each item. Modifications in the list of items taking into 
account comments and new items added by participants were made in subsequent 
rounds. 
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In the second round, consensus criteria were established as ≥80% agreement for the 
categorical question, whereas in the discrete scoring question, consensus was defined 
as 70% of the respondents falling within one point on either side of the modal 
response. Responses falling at the extremes of the ten-point scale required 60% of 
responses to indicate consensus. 
In the third round, consensus criteria were established as ≥75% agreement for the 
categorical question, whilst in the discrete scoring question, consensus was defined as 
70% of the respondents falling within one point on either side of the modal response. 
Responses falling at the limits of the ten-point scale required 60% of responses to 
indicate consensus. For the discrete scoring question consensus was kept the same in 
the second and third rounds. 
After receiving all responses, participation rates (globally and per country) were 
analysed. Consensus was analysed separately for the categorical and discrete scoring 
questions. 
Statistical analysis 
Descriptive statistics were performed using the SPSS v.16 software. 
In order to assess how the number of items achieving consensus changed by selecting 
different consensus criteria, a sensitivity analysis at a 5% interval was performed, both 
for the categorical and the discrete-scoring questions. 
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Results 
Selection of Delphi panel members 
Fifty-eight professionals with relevant knowledge and experience in drug information 
were selected and invited to integrate the Delphi panel of experts. These professionals 
were affiliated to hospitals, community pharmacies and academic and research 
institutions from the following 23 European countries: Austria, Belgium, Croatia, Czech 
Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Lithuania, Malta, Netherlands, Poland, Portugal, Serbia, Slovenia, Spain, Sweden, 
Switzerland, and United Kingdom (UK). The invitation to participate in the Delphi study 
was sent via e-mail in October-November 2009. (Figure 07-01)  
Fig.07-01: Map of Invited countries 
 
 
 
 
From the 58 invitations, 43 professionals accepted to participate, 11 did not reply, three 
e-mail addresses were incorrect, and one professional declined the invitation. Thus, the 
Delphi panel consisted of 43 participants from the following countries: Austria, Belgium, 
Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Lithuania, Malta, Netherlands, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland 
and UK (Figure 07-02).  
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Fig.07-02 Map of countries accepting the invitation to participate in the Delphi study 
 
 
 
Delphi first round 
Following acceptance to participate in the study, the questionnaire for the first round 
was sent by e-mail in October-November 2009 including a link to a webpage containing 
the definitions of the items. Participants were initially given seven days to complete the 
questionnaire, and then sent a reminder giving some extra days to respond to it. 
Reception of questionnaires finished on 30th November, 2009. 
Two members decided to leave the panel in the first round. 32 members completed the 
questionnaire and nine did not respond at all. These 32 participants were from the 
following 18 countries: Austria, Belgium, Croatia, Denmark, Finland, France, Germany, 
Ireland, Lithuania, Malta, Netherlands, Portugal, Serbia, Slovenia, Spain, Sweden, 
Switzerland and the UK (Figure 07-03). 
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Fig.07-03. Map of countries answering in the first round 
 
 
In this first round, consensus was reached in 45 items (28.3%) for the categorical 
question, and 16 items (10.1%) for the discrete-scoring question. Table 07-02 presents 
the percentage of consensus analysed per section. From the original pool of 162 items, 
three items were deleted resulting from the comments of participants in this first round. 
Appendices 07-02 and 07-03 present the frequencies of the scores for the categorical 
and discrete-scoring question.  
Table 07-02. Consensus achieved in the first round (by sections of items)
Sections No. of valid items 
Categorical 
consensus (%) 
Discrete-scoring 
consensus (%) 
1. Characteristics of the medicinal 
product 24 9 (37.5%) 4 (16.7%) 
2. Use of the medicinal product 31 20 (64.5%) 4 (12.9%) 
3. Contraindications  6 3 (50.0%) 2 (33.3%) 
4. Adverse reactions 22 3 (13.6%) 2 (9.1%) 
5. Interactions 10 4 (40.0%) 2 (20.0%) 
6. Overdose 3 2 (66.6%) 2 (66.6%) 
7. Pharmacodynamic properties  12 3 (25.0%) -- 
8. Pharmacokinetic properties 41 1 (2.44%) -- 
9. Safety data 5 -- -- 
10. Evidence 2 -- -- 
11. Prescription data 3 -- -- 
Total 159 45 (28.30%) 16 (10.06%) 
 
By the end of the first round, 37 new items were suggested by 12 panel members, 
resulting in 26 new items being added after analysis and deletion of duplicates (Table 
07-03). Sixty-one additional comments from eleven participants were also received. 
Comments referred to different interpretations of the meaning of the items and 
considerations about the scores. The comments led to nine items being reworded and 
three deleted. For the second round, a document containing an explanation of the 
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items which originated more discussion and confusion was created. In conclusion, the 
pool of items for the second round consisted of 185 items. 
Table 07-03. New items added by members of the Delphi panel after the first round 
Section New item Description of the item (if given) 
1 Grindable tablet  Capability of being grinded for administration 
1 Divisibility of oral dosage form If tablet can be divided and if the scoring line 
enables production of equal doses after 
splitting 
1 Coating of oral dosage forms Information on eventual coating of oral 
dosage forms, (e.g. acid resistant) 
1 Brand name Commercial name of the medicinal product (if 
branded) 
1 Identification elements Number or letters appearing on the 
pharmaceutical form (pills or capsules) 
2 Instructions on how to prepare the medicinal 
product before administration 
(e.g. oral solutions for reconstitution, 
injectable forms) 
2 Use of the medicinal product among 
immunocompromised patients 
 
2 Information on duration of brewing (herbal 
medicines) 
If herbal medicinal products are used as a 
herbal drug (in the form of tea, filter-tea bags), 
the recommendation for duration of brewing 
2 Use during pre-pregnancy period Special precautions needed for the pre-
pregnancy period 
4 Separate description of Adverse Events from 
Adverse Reactions 
 
4 Referral to an open access ADR database 
(official such as FDA, EMEA, local authorities) 
including the latest information 
 
4 Inclusion of telephone numbers of 
pharmacovigilance agency 
 
4 Reminder to communicate ADRs to 
pharmacovigilance services 
 
4 How to communicate ADRs to 
pharmacovigilance services 
 
5 Interaction mechanism or link to section 
'pharmacokinetic properties' 
 
6 Link to literature/reference to published case 
reports of overdosing (accidentally or suicidal) 
 
6 Measured blood-/plasma-/serum- or urine 
concentration(s) in monitored cases of 
overdose 
 
6 Antidote: for drugs with a narrow therapeutic 
window, specific antidote (if it exists). 
 
7 Relationship between concentration (i.e., 
blood) and effect 
 
10 EMA/FDA risk management plan Description of the special conditions for using 
the medicinal product when a risk 
management plan exists 
10 Level of relevance/evidence related to 
comparators, if any 
 
10 Cost-effectiveness studies: description of 
these kind of studies 
 
11 Existence of another drug with the same 
active substance, even if it is not a generic 
drug 
 
11 Reimbursement data  
11 Existence of biosimilars  
11 Prescription conditions Specific conditions applicable to prescribers 
(OTC product, hospital use…) 
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Delphi second round 
The questionnaire for the second round (185 items) was sent in late December 2009 to 
41 members of the panel, 32 of which had participated in the first round, and nine 
others who accepted to participate but did not answer the questionnaire. Participants 
were sent an e-mail two weeks after sending the questionnaire reminding them to 
complete the questionnaire. Reception of answers closed on 31st January 2010. 
Twenty-seven participants completed the questionnaire and one member left the panel 
in the second round. Eight out of nine participants, who did not answer the first round, 
did not answer the second round either, and five participants who responded to the first 
round, did not complete the second. Members participating in the second round 
represented 18 countries: Austria, Belgium, Croatia, Denmark, Finland, France, 
Germany, Hungary, Lithuania, Malta, Netherlands, Portugal, Serbia, Slovenia, Spain, 
Sweden, Switzerland and UK (Figure 07-04). 
Fig 07-04. Map of countries answering in the second round 
 
Eighteen comments and two suggestions for new items from eight participants were 
received in the second round. After analysing the suggestions, one new item was 
added to the questionnaire (section 2): 
- Administration of parenteral drugs: clear instruction for administration (such as type of 
administration, duration of perfusion and frequency, incompatibilities) 
In the second round, consensus was reached in 69 items (48.94%) for the categorical 
question and in 31 items for the discrete-scoring question (18.34%). Data of 
accumulated consensus after the second round are displayed in Table 07-04. 
Appendices 07-04 and 07-05 present the frequencies of the scores for the categorical 
and discrete-scoring question. 
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Table 07-04. Accumulated consensus achieved after the second round (by groups of items)
Sections No. of valid items 
Categorical 
consensus (%) 
Discrete-scoring 
Consensus (%) 
1. Characteristics of the medicinal 
product 29 17 (58.6%) 7 (24.1%) 
2. Use of the medicinal product 35 30 (85.7%)  17 (48.6%) 
3. Contraindications  6 6 (100%) 3 (50.0%) 
4. Adverse reactions 27 15 (55.6%) 4 (14.8%) 
5. Interactions 11 8 (72.7%) 5 (45.5%) 
6. Overdose 6 4 (66.6%) 2 (33.3%) 
7. Pharmacodynamic properties  13 8 (61.5%) 4 (30.8%) 
8. Pharmacokinetic properties 41 21 (51.2%) 3 (7.3%) 
9. Safety data 5 2 (40.0%) ---- 
10. Evidence 5 1 (20.0%) 1 (20.0%) 
11. Prescription data 7 2 (28.6%) 1 (14.3%) 
Total 185 114 (61.62%) 47 (25.41%) 
 
Delphi third round and resulting instruments 
The third and final round was sent to participants between late March and April 2010. 
Participants were sent a reminder e-mail two weeks after sending the questionnaire. 
This questionnaire consisted of 186 items and was sent to 32 participants. Eight 
members were excluded from the panel since they did not participate either in the first 
round or in the second. Reception of answers closed on 20th May 2010. 
One member of the panel had changed the e-mail address, leading to a loss of contact. 
Twenty-nine participants from 18 countries completed the questionnaire in this third 
round: Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Hungary, 
Lithuania, Malta, Netherlands, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland 
and UK (Figure 07-05). 
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Fig 07-05. Map of countries answering in the third round 
 
 
In the third round, consensus was reached in 42 items (57.53%) for the categorical 
question, and 98 items for the non-categorical question (70.50%) (Please refer to Table 
07-05 for accumulated consensus data after the third round). Appendices 07-06 and 
07-07 present the frequencies of the scores for the categorical and discrete-scoring 
question. 
Table 07-05. Accumulated consensus achieved after the third round (by groups of items) 
Sections No. of valid items 
Categorical 
consensus (%) 
Discrete-scoring
consensus (%) 
1. Characteristics of the medicinal 
product 29 22 (75.86%) 19 (65.52%) 
2. Use of the medicinal product 36 34 (94.44%) 31 (86.11%) 
3. Contraindications  6 6 (100%) 6 (100%) 
4. Adverse reactions 27 20 (74.07%) 19 (70.37%) 
5. Interactions 11 10 (90.91%) 10 (90.91%) 
6. Overdose 6 6 (100%) 5 (83.33%) 
7. Pharmacodynamic properties  13 11 (84.62%) 11 (84.62%) 
8. Pharmacokinetic properties 41 37 (90.24%) 23 (56.10%) 
9. Safety data 5 3 (60.00%) 2 (40.00%) 
10. Evidence 5 2 (40.00%) 2 (40.00%) 
11. Prescription data 7 5 (71.43%) 2 (28.57%) 
Total 186 156 (83.87%) 130 (69.89%) 
 
After addition and deletion of items as suggested by panel members, the number of 
items in the questionnaire in each round changed as shown in Table 07-06. 
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Table 07-06. Evolution of number of items in each section during the rounds 
Section Round 1
No. of items 
Round 2
No. of items 
Round 3 
No. of items 
1. Characteristics of the medicinal product 24 29 29 
2. Use of the medicinal product 31 35 36 
3. Contraindications  6 6 6 
4. Adverse reactions 22 27 27 
5. Interactions 10 11 11 
6. Overdose 3 6 6 
7. Pharmacodynamic properties  12 13 13 
8. Pharmacokinetic properties 41 41 41 
9. Safety data 5 5 5 
10. Evidence 2 5 5 
11. Prescription data 3 7 7 
Total 159 185 186 
 
The members of the panel reached consensus in defining 126 items (67.74%) as 
essential items (minimal set of information) (Table 07-07).  
Table 07-07. Consensus list of essential items
Section 1. Characteristics of the medicinal product
101. Name of the holder of the marketing authorization 
105. Identification of the active substance 
106. Quantitative composition: the quantity of the active substance, expressed per dosage unit. 
107. Excipients (qualitative description) 
111. Pharmaceutical form 
112. Visual description of the product 
114. Expiry period 
115. Special precautions for storage 
117. Shelf-life after dilution or reconstitution according to instructions given 
118. Shelf-life after first opening the container 
121. Pharmacotherapeutic group (ATC code) 
125. Grindable tablet 
126. Divisibility of oral dosage form 
127. Coating of oral dosage forms 
128. Brand name 
129. Identification elements 
Section 2. Use of the medicinal product
201. Therapeutic indications 
202. Treatment algorithm 
203. Target population 
204. Instructions for correct administration/use 
205. Posology/Dosing 
206. Statement of the therapeutic window 
207.  Maximum recommended single dose 
208. Maximum recommended daily dose 
209. Maximum recommended total dose 
210. The need for dose titration or not 
211. Need for tapering off  
212. Dosage individualization based on disease/severity being treated 
213. Dosage adjustment in renal impairment 
214. Categories of renal impairment related to the dose or interval adjustment 
215. Dosage adjustment in liver disease 
216. Dosage adjustment in other concomitant diseases 
217. Dosage adjustment related to interactions 
218. Normal duration of treatment 
219. Restrictions on duration 
220. What to do if a dose is missed  
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Table 07-07. Consensus list of essential items
221. Implications of non-compliance, intermittent dosing 
222. Influence of food with the intake of the product 
223. Use in the paediatric population  
224. Use in the elderly  
225. Use during pregnancy 
226. Recommendations on the use of the product at different times during pregnancy in respect to 
gestation 
227. Use during lactation 
228. Influence on fertility 
229. Influence on the ability to drive and use machines 
232. Instructions on how to prepare the medicinal product before administration (e.g. oral solutions for 
reconstitution, injectable forms)  
233. Use of the medicinal product among immunocompromised patients 
234. Information of duration of brewing (herbal medicines) 
235. Use during the pre-pregnancy period 
236. Administration of parenteral drugs: clear instruction for administration (type of administration, duration 
of perfusion and frequency, incompatibilities) 
Section 3. Contraindications
301. Contraindications (disease) 
302. Contraindications (concomitant drug use) 
303. Contraindications (hypersensitivity reactions) 
304. Contraindications (Patient populations not studied in the clinical trials) 
305. Contraindications (Patient populations likely to experience product or class related adverse reactions 
occurring under normal conditions of use) 
306. Steps to take if the contraindicated drug is administered 
Section 4. Adverse reactions
402. Description of only the MOST FREQUENT adverse reactions  
403. Serious adverse reactions to which the healthcare professional should be alert 
405. Circumstances under which patients are at risk of experiencing specified adverse reactions 
406. Relationship between dose and adverse reactions 
407. The action to take in case those serious adverse reactions related to the treatment appear 
408. Warning about adverse reactions related to the excipients (even traces) 
409. Statement of the need to monitor for specific asymptomatic drug reactions (lab tests) 
410. Instructions on how frequently asymptomatic reactions should be monitored (lab tests) 
413. Assessment of severity of adverse reactions 
414. Assessment of frequency of adverse reactions 
415. Inclusion of a table of adverse reactions according to a standard system organ class 
417. Time of onset of adverse reactions 
418. Particular risks on initiating the treatment, such as first dose effects 
419. Particular risks associated with stopping the treatment 
420. Measures to be taken to avoid specific adverse reactions 
422. Reversibility of adverse reactions 
Section 5. Interactions
501. Clinically relevant drug interactions that affect  the effects of the described medicine in the organism  
502. Clinically relevant drug interactions produced by the described medicine and affecting the other 
medicinal products 
503. Interacting medicinal products are listed by drug class 
504. Interacting medicinal products are listed as specific compounds 
505. Description of the severity of the drug interaction 
506. Description of the effect of the drug interaction 
507. Food interactions 
508. Interactions with alcohol 
509. Clinical manifestations and effects on laboratory tests 
510. Effects on the results of lab tests not associated to physiological alterations (potential false positives) 
Section 6. Overdose
601. Description of symptoms and signs of overdose of the medicinal product 
602. Management of overdose 
603. Potential sequelae of overdose 
606. Antidote: for drugs with a narrow therapeutic window, specific antidote (if exists) 
Section 7. Pharmacodynamic properties
701. Description of the mechanism of action of the medicinal product 
702. Identification of main effects on the organism  
703. Efficacy data 
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705. Time to onset of effect (with minimal and maximal time) 
706. Time to peak effect (with minimal and maximal time) 
707. Duration of action/effect with minimal and maximal time 
712. Relationship between dose and effect 
713. Pharmacogenomic alterations on pharmacodynamics 
714. Relationship between concentration (i.e., blood) and effect 
Section 8. Pharmacokinetic properties
801. Absorption 
802. Bioavailability: absolute and/or relative bioavailability 
803. Systemic bioavailability for locally applied medicinal products 
804. Time to peak concentration (Tmax) 
806. Influence of  absorption by food 
812. Blood-brain barrier penetration 
813. Placental barrier penetration 
815. Distribution to milk 
818. Minimal effective plasma concentration  
819. Toxic plasma concentration 
821. Identification of the route/mechanism of metabolism 
822. Enzymes involved in metabolism (including P450 isoenzymes)  
823. Degree of metabolism 
825. Activity of metabolites 
826. What is the contribution of the metabolites (if any) to the effect 
828. List of factors known to increase or decrease metabolism 
829. Induction or inhibition of metabolic enzymes from the medicinal product 
830. Site of metabolism 
831. Elimination half lives 
832. Identification of factors increasing and decreasing half-life 
835. Excretion routes of the unchanged substance 
836. Excretion routes of the metabolites 
838. Variation of pharmacokinetics with respect to characteristics of patients: age, gender, smoking status, 
etc 
840. Variation of pharmacokinetics with respect to pathological situations such as renal impairment, 
hepatic insufficiency, etc 
Section 9. Preclinical safety data
903. Genotoxicity 
904. Carcinogenic potencial 
905. Toxicity to reproduction 
Section 10. Evidence
1001. Level of evidence 
1002. Clinical trials 
Section 11. Prescription data
1104. Includes patient counselling information 
1108 Prescription conditions: specific conditions applicable to prescribers (OTC product, hospital use…) 
 
The members of the panel reached consensus in defining 30 items (16.13%) as non- 
essential items (not to include as minimal set of information) (Table 07-08). 
Table 07-08. Consensus list of non-essential items
Section 1. Characteristics of the medicinal product
108. Excipients (quantitative description) 
110. Residues that may be present from the manufacturing process (expressed quantitatively) 
116. Hygroscopicity of the active substance 
119. Dissolution test of the product 
120. Manufacturing process of the product 
123. Marketing authorization numbers 
Section 4. Adverse reactions
401. Description of ALL adverse reactions attributed to the medicinal product 
404. Mechanism of action of adverse reactions 
423. Preclinical safety data 
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424. Separate description of Adverse Events from Adverse Reactions 
Section 6. Overdose
604. Link to literature/reference to published case reports of overdosing (accidentally or suicidal) 
605. Measured blood-/plasma-/serum- or urine concentration(s) in monitored cases of overdose 
Section 7. Pharmacodynamic properties
708. Graphical display visualising the mechanism of action 
711. Chirality 
Section 8. Pharmacokinetic properties
805. Variability and modifying factors of time to peak concentration 
807. Graphical display of concentration trajectory and variability 
808. Pharmacokinetic model and model parameters 
809. PK/PD dose response or hysteresis loop 
811. Volume of distribution: in L/Kg or absolute values in L 
816. Tissue concentration 
817. Plasma concentration (interval) 
820. Statement of one-compartment kinetics behaviour or deviation from it 
827. Pharmacokinetics of principal metabolite(s) 
834. Inter- and/or intra-subject variability in total clearance 
837. Linearity/non-linearity of the pharmacokinetics of the medicinal product with respect to dose and/or 
time 
839. Variation of pharmacokinetics with respect to polymorphic metabolism 
841. In vivo pharmacokinetic studies of the medicinal product 
Section 11. Prescription data
1105. Existence of another drug of the same active substance, even if it is not a generic drug 
1106. Reimbursement Data 
1107. Existence of biosimilars/bioidenticals 
 
The analysis of consensus scores for the categorical question in each section is 
presented in Table 07-09. 
Table 07-09.  Percentage of essential and non-essential items analysed by sections 
Section % of Essential items % of Non-essential items 
1. Characteristics of the medicinal product 55.17% 20.69% 
2. Use of the medicinal product 94.44% --- 
3. Contraindications 100% --- 
4. Adverse reactions 59.26% 14.81% 
5. Interactions 90.91% --- 
6. Overdose 66.66% 33.33% 
7. Pharmacodynamic properties 69.23% 15.38% 
8. Pharmacokinetic properties 58.54% 31.71% 
9. Preclinical safety data 60.00% --- 
10. Evidence 40.00% --- 
11. Prescription data 28.57% 27.27% 
 
The consensus score values defining the importance of the following items of 
information in drug information sources for healthcare professionals are displayed in 
Table 07-10: 
Table 07-10. Consensus scores of items
Section 1. Characteristics of the medicinal product Score
101. Name of the holder of the marketing authorization 10 
102. Address of the holder of the marketing authorization 5 
103. Telephone of the holder of the marketing authorization 5 
104. Contact to the medical department of the holder of the marketing authorization 5 
105. Identification of the active substance 10 
106. Quantitative composition: the quantity of the active substance, expressed per dosage unit 10 
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107. Excipients (qualitative description) 10 
111. Pharmaceutical form 10 
112. Visual description of the product 7 
115. Special precautions for storage 10 
116. Hygroscopicity of the active substance 4 
117. Shelf-life after dilution or reconstitution according to instructions given 10 
118. Shelf-life after first opening the container 9 
119. Dissolution test of the product 2 
120. Manufacturing process of the product 1 
121. Pharmacotherapeutic group (ATC code) 10 
122. Type of marketing authorization  4 
127. Coating of oral dosage forms 7 
128. Brand name 10 
Section 2. Use of the medicinal product Score
201. Therapeutic indications 10 
202. Treatment algorithm 8 
203. Target population 9 
204. Instructions for correct administration/use 10 
205. Posology/Dosing 10 
206. Statement of the therapeutic window 7 
207.  Maximum recommended single dose 10 
208. Maximum recommended daily dose 10 
209. Maximum recommended total dose 10 
211. Need for tapering off  9 
212. Dosage individualization based on disease/severity being treated 8 
213. Dosage adjustment in renal impairment 10 
214. Categories of renal impairment related to the dose or interval adjustment 8 
215. Dosage adjustment in liver disease 9 
217. Dosage adjustment related to interactions 8 
218. Normal duration of treatment 8 
219. Restrictions on duration 8 
220. What to do if a dose is missed  9 
221. Implications of non-compliance, intermittent dosing 7 
222. Influence of food with the intake of the product 9 
223. Use in the paediatric population  10 
224. Use in the elderly  10 
225. Use during pregnancy 10 
226. Recommendations on the use of the product at different times during pregnancy in respect 
to gestation 10 
227. Use during lactation 10 
229. Influence on the ability to drive and use machines 10 
230. Comparison of risks and benefits with drugs in the same class 8 
231. Comparison of risks and benefits with other drugs for the same condition 8 
232. Instructions on how to prepare the medicinal product before administration (e.g. oral 
solutions for reconstitution, injectable forms)  10 
233. Use of the medicinal product among immunocompromised patients 7 
234. Information of duration of brewing (herbal medicines) 7 
235. Use during pre-pregnancy period 8 
Section 3. Contraindications Score
301. Contraindications (disease) 10 
302. Contraindications (concommitant drug use) 10 
303. Contraindications (hypersensitivity reactions) 10 
304. Contraindications (patient populations not studied in the clinical trials) 8 
305. Contraindications (patient populations likely to experience product or class related adverse 
reactions occurring under normal conditions of use) 9 
306. Steps to take if the contraindicated drug is administered 9 
Section 4. Adverse reactions Score
402. Description of only the MOST FREQUENT adverse reactions  10 
403. Serious adverse reactions to which the healthcare professional should be alert 10 
405. Circumstances under which patients are at risk of experiencing specified adverse reactions 8 
406. Relationship between dose and adverse reactions 8 
407. Action to take in case those serious adverse reactions related to the treatment appear 10 
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408. Warning about the adverse reactions related to the excipients (even traces) 7 
409. Statement of the need to monitor for specific asymptomatic drug reactions (lab tests) 8 
410. Instructions of how frequently asymptomatic reactions should be monitored (lab tests) 8 
411. Instructions on how to respond to monitoring values of asymptomatic drug reactions (lab 
tests) 6 
412. Assessment of causality of adverse reactions 7 
413. Assessment of severity of adverse reactions 8 
414. Assessment of frequency of adverse reactions 8 
415. Inclusion of a table of adverse reactions according to a standard system organ class 7 
417. Time of onset of adverse reactions 8 
418. Particular risks on initiating the treatment, such as first dose effects 8 
419. Particular risks associated with stopping the treatment 8 
420. Measures to be taken to avoid specific adverse reactions 8 
422. Reversibility of adverse reactions 7 
426. Inclusion of telephone numbers of the pharmacovigilance agency 5 
Section 5. Interactions Score
501. Clinically relevant drug interactions that affect  the effects of the described medicine in the 
organism  10 
502. Clinically relevant drug interactions produced by the described medicine and affecting the 
other medicinal products 10 
503. Interacting medicinal products are listed by drug class 8 
504. Interacting medicinal products are listed as specific compounds 8 
505. Description of the severity of the drug interaction 8 
506. Description of the effect of the drug interaction 8 
507. Food interactions 10 
508. Interactions with alcohol 10 
509. Clinical manifestations and effects on laboratory tests 8 
510. Effects on the results of lab tests not associated to physiological alterations (potential false 
positives) 7 
Section 6. Overdose Score
601. Description of symptoms and signs of overdose of the medicinal product 10 
602. Management of overdose 10 
603. Potential sequelae of overdose 8 
605. Measured blood-/plasma-/serum- or urine concentration(s) in monitored cases of overdose 5 
606. Antidote: for drugs with a narrow therapeutic window, specific antidote (if exists) 10 
Section 7. Pharmacodynamic properties Score
701. Description of the mechanism of action of the medicinal product 10 
702. Identification of main effects on the organism  9 
703. Efficacy data 8 
705. Time to onset of effect (with minimal and maximal time) 8 
706. Time to peak effect (with minimal and maximal time) 8 
707. Duration of action/effect with minimal and maximal time 8 
709. Evidence for tachyphylaxis/tolerance and maximum dose 6 
710. Pro-drug: information about whether the medicinal product is a pro-drug or not 5 
712. Relationship between dose and effect 8 
713. Pharmacogenomic alterations on pharmacodynamics 7 
714. Relationship between concentration (ie, blood) and effect 7 
Section 8. Pharmacokinetic properties Score
801. Absorption 8 
802. Bioavailability: absolute and/or relative bioavailability 8 
803. Systemic bioavailability for locally applied medicinal products 8 
804. Time to peak concentration (Tmax) 8 
806. Influence of the absorption by food 8 
810. Plasma protein binding: expressed in % 7 
812. Blood-brain barrier penetration 8 
813. Placental barrier penetration 8 
814. Distribution to cerebrospinal fluid 6 
815. Distribution to milk 8 
818. Minimal effective plasma concentration  7 
819. Toxic plasma concentration 8 
822. Enzymes involved in metabolism (including P450 isoenzymes)  8 
829. Induction or inhibition of metabolic enzymes from the medicinal product 8 
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830. Site of metabolism 8 
831. Elimination half lives 9 
832. Identification of factors increasing and decreasing half-life 8 
835. Excretion routes of the unchanged substance 8 
836. Excretion routes of the metabolites 7 
838. Variation of pharmacokinetics with respect to characteristics of patients: age, gender, 
smoking status, etc 8 
839. Variation of pharmacokinetics with respect to polymorphic metabolism 6 
840. Variation of pharmacokinetics with respect to pathological situations such as renal 
impairment, hepatic insufficiency, etc 8 
841. In vivo pharmacokinetic studies of the medicinal product 5 
Section 9. Preclinical safety data Score
902. Repeated dose toxicity 5 
905. Toxicity to reproduction 9 
Section 10. Evidence Score
1001. Level of evidence 10 
1002. Clinical trials 8 
Section 11. Prescription data Score
1104. Includes patient counselling information 10 
1108 Prescription conditions: specific conditions applicable to prescribers (OTC product, hospital 
use…) 
7 
  
Sensitivity Analysis 
The influence of consensus criteria on the number of items achieving consensus for the 
categorical question is presented in Tables 07-11 to 07-13.  
Table 07-11: Results of categorical question in the first round using different consensus criteria
Section Number of 
items 
Items achieving consensus at different consensus 
criteria* 
95% 90% 85% 80% 75% 70% 
1. Characteristics of the 
medicinal product 24 
5 9 10 10 10 10 
2. Use of the medicinal product 31 13 20 24 26 26 27 
3. Contraindications  6 2 3 5 6 6 6 
4. Adverse reactions 22 1 3 8 12 12 16 
5. Interactions 10 1 4 6 8 8 9 
6. Overdose 3 1 2 2 3 3 3 
7. Pharmacodynamic properties  12 0 3 6 7 7 7 
8. Pharmacokinetic properties 41 0 1 4 14 14 23 
9. Safety data 5 0 0 0 2 2 2 
10. Evidence 2 0 0 1 1 1 1 
11. Prescription data 3 0 0 1 1 1 1 
Bold represents the consensus criteria which was selected by the research team in the first round 
*Percentage of participants agreeing in the answer (either yes or no) 
 
Table 07-12: Results of categorical question in the second round using different consensus criteria
Section Number of items Items achieving consensus at 
different consensus criteria* 
95% 90% 85% 80% 75% 70% 
1. Characteristics of the medicinal 
product 29 
4 13 17 17 17 17 
2. Use of the medicinal product 35 16 24 30 30 30 32 
3. Contraindications  6 2 4 5 6 6 6 
4. Adverse reactions 27 2 7 11 15 15 18 
5. Interactions 11 2 6 7 8 8 9 
6. Overdose 6 2 3 3 4 4 4 
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7. Pharmacodynamic properties  13 1 5 8 8 9 10 
8. Pharmacokinetic properties 41 1 6 20 21 26 27 
9. Safety data 5 0 0 2 2 2 3 
10. Evidence 5 0 0 1 1 1 1 
11. Prescription data 7 0 0 1 2 2 2 
Bold represents the consensus criteria which was selected by the research team in the second round 
*Percentage of participants agreeing in the answer (either yes or no) 
 
Table 07-13: Results of categorical questions in the third round using different consensus criteria
Section Number of items Items achieving consensus at different 
consensus criteria* 
95% 90% 85% 80% 75% 70% 
1. Characteristics of the medicinal 
product 29 
5 13 20 21 22 22 
2. Use of the medicinal product 36 17 25 32 33 34 35 
3. Contraindications  6 2 4 5 6 6 6 
4. Adverse reactions 27 3 8 14 18 20 21 
5. Interactions 11 2 6 7 10 10 10 
6. Overdose 6 2 3 3 5 6 6 
7. Pharmacodynamic properties  13 1 5 10 10 11 11 
8. Pharmacokinetic properties 41 1 6 30 33 37 37 
9. Safety data 5 0 0 3 3 3 3 
10. Evidence 5 0 0 2 2 2 3 
11. Prescription data 7 0 0 1 3 5 5 
Bold represents the consensus criteria which was selected by the research team in the third round 
*Percentage of participants agreeing in the answer (either yes or no) 
 
The influence of consensus criteria on the number of items achieving consensus for the 
discrete-scoring question is presented in Tables 07-14 to 07-16. 
Table 07-14: Results of the discrete-scoring question in the first round using different consensus 
criteria 
Section Number of items 
Items achieving consensus at different consensus 
criteria* 
95/85 90/80 85/75 80/70 75/65 70/60 65/55 
1. Characteristics of the 
medicinal product 24 2 2 4 4 4 5 6 
2. Use of the medicinal 
product 31 3 3 4 4 6 8 12 
3. Contraindications  6 1 1 2 2 3 3 3 
4. Adverse reactions 22 0 1 2 2 2 2 7 
5. Interactions 10 0 1 2 2 2 2 2 
6. Overdose 3 0 0 0 2 2 2 2 
7. Pharmacodynamic 
properties  12 0 0 0 0 0 1 1 
8. Pharmacokinetic 
properties 41 0 0 0 0 0 0 0 
9. Safety data 5 0 0 0 0 0 0 1 
10. Evidence 2 0 0 0 0 0 1 1 
11. Prescription data 3 0 0 0 0 0 1 1 
Bold represents the consensus which was used by the research team in the first round 
*Percentage of participants scoring the mode plus the two adjacent values (please refer to methods: 
‘establishing consensus requirements’) 
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Table 07-15: Results of discrete scoring question in the second round using different consensus 
criteria 
Section Number of items 
Items achieving consensus at different consensus 
criteria* 
95/85 90/80 85/75 80/70 75/65 70/60 65/55 
1. Characteristics of the 
medicinal product 29 2 2 5 6 6 7 10 
2. Use of the medicinal 
product 35 5 7 11 14 16 17 19 
3. Contraindications  6 2 2 3 3 3 3 5 
4. Adverse reactions 27 0 2 2 4 4 4 11 
5. Interactions 11 0 1 2 4 4 5 6 
6. Overdose 6 0 0 0 2 2 2 2 
7. Pharmacodynamic 
properties  13 0 1 1 1 1 4 6 
8. Pharmacokinetic 
properties 41 0 0 0 0 0 2 6 
9. Safety data 5 0 0 0 0 0 0 1 
10. Evidence 5 0 0 0 0 1 1 1 
11. Prescription data 7 0 0 0 0 1 1 1 
Bold represents the consensus which was used by the research team in the second round 
*Percentage of participants scoring the mode plus the two adjacent values (please refer to methods: 
‘establishing consensus requirements’) 
 
Table 07-16: Results of discrete scoring question in the third round using different consensus 
criteria 
Section Number of 
items 
Items achieving consensus at different consensus 
criteria* 
95/85 90/80 85/75 80/70 75/65 70/60 65/55 
1. Characteristics of the 
medicinal product 29 3 5 7 9 14 19 21 
2. Use of the medicinal 
product 36 5 11 15 21 26 31 35 
3. Contraindications  6 2 2 4 6 6 6 6 
4. Adverse reactions 27 0 3 6 10 14 19 23 
5. Interactions 11 0 1 2 6 6 10 11 
6. Overdose 6 0 0 1 4 5 5 6 
7. Pharmacodynamic 
properties  13 0 1 1 4 7 11 11 
8. Pharmacokinetic 
properties 41 0 0 1 3 12 23 30 
9. Safety data 5 0 0 0 0 1 2 3 
10. Evidence 5 0 0 0 0 2 2 2 
11. Prescription data 7 0 0 1 1 2 2 2 
Bold represents the consensus which was used by the research team in the third round 
*Percentage of participants scoring the mode plus the two adjacent values (please refer to methods: 
‘establishing consensus requirements’) 
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Discussion 
Method used 
The Delphi technique is a method used to explore the attitudes, needs and priorities of 
a group of experts on a specific subject.(35) This technique is ideal for international 
research and cooperation as it allows the inexpensive recruitment of a group of experts 
without geographical limitations.(39) Not only does this technique enable the collection 
of data from diverse geographical locations, but it also easily reaches participants from 
different areas of expertise and professional experiences.(35)  
The classic Delphi method consists of four rounds, however recent evidence showed 
that two or three rounds are preferred.(36) Three rounds are usually sufficient to 
achieve consensus, the largest adjustments occurring between rounds one and 
two.(39) In addition, maintaining a high response rate in a Delphi study with several 
rounds is very difficult.(35) 
The most frequently used statistical methods in a Delphi technique are measures of 
central tendency (mean, median and mode). The use of median and mode is generally 
preferred(40), although sometimes the literature recommends the use of median 
scores for Likert scales.(40) Ludwig specifically considers that “a Delphi process has a 
tendency to create convergence, and though this is usually to a single point, there is 
the possibility of polarization or clustering of the results around two or more points. In 
these instances the mean or median could be misleading”.(44) In this study, the mode 
was the statistical measure used, in order to avoid the influence of polarised score 
distributions, since answers were based on a ten-point Likert scale. 
Participation rates in our study were satisfactory, and consensus was reached in both 
questions (categorical and discrete-scoring) for a great majority of items (83.87% for 
the categorical question, and 69.89% for the discrete-scoring question).  
Minimal set of information (essential items) 
When analysing the information needs of healthcare professionals, we aimed at 
defining the minimal set of information needed by these professionals in clinical 
practice. The minimal set of information should comprise the essential items to be 
included in any source of information, regardless of its size (SmPCs, product 
monographs, monographs in drug reference books, drug web pages, etc.).  
The content of this minimal set of information was analysed through the perspective of 
healthcare professionals and academics participating in the Delphi study. When 
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analysing the responses of the panel members, a clear tendency from participants to 
consider most items as essential was shown. These results suggest that healthcare 
professionals and academics tend to consider that ‘the more the drug information 
contained in a given source, the better the source is’. After using an extensive list of 
information items, only 16.13% were considered ‘not essential’. Other authors have 
faced a similar situation, Strang et al. defined as essential for healthcare professionals 
87.1% of the items evaluated in their analysis.(31) 
Some authors have previously analysed the performance of healthcare professionals 
when seeking information and the kind of information that is mostly retrieved by these 
professionals. According to Ely et al., the drug information topic most frequently 
searched for by family physicians is drug dose, being this the only question that 
physicians routinely pursue.(45) Similarly, the most frequent topics of information 
searched for by community pharmacists are adverse effects, dosage and 
administration, drug interactions, and pharmacotherapy.(46) Other authors have 
already pointed out that the most common enquiries categories from healthcare 
professionals are indications and contraindications, dose and administration, adverse 
reactions and interactions.(47) 
It appears that information needs identified in previous studies were coincident with the 
subsections with higher percentage of items to be included in the minimal set of 
information in our study. When analysing the results of the categorical question per 
section, the percentage of essential items identified in each section ranged from 28.6% 
to 100% (please refer to Table 07-09). In the ‘contraindications’ section, 100% of items 
were considered essential. In other sections such as ‘use of the medicinal product’ or 
‘interactions’ more than 90% of items were described as essential. 
The need for practical information about the use of a drug, its contraindications and 
interactions is also strongly linked to patient care. By definition, retrieval of information 
is generated by a need or awareness of a gap in knowledge that demands an answer 
to carry out patient care and professional duties.(48) Other authors have previously 
demonstrated a relationship between the information mostly needed by healthcare 
professionals and the use of drugs in specific patients, since information in clinical 
practice is mainly sought while patients wait.(49) Not only is the need of information 
generated by patient visits, some authors also argue that 60% of questions are simple 
questions related to the use of a drug.(50) Similarly, other authors have shown that 
81% of the information requested by healthcare professionals from a drug information 
centre is used for managing a specific patient.(47)  
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Bastholm et al. concluded that information systems for physicians should indicate 
whether a drug is appropriate for the patient and what effects can be expected with the 
use of a drug, deliver dose suggestions and up-to-date drug recommendations and 
indicate whether there are other preferable drugs for the patient. It should also prevent 
prescribing mistakes using an alert system, warn about interactions (even linking them 
to laboratory tests data and diagnoses), provide pharmacological knowledge and aid 
decision-making.(51) 
A study similar to ours, in which a Delphi panel was used to assess the information 
provided by the pharmaceutical representatives, was published by Strang et al. (31) 
These authors analysed how much information physicians needed to prescribe a drug 
appropriately, and described 31 items to be rated using a seven-point Likert scale 
(never include, rarely include, may omit, include if time permits, always include some 
information, always include considerable information and always include all available 
information). This scoring system evaluated which information should be included in 
the drug-detailing process, where pharmaceutical representatives provide healthcare 
professionals with face-to-face information about a drug.(31) From the 31 items 
analysed by Strang et al, 28 were present in our study. The three items not included in 
our study were: 
 ‘Drug endorsed by local colleagues’: we considered that point was not 
appropriate for a drug information source other than a pharmaceutical 
representative. 
 ‘Indications not approved in Canada’ and ‘other countries where the drug is 
licensed’: they were not considered in our study since we are aiming to create a 
universal tool, not restricted to a single country. 
 ‘Time remaining on patent’: we used the more specific item ‘existence of a 
generic drug of the same active substance’ instead. 
In Strang’s study, 26 out of 31 items (83.9%) described the information that should 
always be included: eleven were rated as ‘always include all available information’, 
eight as ‘always include considerable information’, and seven as ‘always include some 
information’. Moreover, the authors considered that the essential information should 
also contain the items rated as ‘include if time permits’, and even added one more item 
to the essential-item list rated as ‘may omit’ due to the statistically significant 
disagreement between medical specialties. The final list of essential items contained 
27 items (87.1%).  
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In our study, 126 items (67.7%) were identified as essential items by the panel 
members. The difference between these two percentages may arise from the 
difference in the number of items in the checklist, as it differs from 186 in the present 
study to 31 in the study by Strang et al. 
The items considered essential in the study by Strang et al. differ from those in our 
study, as shown below: 
 The item ‘cost to patient and/or drug plan’ which was rated as ‘always 
include considerable information’ in Strang’s research, did not reach 
consensus in our study (only 58.6% of participants considered it was 
essential);  
 The item ‘reimbursement data’ was classified as ‘always include some 
information’ in Strang’s study. In the present study it was agreed as a non-
essential item; 
 ‘Comparison of risks and benefits with drugs in the same class’ was 
classified as ‘always include considerable information’ in Strang’s study, 
whereas in our study it did not reach consensus as essential item (only 
67.9% of participants considered it was essential);  
 ‘Comparison of risks and benefits with drugs for the same condition’ was 
classified as ‘always include considerable information’ in Strang’s study, 
while in our study it did not reach consensus as essential item (only 71.4% 
of participants considered it was essential);  
 ‘Availability of patient teaching aids’ was rated as ‘may omit’ in Strang’s 
study and classified as essential in our study. However, Strang added this 
item to the list of essential items to be included in the ideal drug detail, 
because of the statistically significant disagreement between medical 
specialties. 
In the final results of Strang et al., four items (12.90%) were not included in the list of 
the ideal drug detail, as participants reached consensus in stating that they could or 
should be omitted. In our study, 30 items (16.13%) were defined as non-essential by 
panel members.  
Spyker et al. also analysed the completeness of drug information sources from a 
clinical pharmacology perspective. The ‘Clinical Pharmacology Core Information’ was 
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defined by 25 items of information, all of them included in our checklist. However, for 
four of them, the Delphi panel did not reach consensus to classify them as a minimal 
set of information. The items not reaching consensus were: evidence for 
tachyphylaxis/tolerance, metabolites of the drug, degree of plasma protein binding, and 
total clearance. Additionally, for two items which were part of Spyker’s ‘Clinical 
Pharmacology Core information’, the Delphi panel in our study reached consensus to 
define them as non-minimal information. These items were the ‘volume of distribution’ 
and ‘statement of one-compartment kinetics behaviour or deviation from it’. These 
differences may be explained by the different objectives of the studies: Spyker et al. 
focused on clinical pharmacology information, while we analysed drug information for 
healthcare professionals in general. 
Regarding the sensitivity analysis performed in the present study, it is important to 
remember that our consensus criteria were established based on a progressive filtering 
process, using higher consensus requirements in the first round and then reducing 
these requirements in subsequent rounds. In the first round, consensus was defined at 
≥90% agreement. For the first round, consensus was purposely very restrictive (using 
higher consensus rates, e.g. ≥95%, would not have been very realistic) and thus, only 
strongly agreed items were accepted. However, even if we had used less restrictive 
consensus criteria, that would not have affected the results greatly (please refer to 
Table 07-11). Changes would have been major only for three out of the 11 sections: 
‘contraindications’, ‘pharmacodynamic properties’ and ‘pharmacokinetic properties’. In 
the second round, consensus was established at ≥80% agreement. Increasing or 
reducing consensus criteria would not have changed the results very much (please 
refer to Table 07-12). Finally, in the third round, at a ≥75% consensus value, 
participants reached satisfactory agreement. If higher consensus rates had been used, 
there would have been only slight differences throughout the sections, the section 
‘pharmacokinetic properties’ being the one with greater changes (from 33 agreed items 
at a 80% consensus rate to 37 agreed items at a 75% consensus rate) (please refer to 
Table 07-13). Reducing the consensus rate to 70% would not change the scenario 
greatly (only three out of the 11 sections would have changed slightly).  
In a nutshell, the list of essential items obtained from the Delphi process will help us 
define which items of information are needed in any kind of drug information source for 
healthcare professionals. This allows us to assess the compliance of an information 
source with the minimal content requirements, but also to design more efficient 
abridged information sources by avoiding excessive information. 
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Completeness scoring tool 
This study also aimed at designing a general tool to analyse the completeness of any 
kind of drug information source.  
Completeness has been defined as the capacity of being complete, balanced, and thus 
updated.(6) This “fair balance” of information has also been highlighted by Greene et 
al. when focusing on information about the risks and benefits of a drug.(7) When this 
balance is not achieved, the information may lead to misuse of drugs, with “dangerous 
consequences”.(7)  
The consensus criteria used to create the completeness scoring tool were also based 
on a progressive filtering process. In the first round, consensus was defined at ≥80% of 
the respondents falling within one point on either side of the modal response, and 
≥70% when the mode fell at the extremes of the ten-point scale (zero or ten). Using 
higher consensus criteria would not change the results very much (please refer to 
Table 07-14). In the second round, consensus was defined at ≥70% of the respondents 
falling within one point on either side of the modal response, and ≥60% when the mode 
fell at the extremes of the ten-point scale. A higher consensus criterion was considered 
very restrictive, which would in turn lead to slight differences in sections such as 
‘pharmacodynamic properties’ or ‘pharmacokinetic properties’ (please refer to Table 
07-15). If we had selected less restrictive consensus criteria, eight out of the 11 
sections would have changed moderately, however, some of them such as section four 
(‘adverse reactions’) would have shown a considerable increase in the number of items 
achieving consensus (please refer to Table 07-15). In the last round, consensus criteria 
were the same as in round two. Less restrictive consensus criteria would have changed 
the results, and a greater consensus would have been reached, especially in the 
section ‘pharmacodynamic properties’ (please refer to Table 07-16). Four out of the 
eight sections would not have changed at all. For the other four sections, a total of 20 
items would have been accepted as consensus items (10.75% of the total 186 items). 
However, the consensus of 70%-60% was established as criterion, considering the 
most commonly used criteria in scientific literature.(39) The created tool is defined as 
general, indicating that it is applicable to any information source and any kind of 
medicinal product. As previously mentioned, other authors aimed at assessing specific 
aspects of drug information for healthcare professionals in different sources.(17-26) 
These previous studies differ from ours in that they aim to assess completeness 
regarding specific aspects of drug information (adverse reactions, interactions, 
overdose, etc), focusing on specific drug classes or on specific drug information 
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sources. Conversely, the present study aims to design a tool to analyse completeness 
of drug information, with the following main characteristics: 
 Applicable to any medicinal product regardless of its indications, route of 
administration, pharmaceutical form, etc. 
 Applicable to any kind of drug information source, regardless of its size, origin, 
format, etc. 
 Covering all aspects of drug information: pharmaceutical information, clinical 
information, and administrative and marketing data. 
The following equation allows researchers to measure the completeness of a drug 
information source using a continuous variable, expressed in a percentage of the ideal 
source (which scores the maximum possible points). 
Completeness (%) = Total score for the analysed source of information x 100 
                                                       Total score of the ideal source 
When using this equation, all items of information should be reviewed in the analysed 
source, in order to assess whether information about these items is present. The 
consensus scores of all the items present in the analysed source will be added up to 
obtain the total score for the analysed source of information. However, it is important to 
bear in mind that some items may not be applicable for a specific drug. Thus, the score 
of these non-applicable items should not be added to the total score of the ideal 
source. 
For example, for a medicinal product in which all the 186 items presented in the tool 
are applicable, the total score of the ideal source of information would be the sum of all 
the scores of those 186 items. However, in most cases, not all 186 items will be 
applicable. For instance, item number 803 - ‘systemic bioavailability for locally applied 
medicinal products’ -, will only be applicable to topical drugs. Therefore its eight points 
should not be added up to the ‘total score of the ideal source’ if the medicinal product 
analysed has another administration route.  
Including such an extensive amount of items and some of them being so specific, is 
one of the strengths of this tool, as it allows as many aspects of the information as 
possible to be analysed, including the most specific ones. 
Moreover, another of the advantages of this tool is that, as completeness is calculated 
as a percentage of the ideal source, and only the applicable items are considered in 
the total possible points, the tool allows different sources of information for a specific 
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drug to be compared, and, obviously and more importantly, researchers can use this 
percentage of completeness to compare information sources of different drugs. 
Comparing the completeness of different sources of information using one general tool 
is a challenging task. The results of this analysis may help healthcare professionals 
recognize the most complete information sources and contribute to the improvement of 
information sources regarding completeness. 
One of the utilities of the resulting tool may be the analysis of the completeness of 
sources such as SmPCs. The SmPC is defined as “the basis of information for 
healthcare professionals on how to use the medicinal product safely and 
effectively”.(52) However, European Union legislation has not defined a more complete 
official drug information source for healthcare professionals, which makes SmPCs the 
unique official drug information source. Thus, the analysis of completeness of SmPCs 
is paramount. 
Product monographs, produced by the pharmaceutical industry with no specific 
regulation, may be another source to analyse. Previous studies have evaluated the 
completeness of product monographs by using an ad hoc assessing tool.(53) The tool 
resulting from this Delphi study will not only allow the evaluation of product 
monographs, but also the assessment of their completeness in comparison with 
SmPCs or other drug information sources. 
Limitations 
This Delphi study aimed at evaluating the completeness of a given drug information 
source for healthcare professionals. Nevertheless, it should be noted that neither the 
quality of the information, nor its applicability or reliability were assessed with this 
method. It may happen that the information provided about a topic is complete, by 
scoring fully in the tool, but it may be outdated. According to Eysenbach et al., 
completeness may be evaluated as an integral part of accuracy. However, analysing 
completeness by using checklists also raises the question of accuracy of the 
information provided.(10) 
There is a dearth of research about the clinical and public health impact of information 
on drugs.(7) Therefore, forecasting the impact for patient health outcomes of the 
results of applying the tool developed in this study would be adventurous. However, as 
clinicians need data to make the best choices and to use drugs maximising their 
benefits and minimising harm (54), this study may contribute to producing more 
 176
complete information sources specifically addressed to the needs of healthcare 
professionals. 
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Conclusions 
Experts identified the 126 items of information constituting the essential information 
that any medicines information source for healthcare professionals should include, 
regardless of its size and format. This list of items gives rise to a tool to assess the 
minimal completeness required for any medicines information source for healthcare 
professionals. 
Experts also achieved consensus in scoring 130 information items according to their 
importance for the assessment of completeness in medicines information sources for 
healthcare professionals. This list of items gives rise to a tool to quantitatively assess 
the completeness of any drug information source, expressed as a percentage of the 
ideal source.  
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Appendix 07.01: Glossary with definition of items in the questionnaire 
Section 1: Characteristics of the medicinal product 
101. Name of the holder of the marketing authorization: Name of the person or company in whose name the 
marketing authorization has been granted. This party is responsible for all aspects of the product, including quality and 
compliance with the conditions of marketing authorization.  
102. Address of the holder of the marketing authorization: main location of the company (street, city, country) in 
whose name the marketing authorization has been granted.  
103. Telephone of the holder of the marketing authorization: contact number of company in whose name the 
marketing authorization has been granted. 
104. Contact to the medical department of the holder of the marketing authorization: contact details (telephone, e-
mail address) of the medical department responsible of the product. 
105. Identification of the active substance: name of the therapeutically active ingredient(s). 
106. Quantitative composition: the quantity of the active substance, expressed per dosage unit. 
107. Excipients (qualitative): Components of a finished product other than the claimed therapeutic ingredient(s) 
expressed qualitatively 
108. Excipients (quantitative): Components of a finished product other than the claimed therapeutic ingredient(s) 
expressed quantitatively 
109. Residues that may be present from the manufacturing process (expressed qualitatively): identification of 
traces of substances (not active substances, nor excipients) that may be present in the final product derived from the 
manufacturing process  
110. Residues that may be present from the manufacturing process (expressed quantitatively): quantification of 
traces of substances (not active substances, nor excipients) that may be present in the final product derived from the 
manufacturing process  
111. Pharmaceutical form: form in which the medicinal product is presented (tablets, capsules, powders for 
reconstitution, transdermal patches, etc) 
112. Visual description of the product: appearance of the final product (colour, markings, etc) 
113. Colour pictures for product identification: inclusion of pictures of the appearance of the final product 
114. Expiry date: the date after which the constant character of the medicine is not any longer guaranteed by the 
holder of the marketing authorisation. 
115. Special precautions for storage: identification of any conditions that may affect the product when stored. 
116. Hygroscopicity of the active substance: The property of a substance of absorbing moisture. 
117. Shelf-life after dilution or reconstitution according to instructions given: the length of time the medicine will 
last without deteriorating after the dilution or reconstitution of the product (when necessary) 
118. Shelf-life after first opening the container: the length of time the medicine will last without deteriorating after 
opening the package. 
119. Dissolution test of the product: In vitro dissolution testing has been employed for manufacturing process 
monitoring and control. Many factors can affect the dissolution rate of a drug product including the granulation process 
(wet or dry), the tablet punch pressure, the formulation composition, and the physicochemical properties of both active  
120. Manufacturing process of the product: explanation of the manufacturing process of the product 
121. Pharmacotherapeutic group (ATC code): classifies the medicinal product according to the ATC code 
122. Type of marketing authorization: official document issued by the competent drug regulatory authority for the 
purpose of marketing. Indication of authorization being by centralized procedure, decentralized procedure or mutual 
recognition procedure. 
123. Marketing authorization numbers: code that identifies the marketing authorization of the product 
124. Date of first authorization/renewal of the authorization: Date from which marketing of the product is authorized. 
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Section 2: Use of the medicinal product 
201. Therapeutic indications: definition of the target disease or aim for which the medicinal product is intended 
202. Treatment algorithm: a treatment algorithm is a technique for standardizing decision-making and improving 
technical quality of care. By providing a series of questions, it guides the caregiver to the correct diagnosis and 
treatment for the most commonly observed pathologies. A treatment algorithm is useful for systematizing or 
standardizing clinical behaviour. 
203. Target population: population in which the product should be used 
204. Instructions for correct administration/use: how and when to take the medicine 
205. Dosing: dose recommendations per dose interval for each age category where appropriate 
206. Statement of the therapeutic window: the term therapeutic window refers to the range of doses of a drug that 
are actually effective in treating a particular disease. Doses below the therapeutic window are too weak to have any 
effect; doses above the window cause unacceptable side-effects. 
207. Maximum recommended single dose: the largest quantity of the medicinal product administered at one time 
consistent with safety. 
208. Maximum recommended daily dose: the largest quantity of the medicinal product administered in a day 
consistent with safety 
209. Maximum recommended total dose: the total largest quantity of the medicinal product to be administered 
consistent with safety 
210. The need for dose titration or not: the need of gradually adjusting the dose of the medicinal product until the 
desired effect is achieved 
211. Need for tapering off: statement about the need of decreasing progressively the dose of a medicinal product 
before finishing the treatment. 
212. Dosage individualization based on disease/severity being treated: indication of the amount of the medicinal 
product to be administered according to the disease being treated or the severity o the disease. 
213. Dosage adjustment in renal impairment: indication of the amount of the medicinal product to be administered to 
patients suffering from acute or chronic malfunction of the kidneys to avoid adverse reactions and to ensure efficacy 
214. Categories of renal impairment related to the dose or interval adjustment: indication of the dosage 
adjustment for patients with different degrees of malfunction of the kidneys. Explicitly specifies relationship between 
dose and degree of renal impairment.  
215. Dosage adjustment in liver disease: indication of the amount of the medicinal product to be administered to 
patients suffering from liver disease to avoid adverse reactions and to ensure efficacy 
216. Dosage adjustment in other concomitant diseases: indication of the amount of the medicinal product to be 
administered to patients suffering from other diseases to avoid adverse reactions and to ensure efficacy 
217. Dosage adjustment related to interactions: indication of the amount of the medicinal product to be administered 
to patients when an interaction with other medicinal drug is present. 
218. Normal duration of treatment: duration of use 
219. Restrictions on duration:  warning about non-desirable effects derived from the duration of the treatment (e.g. 
rebound effect) 
220. What to do if a dose is missing: actions to take when the patient forgets to take a dose 
221. Implications of non-compliance, intermittent dosing: explains the consequences of the patient not taking the 
medication or not following the course of therapy. 
222. Influence of food with the intake of the product: whether the medicinal product should be taken before, during 
or after eating and what the effects of food to the product are. 
223. Use in the paediatric population: specific statement about the use of the drug in children (by age groups), and if 
there are (in)sufficient data for geriatric use  
224. Use in the elderly: specific statement about the use of the drug in elderly population (by age groups), and if there 
are (in)sufficient data for paediatric use. 
225. Use during pregnancy: assessment of risks associated with the use of the drug during pregnancy 
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226. Recommendations on the use of the product at different times during pregnancy in respect to gestation: 
specific statement about the consequences of the use of the product related to different weeks of gestation 
227. Use during lactation: information about the excretion of the active substance or its metabolites in milk 
228. Influence on fertility: effects of the intake of the drug on the ability to conceive and have children. 
229. Influence on the ability to drive and use machines: effects of the intake of the drug on the ability to drive or use 
machines 
230. Comparison of risks and benefits with drugs in the same class: includes a table or outline of different risks 
and benefits of the medicinal product compared to other products of the same drug class 
231. Comparison of risks and benefits with other drugs for the same condition: includes a table or outline of 
different risks and benefits of the medicinal product compared to other products pursuing the same objective )treat the 
same disease, prevent the same condition, etc) 
Section 3: Contraindications 
301. Contraindications (disease): patients with concomitant diseases by which the medicinal product should not be 
used due to safety reasons 
302. Contraindications (interactions): medicines which should be specifically avoided for concomitant or consecutive 
use 
303. Contraindications (hypersensitivity reactions): specifies immune reactions that may occur due to the intake of 
the product 
304. Contraindications (Patient populations not studied in the clinical trials): those populations in which there are 
insufficient data for a safe use of the product 
305. Contraindications (Patient populations likely to experience product or class related adverse reactions 
occurring under normal conditions of use): e.g ages, body weight, poor metabolisers of a drug-metabolising enzyme 
306. Steps to take if the contraindicated drug is administered: actions to take when one of the latter 
contraindications occurs 
Section 4: Adverse reactions 
401. Description of ALL adverse reactions attributed to the medicinal product: indication of ALL adverse reactions 
that may occur related to the intake of the medicinal product 
402. Description of ONLY the MOST FREQUENT adverse reactions: description of the most frequent (not all) 
adverse drug reactions 
403. Serious adverse reactions to which the healthcare professional should be alert: any serious adverse reaction 
that may be present related to the intake of the medicinal product 
404. Mechanism of action of adverse reactions: mechanism of undesired side effects 
405. Circumstances under which patients are at risk of experiencing specified adverse reactions: conditions 
under which patients are more likely to experience adverse reactions 
406. Relationship between dose and adverse reactions: specifically indicates how the dosage influences the 
appearance of adverse reactions in patients 
407. The action to take in case those serious adverse reactions related to the treatment appear: measures to be 
taken when specific adverse reactions appear 
408. Warning about the adverse reactions related to the excipients (even traces): any adverse reaction that may 
be present due to any of the excipients present in the medicinal product (even those from traces remaining after the 
manufacturing process) 
409. Statement of the need to monitor for specific asymptomatic drug reactions: specifies if it is needed (or not) to 
monitor for asymptomatic reactions of the medicinal product  
410. Instructions of how frequently asymptomatic reactions should be monitored: in case monitoring of 
asymptomatic reactions is needed, specifies how frequently 
411. Instructions on how to respond to monitoring values of asymptomatic drug reactions: actions to take 
according to the monitoring values present in patients taking the medicinal product 
 181
412. Assessment of causality of adverse reactions: relation between the causes and appearance of an undesirable 
effect 
413. Assessment of severity of adverse reactions: degree of the undesirable effect, e.g. headache 
414. Assessment of frequency of adverse reactions: how often patients experience the adverse reaction 
415. Inclusion of a table of adverse reactions according to a standard system organ class: specific table (not only 
a describing paragraph, but a table lay-out) in which the adverse reactions are organized systematically according to the 
organ affected. 
416. Information on frequencies of adverse reactions related to the clinical trials from which they stem: indicates 
how often patients in clinical trials have experienced the adverse reaction (with references to the trials) 
417. Time of onset of adverse reactions: the time when symptoms of adverse reactions first occurred 
418. Particular risks on iniciating the treatment, such as first dose effects: any risk that may derive from using a 
medicinal product the first time (other than those common adverse effects). 
419. Particular risks associated with stopping the treatment: any risk that may derive from stop taking the medicinal 
product, such as rebound or withdrawal effects 
420. Measures to be taken to avoid specific adverse reactions: actions to take in order to prevent the ocurrance of 
adverse reactions 
421. The action to take in case those serious adverse reactions related to the treatment appear: measures to be 
taken when specific adverse reactions appear 
422. Reversibility of adverse reactions: specifies the quality of returning to the original condition after an adverse 
reaction occurs 
423. Preclinical safety data: Adverse effects not observed in clinical studies, but seen in animals with possible 
relevance to clinical use. 
Section 5: Interactions 
501. Clinically relevant drug interactions suffered by the described medicine: effects resulting from a drug-drug 
interaction alterations pf the effect of the described medicine due to a drug interaction 
502. Clinically relevant drug interactions produced by the described medicine: alterations of the effect of other 
medicines due to a drug interaction of the described medicine 
503. Interacting medicinal products are listed by drug class: drugs interacting with the medicinal product are 
classified by drug class 
504. Interacting medicinal products are listed as specific compounds: the interacting products are not listed as a 
drug class in general but indicating the specific name of each product 
505. Description of the severity of the drug interaction: the interactions are classified, as e.g. the interaction may be 
life threatening, require medical intervention, result in an exacerbation of the patient’s condition, etc) 
506. Description of the effect of the drug interaction: fully describes the effects of the interaction (signs, symptoms. 
etc) 
507. Food interactions: indicates food-drug interactions which may cause the drug to be more or less effective, or 
cause effects on the body that are not expected. 
508. Interactions with alcohol: indicates alcohol-drug interactions which may cause the drug to be more or less 
effective, or cause effects on the body that are not expected. 
509. Clinical manifestations and effects on laboratory tests: effects of the intake of the drug on the results of 
different laboratory determinations 
510. Effects on the results of lab tests not associated to physiological alterations (potential false positives): 
potential modifications in the results of lab tests due to analytical alterations not related to actual physiologic 
modifications 
Section 6: Overdose 
601. Description of symptoms and signs of overdose of the medicinal product: how overdose can be identified in 
a patient taking the medicinal product 
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602. Management of overdose: actions to take in cases of overdose 
603. Potential sequelae of overdose: future consequences of an overdose 
Section 7: Pharmacodynamic properties 
701. Description of the mechanism of action of the medicinal product: indicates the specific biochemical interaction 
through which the drug produces its pharmacological effect. A mechanism of action usually includes mention of the 
specific molecular targets to which the drug binds, such as an enzyme or receptor. 
702. Identification of the principal physiological effects: indicates the specific effects that the medicinal product 
produces in the organism of the patient 
703. Efficacy data: data that demonstrate clinical effect of the medicinal product 
704. Pharmacodynamic effects: relationship between dose and effect of the medicinal product 
705. Time to onset of effect (with minimal and maximal time): the time when the effect of the medicinal product first 
begins (with inter-patient variation) 
706. Time to peak effect (with minimal and maximal time): time when the effect of the medicinal product (not blood 
levels of the medicinal product) reaches its maximum (with inter-patient variation) 
707. Duration of action/effect with minimal and maximal time: how long the effect is present in the patient (with 
inter-patient variation) 
708. Graphical display visualising the mechanism of action: includes graphics, photographs or graphical outlines of 
the mechanism of action 
709. Evidence for tachyphylaxis/tolerance and maximum dose: warns about the effects (if any) produced by the 
medicinal product when used on a continuous basis 
710. Pro-drug: information about whether the medicinal product is a pro-drug or not. A prodrug is a 
pharmacological substance (drug) that is administered in an inactive (or significantly less active) form. Once 
administered, the prodrug is metabolised in vivo into an active metabolite. 
711. Chirality: specifies the structural characteristic of the molecule. A chiral molecule has a structure that makes it 
impossible to superimpose it on its mirror image. 
712. Relationship between dose and effect: indicates how the effect of the medicinal product changes when the dose 
is modified 
Section 8: Pharmacokinetic properties 
801. Absorption: data about whether the absorption is complete or incomplete 
802. Bioavailability: absolute and/or relative bioavailability: bioavailability is used to describe the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation. Absolute bioavailability compares the 
bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, rectal, 
transdermal, subcutaneous, sublingual administration), with the bioavailability of the same drug following intravenous 
administration. Relative bioavailability measures the bioavailability of a certain drug when compared with another 
formulation of the same drug, usually an established standard, or through administration via a different route  
803. Systemic bioavailability for locally applied medicinal products: fraction of a drug that reaches the systemic 
circulation when the drug is applied locally (eyedrops, topical products, etc) 
804. Time to peak concentration (Tmax): time after which the concentration of the medicinal product in the organism 
is at its maximum 
805. Variability and modifying factors of time to peak concentration: Variability and factors that may modify the 
time to peak concentration. 
806. Influence of the absorption by food: how the intake of food may change the absorption of the medicinal product 
807. Graphical display of concentration trajectory and variability: graphical display of concentration (ordinate) vs 
time (abscissa) 
808. Pharmacokinetic model and model parameters: indication of what pharmacokinetic model the medicinal product 
follows in the organism with identification of its values 
809. PK/PD dose response or hysteresis loop: de-synchronising between pharmacokinetics and pharmacodynamics. 
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810. Plasma protein binding (expressed in %): the percentage of the medicinal product that is bound to plasma 
proteins, mostly plasma albumin. 
811. Volume of distribution: in L/Kg or absolute values in L: quantifies the distribution of a medication between 
plasma and the rest of the body after oral or parenteral dosing. It is defined as the volume in which the amount of drug 
would need to be uniformly distributed to produce the observed blood concentration. 
812. Blood-brain barrier penetration: The blood-brain barrier (BBB) is a metabolic or cellular structure in the central 
nervous system (CNS) that restricts the passage of various substances between the bloodstream and the neural tissue 
itself, while still allowing the passage of substances essential to metabolic function. Extent to which the medicinal 
product penetrates this barrier. 
813. Placental barrier penetration: extent to which the medicinal product penetrates the developing fetal tissues  
814. Distribution to cerebrospinal fluid: extent to which the medicinal product reaches the watery fluid which flows in 
the ventricles  within the brain and around the surface of the brain and spinal cord. 
815. Distribution to milk: extent to which the medicinal product is excreted in mothers’ milk 
816. Tissue concentration: concentration of the medicinal product in body tissues 
817. Plasma concentration: concentration of the medicinal product in plasma 
818. Effective plasma concentration: plasma concentration of the medicinal product with a therapeutic  
819. Toxic plasma concentration: plasma concentration of the medicinal product leading to toxic effects 
820. Statement of one-compartment kinetics behaviour or deviation from it: situation wherein the medicinal 
product remains in the same physiological system compartment (mostly the blood compartment) 
821. Identification of the route/mechanism of metabolism: indicates the specific biochemical interaction through 
which the drug is metabolised 
822. Enzymes involved in metabolism: names of enzymes involved in the metabolism of the medicinal product 
(including CYP450 isoenzymes ) 
823. Degree of metabolism: extent to which the medicinal product is metabolised 
824. Metabolites: which metabolites: name of the metabolites that are originated from metabolism from the medicinal 
product 
825. Activity of metabolites: existence of pharmacologic activity of the metabolites 
826. What is the contribution of the metabolites (if any) to the effect: the extent to which metabolites contribute to 
the global effect of the medicinal product 
827. Pharmacokinetics of principal metabolite(s): distribution and elimination data of the metabolites 
828. List of factors known to increase or decrease metabolism: indicates which factors may modify the metabolism 
of the medicinal product 
829. Induction or inhibition of metabolic enzymes from the medicinal product: indicates if the medicinal product 
modifies the activity of any metabolic enzymes 
830. Site of metabolism: where metabolism takes place 
831. Elimination half lives: The time it takes for the body to eliminate or breakdown half of a dose of the medicinal 
product and its active metabolite(s). 
832. Identification of factors increasing and decreasing half-life: indicates which factors may modify the half-life of 
the medicinal product 
833. Total clearance: in L/min or L/min/Kg: the amount of liquid filtered out of the blood that gets processed by the 
kidneys or the amount of blood cleaned per time (normally 120 ml/min).. 
834. Inter- and/or intra-subject variability in total clearance: indicates possible variation of the clearance values and 
its modifying factors 
835. Excretion routes of the unchanged substance: Routes through which the medicinal product is discharged from 
the organism 
836. Excretion routes of the metabolites: Routes through which the metabolites of the medicinal product are 
discharged from the organism 
837. Linearity/non-linearity of the pharmacokinetics of the medicinal product with respect to dose and/or time: 
statement of linearity or non-linearity of pharmacokinetics, considering that in case of linearity the plasma curve is dose 
related within the considered time frame. 
838. Variation of pharmacokinetics with respect to characteristics of patients: age, gender, smoking status, etc 
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839. Variation of pharmacokinetics with respect to polymorphic metabolism: how pharmacokinetics of the 
medicinal product change due to the drug metabolism status of a patient 
840. Variation of pharmacokinetics with respect to pathological situations such as renal impairment, hepatic 
insufficiency, etc: how pharmacokinetics of the medicinal product change due to any pathological situation 
841. In vivo pharmacokinetic studies of the medicinal product: references to the in-vivo studies related to 
pharmacokinetics 
Section 9: Safety data 
901. Toxicity study (LD50): LD50 is the dose in which 50% of subjects will die 
902. Repeated dose toxicity: information on the toxicity of a product when repeated exposure to the medicinal product 
is anticipated 
903. Genotoxicity: describes a deleterious action on a cell genetic material affecting its integrity.  
904. Carcinogenic potencial: The term carcinogen refers to any medicinal product directly involved in the promotion of 
cancer or in its propagation. 
905. Toxicity to reproduction: if the medicinal product affects negatively the capacity to conceive children, including 
teratogenic effects. 
Section 10: Evidence 
1001. Level of evidence: refers the level of evidence and cites the original research 
1002. Clinical trials: gives information on the clinical trials carried out for the medicinal product and their results, 
including clinical trial registered number. 
Section 11: Prescription data 
1101. Existence of a generic drug of the same active substance: indicates if there is a generic drug with the same 
active substance in the market 
1102. Cost of the Package: specifies the cost of the medicinal product 
1103. Sales situation of the product: indicates sales numbers of the medicinal product in the country 
1104. Includes patient counseling information: includes the basic information patients need to know when taking the 
medicinal product 
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Appendix 07.02. Frequencies of scores for the categorical question in the 
first round. 
  Y  N 
Item101  97%  3% 
Item102  63%  38% 
Item103  63%  38% 
Item104  53%  47% 
Item105  100%  0% 
Item106  94%  6% 
Item107  91%  9% 
Item108  56%  44% 
Item109  59%  41% 
Item110  34%  66% 
Item111  100%  0% 
Item112  84%  16% 
Item113  63%  38% 
Item114  88%  13% 
Item115  100%  0% 
Item116  38%  63% 
Item117  94%  6% 
Item118  97%  3% 
Item119  34%  66% 
Item120  19%  81% 
Item121  94%  6% 
Item122  56%  44% 
Item123  34%  66% 
Item124  50%  50% 
Item201  100%  0% 
Item202  69%  31% 
Item203  84%  16% 
Item204  100%  0% 
Item205  100%  0% 
Item206  72%  28% 
Item207  100%  0% 
Item208  97%  3% 
Item209  78%  22% 
Item210  91%  9% 
Item211  91%  9% 
Item212  91%  9% 
Item213  100%  0% 
Item214  78%  22% 
Item215  97%  3% 
Item216  91%  9% 
Item217  91%  9% 
Item218  88%  13% 
Item219  88%  13% 
Item220  94%  6% 
Item221  66%  34% 
Item222  97%  3% 
Item223  100%  0% 
Item224  100%  0% 
Item225  100%  0% 
Item226  91%  9% 
Item227  100%  0% 
Item228  81%  19% 
Item229  100%  0% 
Item230  69%  31% 
Item231  66%  34% 
Item301  97%  3% 
Item302  97%  3% 
Item303  94%  6% 
Item304  75%  25% 
Item305  81%  19% 
Item306  81%  19% 
Item401  44%  56% 
Item402  84%  16% 
Item403  97%  3% 
Item404  47%  53% 
Item405  81%  19% 
Item406  81%  19% 
Item407  94%  6% 
Item408  72%  28% 
Item409  78%  22% 
Item410  72%  28% 
Item411  63%  38% 
Item412  59%  41% 
Item413  78%  22% 
Item414  78%  22% 
Item415  66%  34% 
Item416  56%  44% 
Item417  72%  28% 
Item418  84%  16% 
Item419  91%  9% 
Item420  78%  22% 
Item421  91%  9% 
Item422  81%  19% 
Item423  47%  53% 
Item501  94%  6% 
Item502  97%  3% 
Item503  63%  38% 
Item504  75%  25% 
Item505  84%  16% 
Item506  88%  13% 
Item507  94%  6% 
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Item508  94%  6% 
Item509  78%  22% 
Item510  72%  28% 
Item601  97%  3% 
Item602  94%  6% 
Item603  75%  25% 
Item701  94%  6% 
Item702  81%  19% 
Item703  75%  25% 
Item704  74%  26% 
Item705  91%  9% 
Item706  88%  13% 
Item707  88%  13% 
Item708  41%  59% 
Item709  61%  39% 
Item710  66%  34% 
Item711  32%  68% 
Item712  94%  6% 
Item713  66%  34% 
Item801  75%  25% 
Item802  72%  28% 
Item803  72%  28% 
Item804  75%  25% 
Item805  59%  41% 
Item806  84%  16% 
Item807  34%  66% 
Item808  31%  69% 
Item809  39%  61% 
Item810  63%  38% 
Item811  59%  41% 
Item812  78%  22% 
Item813  88%  13% 
Item814  59%  41% 
Item815  91%  9% 
Item816  47%  53% 
Item817  50%  50% 
Item818  72%  28% 
Item819  75%  25% 
Item820  41%  59% 
Item821  75%  25% 
Item822  78%  22% 
Item823  72%  28% 
Item824  59%  41% 
Item825  78%  22% 
Item826  69%  31% 
Item827  50%  50% 
Item828  75%  25% 
Item829  72%  28% 
Item830  72%  28% 
Item831  84%  16% 
Item832  78%  22% 
Item833  59%  41% 
Item834  53%  47% 
Item835  72%  28% 
Item836  72%  28% 
Item837  56%  44% 
Item838  75%  25% 
Item839  53%  47% 
Item840  78%  22% 
Item841  45%  55% 
Item901  63%  38% 
Item902  59%  41% 
Item903  66%  34% 
Item904  78%  22% 
Item905  78%  22% 
Item1001  84%  16% 
Item1002  69%  31% 
Item1101  56%  44% 
Item1102  69%  31% 
Item1103  31%  69% 
Item1104  88%  13% 
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Appendix 07.03 Frequencies of scores for the discrete-scoring question in 
the first round. 
  0  1  2  3 4 5 6 7 8  9  10
Item101  0%  0%  0%  0% 3% 16% 3% 6% 19%  3%  50%
Item102  10%  6%  16%  0% 6% 19% 6% 6% 13%  3%  13%
Item103  9%  9%  6%  9% 3% 13% 16% 6% 13%  9%  6%
Item104  13%  9%  6%  6% 3% 16% 3% 22% 13%  6%  3%
Item105  0%  0%  0%  0% 0% 0% 0% 0% 3%  3%  94%
Item106  0%  3%  0%  3% 0% 0% 0% 0% 3%  9%  81%
Item107  0%  0%  0%  6% 0% 9% 3% 9% 16%  13%  44%
Item108  6%  10%  13%  6% 3% 6% 10% 6% 13%  6%  19%
Item109  9%  6%  6%  3% 6% 19% 19% 13% 3%  6%  9%
Item110  13%  16%  13%  3% 10% 13% 16% 6% 0%  3%  6%
Item111  0%  0%  0%  0% 0% 6% 3% 0% 13%  9%  69%
Item112  6%  3%  0%  0% 6% 19% 16% 13% 19%  3%  16%
Item113  13%  3%  3%  3% 9% 25% 6% 6% 22%  3%  6%
Item114  9%  0%  3%  0% 0% 3% 0% 6% 13%  3%  63%
Item115  0%  0%  0%  0% 0% 3% 9% 6% 9%  19%  53%
Item116  16%  6%  3%  16% 9% 13% 16% 3% 6%  3%  9%
Item117  0%  3%  0%  6% 0% 3% 9% 9% 6%  13%  50%
Item118  0%  0%  0%  0% 0% 3% 16% 13% 16%  9%  44%
Item119  29%  3%  6%  13% 13% 13% 3% 3% 10%  6%  0%
Item120  34%  10%  7%  7% 17% 14% 7% 3% 0%  0%  0%
Item121  0%  0%  0%  3% 0% 13% 13% 9% 13%  9%  41%
Item122  13%  6%  16%  6% 0% 19% 13% 3% 9%  3%  13%
Item123  10%  20%  3%  17% 10% 10% 7% 7% 7%  0%  10%
Item124  16%  6%  6%  6% 3% 25% 13% 3% 13%  0%  9%
Item201  0%  0%  0%  0% 0% 0% 0% 0% 6%  3%  91%
Item202  6%  3%  0%  0% 6% 9% 6% 13% 34%  3%  19%
Item203  3%  0%  3%  3% 0% 6% 6% 16% 13%  13%  38%
Item204  0%  0%  0%  0% 0% 0% 0% 0% 13%  6%  81%
Item205  0%  0%  0%  0% 0% 0% 0% 3% 6%  6%  84%
Item206  3%  0%  0%  6% 6% 13% 0% 22% 16%  6%  28%
Item207  0%  0%  0%  0% 3% 3% 3% 6% 28%  9%  47%
Item208  0%  0%  0%  0% 3% 3% 3% 9% 22%  9%  50%
Item209  3%  0%  0%  0% 3% 6% 6% 0% 25%  6%  50%
Item210  0%  0%  0%  0% 3% 3% 6% 9% 31%  0%  47%
Item211  0%  0%  0%  3% 3% 0% 3% 13% 23%  10%  45%
Item212  0%  3%  0%  0% 9% 3% 13% 3% 25%  9%  34%
Item213  0%  0%  0%  0% 0% 3% 9% 9% 13%  9%  56%
Item214  3%  0%  0%  0% 6% 6% 9% 16% 16%  9%  34%
Item215  0%  0%  0%  0% 0% 9% 6% 13% 22%  13%  38%
Item216  0%  0%  0%  0% 6% 19% 3% 16% 13%  3%  41%
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Item217  0%  3%  0%  0% 3% 13% 3% 16% 22%  6%  34%
Item218  0%  3%  0%  3% 0% 3% 3% 9% 34%  6%  38%
Item219  3%  0%  0%  3% 6% 3% 6% 6% 25%  6%  41%
Item220  0%  0%  0%  3% 3% 6% 16% 6% 28%  6%  31%
Item221  3%  3%  3%  6% 6% 9% 3% 19% 19%  6%  22%
Item222  0%  0%  0%  0% 3% 6% 6% 19% 25%  9%  31%
Item223  0%  0%  0%  0% 0% 0% 6% 3% 34%  9%  47%
Item224  0%  0%  0%  3% 0% 3% 3% 6% 31%  9%  44%
Item225  0%  0%  0%  0% 0% 3% 0% 3% 16%  13%  66%
Item226  0%  3%  0%  0% 6% 3% 3% 13% 19%  3%  50%
Item227  0%  0%  0%  0% 0% 3% 0% 9% 22%  16%  50%
Item228  0%  3%  0%  3% 3% 3% 9% 6% 25%  9%  38%
Item229  0%  0%  0%  0% 0% 0% 3% 6% 28%  16%  47%
Item230  13%  3%  0%  0% 3% 0% 13% 13% 22%  9%  25%
Item231  9%  6%  0%  0% 6% 0% 9% 13% 28%  6%  22%
Item301  0%  0%  0%  0% 0% 0% 0% 3% 3%  9%  84%
Item302  0%  0%  0%  0% 0% 3% 0% 3% 19%  9%  66%
Item303  3%  0%  0%  0% 3% 6% 0% 3% 16%  9%  59%
Item304  6%  0%  0%  3% 6% 13% 6% 13% 16%  3%  34%
Item305  6%  0%  0%  0% 3% 9% 0% 9% 22%  9%  41%
Item306  6%  0%  3%  3% 3% 0% 0% 3% 31%  3%  47%
Item401  9%  3%  6%  3% 6% 16% 3% 9% 19%  0%  25%
Item402  6%  0%  3%  0% 3% 0% 0% 0% 16%  6%  65%
Item403  0%  0%  0%  0% 0% 0% 0% 3% 13%  6%  78%
Item404  16%  3%  6%  6% 6% 6% 13% 9% 25%  0%  9%
Item405  0%  3%  3%  0% 3% 3% 13% 16% 41%  0%  19%
Item406  3%  0%  3%  0% 3% 3% 13% 0% 38%  6%  31%
Item407  0%  3%  0%  0% 0% 0% 13% 0% 28%  9%  47%
Item408  3%  6%  3%  0% 9% 13% 13% 16% 16%  13%  9%
Item409  3%  6%  0%  3% 3% 13% 13% 13% 19%  0%  28%
Item410  3%  3%  0%  3% 0% 16% 13% 16% 19%  6%  22%
Item411  6%  3%  3%  0% 3% 19% 16% 25% 13%  0%  13%
Item412  9%  3%  3%  3% 3% 6% 19% 19% 16%  0%  19%
Item413  6%  0%  0%  0% 3% 9% 6% 25% 31%  3%  16%
Item414  6%  0%  0%  0% 3% 6% 9% 19% 28%  13%  16%
Item415  6%  3%  0%  0% 13% 9% 16% 25% 16%  6%  6%
Item416  9%  3%  3%  9% 6% 6% 6% 25% 22%  3%  6%
Item417  3%  3%  0%  0% 3% 9% 16% 6% 41%  0%  19%
Item418  3%  3%  0%  6% 0% 9% 9% 3% 31%  6%  28%
Item419  3%  3%  0%  3% 6% 0% 3% 9% 31%  9%  31%
Item420  6%  3%  0%  0% 0% 9% 0% 16% 19%  13%  34%
Item421  0%  0%  0%  3% 0% 0% 9% 9% 19%  6%  53%
Item422  6%  0%  0%  0% 0% 13% 6% 25% 13%  9%  28%
Item423  6%  9%  6%  16% 9% 16% 9% 6% 16%  0%  6%
Item501  0%  0%  0%  0% 0% 0% 3% 6% 13%  9%  69%
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Item502  0%  0%  0%  0% 0% 0% 3% 3% 13%  13%  69%
Item503  6%  3%  0%  0% 6% 6% 6% 6% 32%  10%  23%
Item504  3%  0%  3%  0% 0% 10% 13% 10% 26%  6%  29%
Item505  3%  3%  0%  0% 0% 9% 3% 9% 31%  0%  41%
Item506  0%  3%  0%  0% 6% 9% 6% 9% 19%  13%  34%
Item507  0%  0%  0%  3% 0% 6% 6% 9% 22%  9%  44%
Item508  3%  0%  0%  0% 3% 6% 9% 13% 13%  13%  41%
Item509  3%  3%  0%  6% 6% 3% 9% 9% 28%  0%  31%
Item510  3%  3%  6%  3% 13% 6% 9% 19% 19%  3%  16%
Item601  0%  0%  0%  0% 0% 3% 0% 9% 16%  3%  69%
Item602  0%  0%  0%  3% 0% 3% 0% 3% 16%  3%  72%
Item603  9%  3%  0%  3% 0% 3% 9% 13% 25%  3%  31%
Item701  0%  0%  3%  0% 3% 3% 6% 3% 19%  13%  50%
Item702  0%  3%  0%  0% 6% 3% 9% 9% 19%  9%  41%
Item703  3%  3%  0%  0% 6% 3% 3% 6% 38%  3%  34%
Item704  3%  0%  3%  0% 6% 6% 0% 13% 29%  10%  29%
Item705  0%  3%  0%  3% 3% 3% 3% 6% 31%  6%  41%
Item706  0%  3%  0%  3% 6% 3% 6% 16% 28%  6%  28%
Item707  0%  3%  0%  3% 6% 0% 6% 6% 28%  13%  34%
Item708  16%  10%  6%  6% 6% 19% 6% 10% 10%  3%  6%
Item709  13%  3%  3%  3% 6% 16% 6% 13% 16%  0%  19%
Item710  6%  3%  0%  0% 6% 22% 9% 16% 16%  6%  16%
Item711  13%  7%  13%  10% 17% 13% 13% 3% 3%  0%  7%
Item712  0%  0%  0%  0% 0% 13% 9% 9% 22%  9%  38%
Item713  6%  0%  0%  6% 9% 13% 6% 19% 25%  0%  16%
Item801  0%  3%  9%  3% 3% 9% 3% 3% 22%  3%  41%
Item802  3%  3%  3%  3% 9% 6% 9% 9% 19%  3%  31%
Item803  3%  6%  3%  9% 3% 6% 0% 13% 19%  6%  31%
Item804  0%  0%  6%  9% 0% 9% 13% 9% 28%  3%  22%
Item805  3%  3%  9%  9% 9% 6% 9% 16% 13%  3%  19%
Item806  3%  0%  3%  0% 3% 13% 3% 16% 19%  6%  34%
Item807  13%  6%  13%  6% 10% 23% 13% 6% 10%  0%  0%
Item808  16%  6%  6%  6% 16% 16% 9% 13% 6%  0%  6%
Item809  16%  6%  6%  10% 10% 16% 6% 10% 13%  0%  6%
Item810  3%  3%  13%  3% 6% 6% 6% 16% 22%  3%  19%
Item811  6%  3%  16%  6% 0% 16% 19% 13% 9%  3%  9%
Item812  0%  3%  3%  0% 16% 6% 9% 6% 19%  13%  25%
Item813  0%  0%  3%  3% 0% 13% 9% 9% 22%  19%  22%
Item814  6%  3%  3%  0% 13% 13% 13% 6% 22%  3%  19%
Item815  0%  0%  3%  3% 6% 6% 3% 22% 25%  9%  22%
Item816  6%  3%  16%  6% 13% 6% 19% 9% 9%  3%  9%
Item817  6%  3%  6%  13% 13% 6% 13% 9% 9%  3%  19%
Item818  6%  6%  6%  3% 6% 9% 6% 13% 13%  9%  22%
Item819  6%  3%  6%  6% 6% 6% 6% 9% 22%  3%  25%
Item820  13%  9%  13%  9% 6% 22% 3% 9% 6%  6%  3%
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Item821  0%  6%  6%  0% 3% 3% 6% 13% 28%  9%  25%
Item822  0%  3%  6%  6% 0% 6% 3% 16% 28%  3%  28%
Item823  3%  3%  9%  3% 3% 3% 9% 13% 25%  6%  22%
Item824  6%  3%  13%  3% 6% 3% 6% 9% 25%  9%  16%
Item825  3%  3%  6%  3% 6% 6% 3% 6% 31%  6%  25%
Item826  3%  3%  9%  3% 3% 9% 9% 3% 41%  0%  16%
Item827  13%  3%  6%  0% 6% 19% 6% 6% 28%  3%  9%
Item828  3%  3%  3%  3% 3% 9% 6% 13% 22%  6%  28%
Item829  3%  3%  3%  3% 6% 13% 3% 13% 22%  3%  28%
Item830  3%  3%  9%  0% 9% 6% 3% 16% 28%  3%  19%
Item831  0%  0%  3%  6% 9% 6% 3% 6% 13%  19%  34%
Item832  0%  0%  9%  0% 6% 9% 6% 13% 28%  6%  22%
Item833  6%  3%  16%  0% 3% 13% 13% 9% 19%  13%  6%
Item834  13%  3%  9%  6% 6% 9% 16% 16% 9%  3%  9%
Item835  3%  3%  6%  9% 6% 6% 3% 13% 19%  3%  28%
Item836  3%  3%  9%  16% 3% 0% 0% 16% 25%  3%  22%
Item837  3%  6%  13%  3% 3% 22% 13% 9% 19%  3%  6%
Item838  0%  3%  9%  0% 0% 9% 3% 16% 28%  6%  25%
Item839  9%  3%  6%  0% 3% 16% 13% 13% 22%  3%  13%
Item840  3%  3%  6%  0% 0% 13% 6% 9% 19%  19%  22%
Item841  13%  3%  6%  3% 10% 16% 10% 6% 23%  0%  10%
Item901  13%  9%  3%  0% 6% 6% 13% 9% 16%  0%  25%
Item902  9%  6%  6%  3% 3% 13% 9% 16% 16%  3%  16%
Item903  9%  6%  3%  6% 3% 9% 6% 6% 16%  0%  34%
Item904  3%  3%  3%  3% 6% 6% 6% 6% 13%  9%  41%
Item905  3%  3%  0%  0% 6% 6% 6% 6% 3%  10%  55%
Item1001  0%  0%  3%  0% 3% 3% 0% 10% 19%  3%  58%
Item1002  3%  0%  3%  3% 10% 6% 3% 6% 19%  3%  42%
Item1101  23%  13%  3%  6% 0% 3% 3% 6% 13%  6%  23%
Item1102  6%  6%  6%  0% 0% 13% 6% 13% 16%  3%  29%
Item1103  23%  6%  0%  6% 13% 16% 3% 6% 6%  3%  16%
Item1104  3%  0%  6%  0% 3% 6% 0% 9% 13%  6%  53%
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Appendix 07.04. Frequencies of scores for the categorical question in the 
second round. 
  Y  N 
Item102  56%  44% 
Item103  56%  44% 
Item104  44%  56% 
Item108  33%  67% 
Item109  52%  48% 
Item110  15%  85% 
Item112  93%  7% 
Item113  50%  50% 
Item114  63%  37% 
Item116  22%  78% 
Item119  12%  88% 
Item120  4%  96% 
Item122  48%  52% 
Item123  30%  70% 
Item124  44%  56% 
Item125  85%  15% 
Item126  93%  7% 
Item127  92%  8% 
Item128  85%  15% 
Item129  59%  41% 
Item202  85%  15% 
Item203  93%  7% 
Item206  85%  15% 
Item209  100%  0% 
Item214  89%  11% 
Item218  88%  12% 
Item219  100%  0% 
Item221  70%  30% 
Item228  85%  15% 
Item230  67%  33% 
Item231  63%  38% 
Item232  96%  4% 
Item233  74%  26% 
Item234  85%  15% 
Item235  67%  33% 
Item304  89%  11% 
Item305  93%  7% 
Item306  81%  19% 
Item401  30%  70% 
Item402  89%  11% 
Item404  33%  67% 
Item405  93%  7% 
Item406  96%  4% 
Item408  74%  26% 
Item409  85%  15% 
Item410  85%  15% 
Item411  62%  38% 
Item412  48%  52% 
Item413  81%  19% 
Item414  81%  19% 
Item415  74%  26% 
Item416  44%  56% 
Item417  74%  26% 
Item418  93%  7% 
Item420  85%  15% 
Item422  93%  7% 
Item423  19%  81% 
Item424  12%  88% 
Item425  52%  48% 
Item426  52%  48% 
Item427  63%  37% 
Item428  44%  56% 
Item503  67%  33% 
Item504  85%  15% 
Item505  96%  4% 
Item506  93%  7% 
Item509  85%  15% 
Item510  70%  30% 
Item511  63%  37% 
Item603  81%  19% 
Item604  37%  63% 
Item605  41%  59% 
Item606  96%  4% 
Item702  89%  11% 
Item703  74%  26% 
Item706  89%  11% 
Item707  93%  7% 
Item708  11%  89% 
Item709  52%  48% 
Item710  56%  44% 
Item711  4%  96% 
Item713  68%  32% 
Item714  78%  22% 
Item801  89%  11% 
Item802  81%  19% 
Item803  89%  11% 
Item804  78%  22% 
Item805  41%  59% 
Item806  96%  4% 
Item807  7%  93% 
Item808  7%  93% 
 192
Item809  11%  89% 
Item810  60%  40% 
Item811  41%  59% 
Item812  85%  15% 
Item813  93%  7% 
Item814  44%  56% 
Item816  22%  78% 
Item817  26%  74% 
Item818  63%  37% 
Item819  85%  15% 
Item820  11%  89% 
Item821  78%  22% 
Item822  85%  15% 
Item823  78%  22% 
Item824  48%  52% 
Item825  89%  11% 
Item826  70%  30% 
Item827  26%  74% 
Item828  85%  15% 
Item829  89%  11% 
Item830  78%  22% 
Item831  93%  7% 
Item832  89%  11% 
Item833  48%  52% 
Item834  37%  63% 
Item835  85%  15% 
Item836  78%  22% 
Item837  33%  67% 
Item838  89%  11% 
Item839  37%  63% 
Item840  89%  11% 
Item841  22%  78% 
Item901  56%  44% 
Item902  52%  48% 
Item903  70%  30% 
Item904  85%  15% 
Item905  89%  11% 
Item1001  89%  11% 
Item1002  63%  37% 
Item1003  59%  41% 
Item1004  41%  59% 
Item1005  59%  41% 
Item1101  52%  48% 
Item1102  58%  42% 
Item1104  88%  12% 
Item1105  26%  74% 
Item1106  42%  58% 
Item1107  41%  59% 
Item1108  81%  19% 
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Appendix 07-05. Frequencies of scores for the discrete-scoring question 
in the second round. 
  0  1  2  3 4 5 6 7 8  9  10
Item101  0%  0%  0%  0% 4% 4% 4% 4% 15%  11%  59%
Item102  4%  4%  0%  19% 22% 22% 7% 4% 11%  0%  7%
Item103  4%  7%  0%  7% 11% 33% 11% 7% 4%  7%  7%
Item104  8%  8%  4%  0% 8% 42% 15% 4% 8%  4%  0%
Item107  0%  0%  0%  0% 4% 4% 4% 4% 7%  30%  48%
Item108  7%  7%  7%  4% 11% 30% 15% 4% 4%  4%  7%
Item109  7%  7%  4%  19% 7% 19% 30% 4% 4%  0%  0%
Item110  23%  12%  8%  19% 15% 19% 4% 0% 0%  0%  0%
Item112  0%  0%  0%  4% 4% 7% 22% 30% 22%  7%  4%
Item113  8%  12%  0%  4% 12% 36% 8% 12% 4%  0%  4%
Item114  8%  0%  8%  12% 8% 4% 4% 8% 15%  0%  35%
Item116  12%  4%  8%  19% 31% 15% 4% 0% 0%  0%  8%
Item117  0%  0%  0%  0% 0% 0% 7% 15% 19%  4%  56%
Item118  0%  0%  0%  0% 0% 0% 4% 11% 22%  22%  41%
Item119  23%  19%  15%  27% 4% 8% 4% 0% 0%  0%  0%
Item120  27%  31%  31%  12% 0% 0% 0% 0% 0%  0%  0%
Item121  0%  0%  0%  0% 4% 0% 15% 7% 19%  19%  37%
Item122  15%  4%  11%  11% 15% 30% 11% 0% 4%  0%  0%
Item123  8%  19%  12%  31% 12% 8% 0% 4% 4%  0%  4%
Item124  8%  4%  8%  8% 4% 29% 17% 13% 4%  0%  4%
Item125  7%  0%  0%  0% 7% 15% 11% 15% 22%  0%  22%
Item126  4%  0%  0%  4% 0% 7% 19% 19% 19%  4%  26%
Item127  0%  0%  4%  0% 7% 11% 11% 30% 19%  4%  15%
Item128  4%  0%  4%  4% 7% 0% 4% 7% 15%  4%  52%
Item129  11%  0%  0%  19% 11% 7% 4% 4% 22%  0%  22%
Item202  4%  4%  0%  0% 0% 7% 15% 0% 52%  7%  11%
Item203  0%  0%  4%  0% 0% 4% 4% 11% 26%  33%  19%
Item206  4%  0%  0%  4% 0% 4% 4% 37% 15%  11%  22%
Item207  0%  0%  0%  0% 0% 0% 4% 7% 15%  33%  41%
Item208  0%  0%  0%  0% 0% 0% 0% 12% 12%  19%  58%
Item209  0%  0%  0%  0% 0% 0% 0% 11% 19%  26%  44%
Item210  0%  0%  0%  0% 0% 0% 4% 19% 33%  11%  33%
Item211  0%  0%  0%  0% 0% 0% 7% 15% 7%  37%  33%
Item212  0%  0%  0%  4% 0% 4% 15% 4% 33%  22%  19%
Item213  0%  0%  0%  0% 0% 4% 0% 0% 19%  7%  70%
Item214  0%  0%  0%  0% 0% 11% 11% 11% 22%  15%  30%
Item215  0%  0%  0%  0% 0% 4% 7% 7% 22%  19%  41%
Item216  0%  0%  0%  0% 0% 4% 19% 4% 26%  4%  44%
Item217  0%  4%  0%  0% 0% 4% 4% 11% 33%  15%  30%
Item218  0%  4%  0%  0% 0% 4% 0% 11% 41%  7%  33%
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Item219  0%  0%  0%  0% 0% 0% 7% 15% 41%  7%  30%
Item220  0%  0%  0%  0% 0% 4% 4% 16% 20%  20%  36%
Item221  0%  0%  7%  7% 0% 7% 11% 37% 15%  11%  4%
Item222  0%  0%  0%  0% 0% 0% 7% 7% 30%  30%  26%
Item223  0%  0%  0%  0% 0% 0% 4% 0% 8%  38%  50%
Item224  0%  0%  0%  4% 0% 0% 0% 4% 12%  27%  54%
Item226  0%  0%  0%  0% 0% 7% 0% 15% 4%  19%  56%
Item227  0%  0%  0%  0% 0% 0% 4% 7% 4%  26%  59%
Item228  0%  4%  0%  0% 4% 7% 7% 7% 26%  15%  30%
Item229  0%  0%  0%  0% 0% 0% 4% 7% 7%  19%  63%
Item230  11%  4%  0%  0% 7% 4% 15% 11% 22%  11%  15%
Item231  8%  4%  4%  0% 8% 4% 4% 13% 42%  4%  8%
Item232  0%  0%  0%  0% 0% 0% 4% 4% 15%  22%  56%
Item233  0%  0%  0%  7% 4% 19% 11% 19% 22%  4%  15%
Item234  4%  4%  0%  7% 4% 15% 11% 7% 26%  7%  15%
Item235  4%  0%  4%  7% 11% 4% 0% 7% 30%  4%  30%
Item303  0%  0%  0%  0% 0% 0% 4% 4% 4%  4%  83%
Item304  0%  0%  0%  4% 0% 7% 0% 22% 26%  11%  30%
Item305  0%  0%  0%  0% 0% 4% 7% 7% 26%  26%  30%
Item306  4%  0%  4%  0% 0% 4% 0% 7% 22%  26%  33%
Item401  4%  0%  12%  8% 8% 19% 15% 8% 12%  12%  4%
Item404  11%  0%  11%  4% 7% 11% 33% 7% 7%  0%  7%
Item405  0%  0%  0%  7% 0% 7% 11% 19% 37%  7%  11%
Item406  0%  0%  0%  4% 0% 4% 11% 15% 41%  11%  15%
Item407  0%  0%  0%  0% 0% 0% 0% 4% 15%  27%  54%
Item408  0%  4%  0%  7% 4% 19% 22% 30% 4%  7%  4%
Item409  0%  0%  0%  0% 4% 19% 19% 15% 30%  11%  4%
Item410  0%  0%  0%  0% 0% 15% 19% 19% 19%  19%  11%
Item411  0%  7%  0%  0% 11% 15% 33% 19% 7%  0%  7%
Item412  7%  4%  4%  0% 15% 7% 11% 26% 22%  0%  4%
Item413  4%  0%  0%  0% 4% 4% 15% 15% 48%  4%  7%
Item414  4%  0%  0%  0% 4% 4% 7% 15% 48%  0%  19%
Item415  0%  4%  4%  4% 0% 15% 19% 37% 11%  4%  4%
Item416  4%  4%  8%  4% 12% 4% 12% 38% 8%  4%  4%
Item417  4%  4%  0%  0% 0% 15% 11% 19% 37%  0%  11%
Item418  0%  0%  0%  4% 0% 4% 7% 15% 48%  4%  19%
Item419  0%  0%  0%  4% 4% 0% 4% 8% 42%  21%  17%
Item420  0%  0%  0%  4% 0% 4% 11% 11% 44%  11%  15%
Item422  0%  0%  0%  0% 4% 7% 15% 26% 30%  4%  15%
Item423  8%  15%  12%  8% 19% 31% 4% 4% 0%  0%  0%
Item424  25%  17%  8%  8% 0% 25% 8% 4% 0%  4%  0%
Item425  11%  7%  0%  7% 11% 19% 11% 7% 11%  0%  15%
Item426  11%  11%  4%  11% 0% 30% 7% 4% 4%  7%  11%
Item427  15%  4%  4%  11% 7% 11% 11% 11% 4%  7%  15%
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Item428  19%  11%  4%  4% 4% 19% 15% 15% 4%  7%  0%
Item503  7%  0%  4%  0% 11% 0% 7% 15% 37%  11%  7%
Item504  4%  0%  0%  0% 0% 7% 19% 15% 19%  19%  19%
Item505  0%  0%  0%  0% 0% 7% 4% 11% 56%  7%  15%
Item506  0%  0%  0%  4% 0% 4% 4% 11% 41%  11%  26%
Item507  0%  0%  0%  0% 0% 7% 0% 7% 11%  26%  48%
Item508  0%  0%  0%  0% 4% 4% 4% 7% 7%  30%  44%
Item509  0%  0%  4%  0% 7% 11% 4% 15% 37%  7%  15%
Item510  0%  0%  4%  4% 7% 7% 15% 44% 7%  4%  7%
Item511  0%  0%  0%  11% 19% 15% 15% 15% 19%  0%  7%
Item603  8%  0%  4%  0% 4% 0% 12% 15% 38%  4%  15%
Item604  12%  8%  4%  8% 19% 12% 19% 12% 8%  0%  0%
Item605  7%  15%  0%  4% 19% 26% 15% 11% 4%  0%  0%
Item606  0%  0%  0%  4% 0% 0% 11% 7% 15%  15%  48%
Item701  0%  0%  0%  0% 0% 0% 4% 11% 26%  15%  44%
Item702  0%  0%  4%  0% 0% 0% 4% 0% 35%  42%  15%
Item703  4%  0%  4%  0% 0% 11% 4% 11% 37%  19%  11%
Item705  0%  0%  0%  0% 0% 4% 7% 7% 44%  19%  19%
Item706  0%  4%  0%  0% 4% 4% 7% 15% 52%  7%  7%
Item707  0%  0%  4%  0% 0% 4% 4% 4% 56%  11%  19%
Item708  12%  19%  4%  4% 12% 38% 4% 4% 4%  0%  0%
Item709  7%  0%  4%  4% 15% 19% 33% 4% 7%  4%  4%
Item710  7%  4%  0%  4% 11% 33% 4% 26% 11%  0%  0%
Item711  15%  19%  8%  8% 35% 12% 0% 0% 4%  0%  0%
Item712  0%  0%  0%  0% 0% 4% 15% 8% 31%  23%  19%
Item713  0%  0%  0%  4% 7% 19% 15% 41% 11%  0%  4%
Item714  0%  0%  0%  4% 7% 11% 11% 26% 26%  7%  7%
Item801  0%  4%  0%  4% 0% 7% 15% 15% 26%  19%  11%
Item802  4%  4%  0%  0% 0% 4% 11% 11% 44%  7%  15%
Item803  0%  4%  0%  7% 0% 4% 19% 7% 30%  22%  7%
Item804  0%  4%  4%  7% 4% 0% 19% 11% 44%  0%  7%
Item805  4%  7%  4%  7% 15% 19% 15% 26% 4%  0%  0%
Item806  0%  0%  0%  0% 0% 4% 4% 11% 48%  15%  19%
Item807  12%  12%  4%  8% 19% 38% 0% 4% 0%  0%  0%
Item808  19%  12%  15%  4% 31% 19% 0% 0% 0%  0%  0%
Item809  15%  8%  12%  8% 23% 27% 0% 4% 0%  0%  4%
Item810  7%  0%  11%  0% 7% 0% 19% 33% 19%  0%  4%
Item811  11%  4%  15%  7% 0% 15% 30% 7% 7%  0%  4%
Item812  0%  0%  4%  4% 0% 4% 15% 15% 37%  15%  7%
Item813  0%  0%  4%  4% 0% 4% 7% 15% 37%  15%  15%
Item814  4%  0%  8%  0% 0% 27% 19% 12% 19%  4%  8%
Item815  0%  0%  0%  4% 0% 4% 7% 22% 37%  15%  11%
Item816  11%  0%  15%  11% 7% 19% 26% 4% 4%  0%  4%
Item817  11%  0%  4%  7% 22% 11% 30% 4% 7%  0%  4%
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Item818  7%  0%  7%  0% 15% 11% 4% 26% 19%  4%  7%
Item819  4%  0%  0%  0% 7% 19% 4% 19% 37%  0%  11%
Item820  15%  0%  23%  12% 23% 19% 0% 4% 4%  0%  0%
Item821  4%  0%  15%  0% 4% 7% 0% 11% 37%  15%  7%
Item822  4%  0%  4%  4% 0% 11% 4% 11% 33%  15%  15%
Item823  8%  0%  12%  0% 8% 4% 8% 19% 38%  4%  0%
Item824  7%  0%  15%  4% 15% 7% 4% 15% 26%  7%  0%
Item825  0%  0%  4%  4% 4% 7% 15% 4% 44%  11%  7%
Item826  0%  4%  7%  0% 15% 7% 4% 15% 37%  4%  7%
Item827  12%  4%  12%  0% 15% 31% 12% 8% 8%  0%  0%
Item828  4%  0%  4%  4% 4% 4% 11% 7% 52%  4%  7%
Item829  4%  0%  4%  0% 4% 7% 15% 7% 37%  11%  11%
Item830  4%  0%  11%  0% 4% 0% 15% 15% 44%  4%  4%
Item831  0%  0%  4%  4% 0% 4% 4% 0% 30%  30%  26%
Item832  0%  0%  4%  0% 4% 4% 19% 15% 33%  15%  7%
Item833  7%  4%  11%  7% 7% 11% 19% 4% 22%  4%  4%
Item834  11%  7%  0%  4% 19% 15% 22% 7% 11%  4%  0%
Item835  4%  0%  4%  4% 7% 11% 11% 7% 44%  0%  7%
Item836  4%  0%  11%  4% 7% 7% 4% 22% 30%  0%  11%
Item837  8%  0%  12%  19% 4% 27% 19% 4% 8%  0%  0%
Item838  0%  0%  11%  0% 0% 7% 7% 22% 33%  7%  11%
Item839  11%  0%  11%  0% 4% 15% 30% 11% 11%  4%  4%
Item840  0%  0%  7%  0% 0% 11% 4% 7% 30%  22%  19%
Item841  15%  4%  4%  4% 19% 38% 8% 4% 4%  0%  0%
Item901  15%  4%  11%  4% 7% 11% 11% 19% 15%  0%  4%
Item902  4%  0%  4%  19% 11% 15% 11% 19% 11%  0%  7%
Item903  4%  4%  4%  15% 0% 7% 15% 15% 22%  0%  15%
Item904  0%  0%  0%  11% 4% 7% 15% 0% 22%  15%  26%
Item905  0%  0%  0%  0% 7% 7% 15% 0% 15%  7%  48%
Item1001  0%  0%  4%  0% 0% 4% 4% 0% 22%  11%  56%
Item1002  7%  0%  4%  0% 11% 0% 7% 7% 33%  22%  7%
Item1003  0%  4%  7%  0% 19% 7% 7% 15% 15%  7%  19%
Item1004  11%  4%  7%  0% 19% 7% 7% 15% 22%  4%  4%
Item1005  22%  4%  4%  0% 4% 4% 11% 7% 37%  4%  4%
Item1101  15%  7%  4%  0% 7% 15% 11% 26% 15%  0%  0%
Item1102  15%  4%  4%  0% 8% 4% 12% 27% 19%  0%  8%
Item1104  4%  0%  4%  0% 0% 0% 0% 0% 23%  8%  62%
Item1105  19%  8%  4%  4% 15% 15% 15% 4% 8%  0%  8%
Item1106  20%  8%  0%  4% 12% 12% 16% 0% 20%  0%  8%
Item1107  19%  8%  8%  0% 8% 15% 8% 12% 15%  0%  8%
Item1108  7%  4%  0%  7% 0% 11% 11% 26% 11%  11%  11%
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Appendix 07.06. Frequencies of scores for the categorical question in the 
third round. 
  Y  N 
Item102  55%  45% 
Item103  59%  41% 
Item104  31%  69% 
Item108  21%  79% 
Item109  52%  48% 
Item113  45%  55% 
Item114  86%  14% 
Item116  18%  82% 
Item122  31%  69% 
Item123  14%  86% 
Item124  34%  66% 
Item129  81%  19% 
Item221  85%  15% 
Item230  68%  32% 
Item231  71%  29% 
Item233  89%  11% 
Item235  85%  15% 
Item236  96%  4% 
Item401  24%  76% 
Item404  17%  83% 
Item408  89%  11% 
Item411  71%  29% 
Item412  36%  64% 
Item415  96%  4% 
Item416  32%  68% 
Item417  89%  11% 
Item425  57%  43% 
Item426  50%  50% 
Item427  68%  32% 
Item428  43%  57% 
Item503  83%  17% 
Item510  83%  17% 
Item511  66%  34% 
Item604  17%  83% 
Item605  21%  79% 
Item703  89%  11% 
Item709  52%  48% 
Item710  59%  41% 
Item713  79%  21% 
Item714  89%  11% 
  Y  N 
Item804  83% 17%
Item805  25% 75%
Item810  72% 28%
Item811  24% 76%
Item814  38% 62%
Item816  10% 90%
Item817  10% 90%
Item818  79% 21%
Item821  93% 7%
Item823  90% 10%
Item824  38% 62%
Item826  86% 14%
Item827  14% 86%
Item830  89% 11%
Item833  38% 62%
Item834  24% 76%
Item836  86% 14%
Item837  17% 83%
Item839  14% 86%
Item841  10% 90%
Item901  59% 41%
Item902  55% 45%
Item903  86% 14%
Item1002 86% 14%
Item1003 72% 28%
Item1004 31% 69%
Item1005 57% 43%
Item1101 59% 41%
Item1102 59% 41%
Item1105 21% 79%
Item1106 21% 79%
Item1107 17% 83%
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Appendix 07-07. Frequencies of scores for the discrete-scoring question 
in the third round. 
  0  1  2  3 4 5 6 7 8  9  10
Item102  3%  3%  0%  7% 21% 41% 14% 7% 3%  0%  0%
Item103  7%  0%  3%  3% 7% 59% 7% 10% 3%  0%  0%
Item104  7%  0%  3%  3% 7% 59% 10% 7% 3%  0%  0%
Item108  10%  3%  10%  3% 17% 34% 3% 10% 3%  0%  3%
Item109  11%  4%  11%  11% 4% 46% 7% 7% 0%  0%  0%
Item110  15%  22%  11%  33% 11% 4% 4% 0% 0%  0%  0%
Item113  7%  3%  3%  10% 7% 48% 3% 0% 14%  0%  3%
Item114  3%  0%  7%  0% 3% 3% 0% 24% 17%  7%  34%
Item116  11%  4%  14%  14% 43% 0% 0% 7% 0%  0%  7%
Item117  0%  0%  0%  0% 0% 0% 4% 0% 14%  18%  64%
Item118  0%  0%  0%  0% 0% 0% 0% 4% 11%  46%  39%
Item119  18%  25%  39%  11% 4% 0% 0% 0% 4%  0%  0%
Item120  0%  100%  0%  0% 0% 0% 0% 0% 0%  0%  0%
Item121  0%  0%  0%  0% 0% 4% 4% 7% 4%  39%  43%
Item122  7%  3%  3%  14% 34% 24% 3% 7% 0%  0%  3%
Item123  3%  14%  14%  52% 3% 3% 0% 3% 7%  0%  0%
Item124  7%  0%  4%  21% 0% 50% 14% 4% 0%  0%  0%
Item125  7%  0%  0%  0% 3% 7% 10% 45% 14%  7%  7%
Item126  3%  0%  0%  0% 3% 3% 7% 34% 21%  14%  14%
Item127  0%  0%  0%  0% 10% 3% 0% 66% 14%  0%  7%
Item128  3%  0%  0%  3% 3% 0% 0% 10% 14%  3%  62%
Item129  7%  0%  0%  3% 7% 28% 24% 14% 17%  0%  0%
Item206  3%  0%  0%  0% 0% 3% 0% 55% 17%  10%  10%
Item210  0%  0%  0%  0% 0% 0% 0% 10% 52%  7%  31%
Item212  0%  0%  0%  3% 0% 0% 0% 7% 66%  10%  14%
Item214  0%  0%  0%  0% 0% 0% 3% 3% 45%  24%  24%
Item215  0%  0%  0%  0% 0% 0% 3% 3% 17%  45%  31%
Item216  0%  0%  0%  0% 0% 0% 7% 7% 34%  28%  24%
Item217  0%  3%  0%  0% 0% 0% 3% 3% 48%  21%  21%
Item218  0%  3%  0%  0% 0% 0% 3% 0% 59%  14%  21%
Item219  0%  0%  0%  0% 0% 0% 0% 7% 59%  17%  17%
Item220  0%  0%  0%  0% 0% 0% 3% 3% 17%  45%  31%
Item221  3%  0%  0%  0% 0% 3% 14% 41% 38%  0%  0%
Item222  0%  0%  0%  0% 0% 0% 7% 0% 18%  57%  18%
Item228  0%  0%  4%  0% 4% 4% 0% 7% 43%  14%  25%
Item230  10%  0%  3%  3% 3% 3% 0% 28% 41%  7%  0%
Item231  7%  3%  0%  7% 3% 3% 0% 14% 55%  7%  0%
Item233  0%  0%  0%  7% 0% 3% 14% 34% 34%  0%  7%
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Item234  4%  4%  0%  4% 0% 11% 11% 46% 18%  0%  4%
Item235  0%  0%  3%  7% 0% 0% 3% 14% 48%  3%  21%
Item236  0%  0%  0%  0% 0% 0% 8% 4% 23%  19%  46%
Item304  0%  0%  0%  0% 4% 4% 4% 7% 50%  25%  7%
Item305  0%  0%  0%  0% 0% 4% 0% 14% 7%  46%  29%
Item306  4%  0%  0%  4% 0% 0% 0% 7% 0%  54%  32%
Item401  4%  0%  11%  7% 11% 36% 11% 7% 11%  4%  0%
Item404  11%  0%  7%  4% 7% 18% 43% 7% 4%  0%  0%
Item405  0%  0%  0%  7% 0% 0% 14% 11% 57%  4%  7%
Item406  0%  0%  0%  0% 4% 0% 7% 7% 75%  0%  7%
Item408  0%  0%  0%  3% 7% 3% 28% 45% 7%  0%  7%
Item409  0%  0%  0%  0% 0% 11% 14% 18% 54%  0%  4%
Item410  0%  0%  0%  0% 0% 7% 14% 36% 39%  0%  4%
Item411  3%  0%  3%  0% 3% 7% 62% 14% 7%  0%  0%
Item412  7%  0%  7%  3% 3% 3% 21% 41% 10%  0%  3%
Item413  0%  0%  0%  0% 0% 3% 10% 10% 69%  3%  3%
Item414  0%  0%  0%  0% 0% 3% 14% 10% 55%  10%  7%
Item415  0%  0%  0%  0% 0% 3% 21% 55% 17%  0%  3%
Item416  3%  0%  10%  0% 3% 14% 7% 48% 14%  0%  0%
Item417  3%  0%  3%  0% 0% 3% 10% 28% 41%  10%  0%
Item418  0%  0%  0%  0% 3% 0% 3% 14% 69%  3%  7%
Item420  0%  0%  0%  0% 3% 0% 3% 10% 62%  14%  7%
Item422  0%  0%  0%  0% 4% 4% 7% 43% 36%  4%  4%
Item423  7%  11%  7%  11% 29% 32% 0% 4% 0%  0%  0%
Item424  21%  14%  25%  14% 14% 4% 0% 7% 0%  0%  0%
Item425  11%  7%  0%  7% 14% 39% 11% 0% 7%  0%  4%
Item426  10%  7%  0%  3% 7% 45% 21% 3% 3%  0%  0%
Item427  10%  0%  3%  7% 10% 28% 28% 7% 7%  0%  0%
Item428  14%  0%  7%  3% 7% 34% 24% 3% 3%  3%  0%
Item503  0%  7%  3%  3% 0% 0% 3% 3% 69%  7%  3%
Item504  4%  0%  4%  0% 0% 4% 4% 7% 63%  4%  11%
Item506  0%  0%  0%  4% 0% 0% 4% 11% 68%  4%  11%
Item509  0%  0%  4%  0% 0% 7% 7% 7% 67%  4%  4%
Item510  0%  0%  3%  0% 7% 3% 7% 66% 10%  0%  3%
Item511  0%  0%  7%  0% 3% 17% 28% 31% 7%  0%  7%
Item603  4%  0%  0%  4% 4% 4% 0% 11% 61%  11%  4%
Item604  10%  7%  3%  7% 24% 31% 10% 3% 3%  0%  0%
Item605  7%  7%  3%  0% 28% 41% 10% 0% 0%  3%  0%
Item606  0%  0%  0%  0% 4% 0% 0% 4% 14%  25%  54%
Item701  0%  0%  0%  0% 0% 0% 0% 7% 26%  26%  41%
Item703  0%  0%  0%  4% 0% 4% 4% 7% 57%  14%  11%
Item708  10%  17%  3%  7% 17% 38% 3% 3% 0%  0%  0%
Item709  7%  0%  0%  7% 0% 34% 48% 0% 3%  0%  0%
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Item710  7%  0%  0%  10% 7% 48% 17% 7% 3%  0%  0%
Item711  18%  11%  11%  14% 43% 4% 0% 0% 0%  0%  0%
Item712  0%  0%  0%  0% 0% 4% 14% 0% 54%  21%  7%
Item713  0%  0%  0%  3% 3% 7% 14% 62% 7%  0%  3%
Item714  0%  0%  0%  3% 0% 7% 17% 48% 17%  3%  3%
Item801  0%  3%  0%  0% 0% 10% 0% 7% 69%  7%  3%
Item802  3%  3%  0%  0% 0% 3% 3% 14% 66%  3%  3%
Item803  0%  3%  0%  3% 3% 3% 3% 7% 72%  0%  3%
Item804  0%  3%  0%  7% 0% 7% 0% 10% 66%  3%  3%
Item805  3%  7%  3%  3% 17% 17% 28% 7% 14%  0%  0%
Item807  10%  14%  7%  14% 10% 41% 3% 0% 0%  0%  0%
Item808  17%  7%  14%  17% 34% 10% 0% 0% 0%  0%  0%
Item809  14%  7%  17%  10% 31% 14% 7% 0% 0%  0%  0%
Item811  10%  7%  3%  3% 3% 24% 38% 3% 7%  0%  0%
Item812  0%  0%  3%  0% 3% 0% 7% 17% 55%  7%  7%
Item813  0%  0%  3%  0% 3% 0% 7% 7% 62%  7%  10%
Item814  3%  0%  0%  3% 0% 24% 38% 10% 10%  3%  7%
Item816  7%  4%  14%  4% 7% 29% 29% 0% 7%  0%  0%
Item817  11%  4%  4%  11% 4% 32% 25% 4% 7%  0%  0%
Item818  4%  0%  0%  11% 0% 7% 4% 56% 11%  4%  4%
Item819  4%  0%  0%  0% 4% 4% 7% 14% 57%  4%  7%
Item820  14%  0%  14%  32% 21% 14% 0% 4% 0%  0%  0%
Item821  0%  0%  4%  0% 7% 7% 11% 7% 50%  7%  7%
Item822  0%  0%  0%  0% 7% 4% 7% 11% 61%  4%  7%
Item823  0%  0%  0%  7% 4% 7% 7% 25% 43%  0%  7%
Item824  7%  0%  4%  11% 7% 11% 32% 14% 11%  0%  4%
Item825  0%  0%  0%  7% 4% 4% 7% 7% 57%  4%  11%
Item826  0%  4%  0%  7% 4% 7% 11% 32% 25%  0%  11%
Item827  11%  4%  0%  11% 7% 54% 4% 4% 4%  4%  0%
Item828  0%  0%  0%  0% 0% 11% 15% 0% 63%  4%  7%
Item829  0%  0%  0%  0% 0% 7% 15% 4% 59%  7%  7%
Item830  0%  0%  0%  4% 4% 7% 4% 7% 68%  0%  7%
Item831  0%  0%  0%  0% 4% 4% 4% 4% 21%  54%  11%
Item832  0%  0%  0%  4% 0% 4% 7% 7% 59%  7%  11%
Item833  7%  4%  4%  7% 0% 14% 36% 14% 7%  7%  0%
Item834  7%  4%  7%  0% 11% 46% 11% 4% 4%  7%  0%
Item835  0%  0%  0%  0% 4% 7% 7% 18% 57%  0%  7%
Item836  0%  0%  0%  4% 11% 4% 11% 32% 32%  0%  7%
Item837  7%  0%  7%  18% 4% 54% 7% 4% 0%  0%  0%
Item838  0%  0%  0%  0% 4% 4% 11% 21% 54%  0%  7%
Item839  11%  4%  4%  7% 4% 18% 46% 7% 0%  0%  0%
Item840  0%  0%  4%  4% 0% 0% 11% 18% 43%  11%  11%
Item841  14%  0%  4%  7% 7% 61% 4% 4% 0%  0%  0%
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Item901  14%  3%  0%  7% 7% 21% 21% 24% 3%  0%  0%
Item902  3%  3%  3%  3% 7% 45% 21% 7% 3%  0%  3%
Item903  0%  0%  3%  3% 3% 7% 14% 28% 38%  0%  3%
Item904  0%  0%  0%  3% 7% 3% 7% 10% 34%  17%  17%
Item905  0%  0%  0%  3% 3% 0% 3% 10% 14%  34%  31%
Item1002  0%  0%  0%  3% 3% 0% 3% 7% 62%  10%  10%
Item1003  0%  0%  3%  10% 3% 7% 0% 31% 17%  21%  7%
Item1004  10%  0%  7%  3% 3% 10% 31% 10% 24%  0%  0%
Item1005  21%  3%  3%  0% 0% 3% 14% 17% 38%  0%  0%
Item1101  14%  3%  7%  3% 0% 10% 21% 31% 10%  0%  0%
Item1102  17%  7%  3%  0% 3% 0% 14% 38% 14%  3%  0%
Item1105  21%  14%  0%  10% 17% 17% 14% 3% 3%  0%  0%
Item1106  17%  7%  3%  0% 14% 34% 14% 0% 7%  0%  3%
Item1107  17%  7%  7%  3% 10% 31% 10% 7% 3%  0%  3%
Item1108  0%  3%  0%  0% 0% 10% 14% 48% 14%  3%  7%
 
 
 
 
 
202 
 
1. Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R. 
Assessing the quality of drug detailing. J Clin Epidemiol. 2002 Aug;55(8):825-32. 
2. Berland GK, Elliott MN, Morales LS, Algazy JI, Kravitz RL, Broder MS, Kanouse 
DE, Munoz JA, Puyol JA, Lara M, Watkins KE, Yang H, McGlynn EA. Health 
information on the Internet: accessibility, quality, and readability in English and 
Spanish. JAMA. 2001 May 23-30;285(20):2612-21. 
3. Aronson JK. Drug interactions-information, education, and the British National 
Formulary. Br J Clin Pharmacol. 2004 Apr;57(4):371-2. 
4. Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a 
guidebook to the medical information jungle. J Fam Pract. 1994 Nov;39(5):489-
99. 
5. Curley SP, Connelly DP, Rich EC. Physicians' use of medical knowledge 
resources: preliminary theoretical framework and findings. Med Decis Making. 
1990 Oct-Dec;10(4):231-41. 
6. Fernandez-Llimos F. Drug information in the community pharmacy. 
Pharmaceutical Care España 1999;1:90-6. 
7. Greene JA, Kesselheim AS. Pharmaceutical marketing and the new social media. 
N Engl J Med. 2010 Nov 25;363(22):2087-9. 
8. Mack J. Quality of medical information on the Internet. JAMA. 1997 Aug 
27;278(8):632; author reply -3. 
9. HON. The commitment to reliable health and medical information on the internet; 
Available from: http://www.hon.ch/HONcode/Pro/Visitor/visitor.html (accessed 9 
May 2011) 
10. Eysenbach G, Powell J, Kuss O, Sa ER. Empirical studies assessing the quality 
of health information for consumers on the world wide web: a systematic review. 
JAMA. 2002 May 22-29;287(20):2691-700. 
11. Eysenbach G. Infodemiology: The epidemiology of (mis)information. Am J Med. 
2002 Dec 15;113(9):763-5. 
12. FDA. How to Evaluate Health Information on the Internet.; Available from: 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSa
fely/BuyingMedicinesOvertheInternet/ucm202863.htm (accessed 9 May 2011) 
13. EFPIA. Guidelines for internet web sites available to health professionals, 
patients and the public in the EU.; Available from: 
http://www.efpia.org/Objects/2/Files/Internetguidelines.pdf (accessed 9 May 
2011) 
14. Narhi U, Pohjanoksa-Mantyla M, Karjalainen A, Saari JK, Wahlroos H, Airaksinen 
MS, Bell SJ. The DARTS tool for assessing online medicines information. Pharm 
World Sci. 2008 Dec;30(6):898-906. 
15. Silberg WM, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring 
the quality of medical information on the Internet: Caveant lector et viewor--Let 
the reader and viewer beware. JAMA. 1997 Apr 16;277(15):1244-5. 
16. AGREE Next Steps Consortium 2009. The AGREE II Instrument [Electronic 
version]; Available from: http://www.agreetrust.org (accessed 8 Dec 2011) . 
17. Ferner RE, Coleman J, Pirmohamed M, Constable SA, Rouse A. The quality of 
information on monitoring for haematological adverse drug reactions. Br J Clin 
Pharmacol. 2005 Oct;60(4):448-51. 
18. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin 
Pharmacol. 2007 Jun;63(6):709-14. 
19. Mullen WH, Anderson IB, Kim SY, Blanc PD, Olson KR. Incorrect overdose 
management advice in the Physicians' Desk Reference. Ann Emerg Med. 1997 
Feb;29(2):255-61. 
20. Brubacher JR, Purssell R, Kent DA. Salty broth for salicylate poisoning? 
Adequacy of overdose management advice in the 2001 Compendium of 
Pharmaceuticals and Specialties. CMAJ. 2002 Oct 29;167(9):992-6. 
203 
 
21. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four 
sources of drug information regarding adjustment of dose for renal function. BMJ. 
2005 Jul 30;331(7511):263. 
22. Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp 
C, Montane E, Rago L, Rocchi F. Prescribing information in 26 countries: a 
comparative study. Eur J Clin Pharmacol. 2003 Aug;59(4):263-70. 
23. Cohen JS. Adverse drug effects, compliance, and initial doses of 
antihypertensive drugs recommended by the Joint National Committee vs the 
Physicians' Desk Reference. Arch Intern Med. 2001 Mar 26;161(6):880-5. 
24. Guo JJ, Wigle PR, Lammers K, Vu O. Comparison of potentially hepatotoxic 
drugs among major US drug compendia. Res Social Adm Pharm. 2005 
Sep;1(3):460-79. 
25. Willy ME, Li Z. What is prescription labeling communicating to doctors about 
hepatotoxic drugs? A study of FDA approved product labeling. 
Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):201-6. 
26. McKibbon KA, Fridsma DB. Effectiveness of clinician-selected electronic 
information resources for answering primary care physicians' information needs. 
J Am Med Inform Assoc. 2006 Nov-Dec;13(6):653-9. 
27. Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson 
AJ, Jr., Woosley RL, Abernethy DR, Cantilena LR. Assessment and reporting of 
clinical pharmacology information in drug labeling. Clin Pharmacol Ther. 2000 
Mar;67(3):196-200. 
28. Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: performance 
of personal digital assistant versus online drug information databases. 
Pharmacotherapy. 2007 Dec;27(12):1651-8. 
29. Iijima H, Kamei M, Koshimizu T, Shiragami M. Objective evaluation of generic 
drug information. Yakugaku Zasshi. 2004 Jun;124(6):341-7. 
30. Fernandez-Llimos F, Vazquez Gomez I. Information provided by generic and 
brand-name pharmaceutical manufacturers in response to a request. Pharm 
World Sci. 2007 Dec;29(6):683-7. 
31. Strang DG, Gagnon M, Molloy DW, Darzins P, Etchells E, Bedard M, Davidson 
W. Development of a standardized, comprehensive "ideal drug detail". Can J Clin 
Pharmacol. 2001 Summer;8(2):73-7. 
32. Hersh WR, Crabtree MK, Hickam DH, Sacherek L, Rose L, Friedman CP. 
Factors associated with successful answering of clinical questions using an 
information retrieval system. Bull Med Libr Assoc. 2000 Oct;88(4):323-31. 
33. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, 
Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, 
Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet. 
2005 Dec 17;366(9503):2112-7. 
34. Kennedy HP. Enhancing Delphi research: methods and results. J Adv Nurs. 2004 
Mar;45(5):504-11. 
35. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a 
research methodology for nursing. Int J Nurs Stud. 2001 Apr;38(2):195-200. 
36. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey 
technique. J Adv Nurs. 2000 Oct;32(4):1008-15. 
37. Goodman CM. The Delphi technique: a critique. J Adv Nurs. 1987 Nov;12(6):729-
34. 
38. Linstone HA, Turoff M. The Delphi Method: Techniques and Applications.   [9-
May-2011]; Available from: http://is.njit.edu/pubs/delphibook. 
39. de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences 
education research. Med Teach. 2005 Nov;27(7):639-43. 
40. Hsu CC SB. The Delphi technique: making sense of consensus. Practical 
Assessment, Research & Evaluation. 2007;12:1-8. 
204 
 
41. Jones J, Hunter D. Consensus methods for medical and health services 
research. BMJ. 1995 Aug 5;311(7001):376-80. 
42. McKenna HP. The Delphi technique: a worthwhile research approach for 
nursing? J Adv Nurs. 1994 Jun;19(6):1221-5. 
43. Ulschak FL. Human Resource Development: The Theory and Practice of Need 
Assessment Virginia Reston; 1983. 
44. Ludwig B. Predicting the future: have you considered using the Delphi 
methodology? Journal of Extension 1997;35(5):1-4. 
45. Ely JW, Osheroff JA, Ebell MH, Bergus GR, Levy BT, Chambliss ML, Evans ER. 
Analysis of questions asked by family doctors regarding patient care. BMJ. 1999 
Aug 7;319(7206):358-61. 
46. Iwanowicz SL, Marciniak MW, Zeolla MM. Obtaining and providing health 
information in the community pharmacy setting. Am J Pharm Educ. 2006 Jun 
15;70(3):57. 
47. McEntee JE, Henderson SL, Rutter PM, Rutter J, Davis HJ. Utility and value of a 
medicines information service provided by pharmacists: a survey of health 
professionals. Int J Pharm Pract. 2010 Dec;18(6):353-61. 
48. Castillo P. Promoción y Publicidad de medicamentos: quo vadis? . Med Clin 
(Barc) 1992;99:305-9. 
49. Andrews JE, Pearce KA, Ireson C, Love MM. Information-seeking behaviors of 
practitioners in a primary care practice-based research network (PBRN). J Med 
Libr Assoc. 2005 Apr;93(2):206-12. 
50. Davies K, Harrison J. The information-seeking behaviour of doctors: a review of 
the evidence. Health Info Libr J. 2007 Jun;24(2):78-94. 
51. Rahmner PB, Eiermann B, Korkmaz S, Gustafsson LL, Gruven M, Maxwell S, 
Eichle HG, Veg A. Physicians' reported needs of drug information at point of care 
in Sweden. Br J Clin Pharmacol.  Jan;73(1):115-25. 
52. European_Commision. A Guideline on Summary of Product Characteristics 
(SmPC).; Available from: http://ec.europa.eu/health/files/eudralex/vol-
2/c/smpc_guideline_rev2_en.pdf (accessed 9 May 2011) 
53. Fernandez-Llimos F, Loza MI. Product monographs supplied by drug 
manufacturers to community pharmacists in Spain. Ann Pharmacother. 2000 
Mar;34(3):407. 
54. Herxheimer A. Open access to industry's clinically relevant data. BMJ. 2004 Jul 
10;329(7457):64-5. 
 
 
  
 
 
 
Chapter 8 
 
 
Concluding Remarks 
 
 
 206
Concluding remarks 
The focus of this research was to assess the characteristics of medicines information 
sources designed for healthcare professionals. For this purpose, we conducted a 
series of studies aiming at five different and complementary specific objectives. 
Due to the fact that scientific literature varies considerably when identifying the most 
used sources of medicines information among healthcare professionals (1-5), this 
research was initiated by aiming at exploring which sources of medicines information 
were preferred by healthcare professionals at a global level. Additionally, we analysed 
whether there were demographic or socio-economic factors associated to the selection 
of specific information sources. Aiming at a global population, the most appropriate 
method was to design a web-based survey, and invite a wide range of healthcare 
professionals and researchers to participate in the study, trying to cover a broad 
spectrum of areas of work in the healthcare sector. The response rate was 
approximately 57% of countries, comprising 88% of the world’s population. The 
percentage of responding countries was not equally distributed among continents, and  
countries members of the ‘Organisation for Economic Co-operation and Development’ 
(OECD), with higher Gross Domestic Product (GDP) per capita, a higher percentage of 
GDP as health expenditure and higher Human Development Index (HDI), and Healthy 
Life Expectancy at birth (HALE) were significantly associated with a higher response 
rate. Conversely, countries classified by the World Bank as low income countries were 
the countries with a smaller response rate. Developing countries often lack the 
resources to participate in costly research projects, and the use of Internet may not be 
so widespread. However, for those healthcare professionals with a valid e-mail 
address,  participation in the study was easy, simple and free, and resource limitation 
could not explain the observed low response rates. Our results showed that medicines 
compendia are the leading information source among healthcare professionals. There 
is a tendency to choose medicines compendia as the preferred information source in 
highly developed countries and high income countries, as represented by some of the 
characteristics analysed, such as OECD membership, GDP per capita, HDI and data 
on health expenditure. Use of information sources was homogeneous across different 
areas of work of participants. In our immediate environment, Europe, compendia were 
also the preferred medicines information source, followed by information retrieved from 
the Internet. It is noteworthy that Summaries of Product Characteristics (SmPCs) were 
the third preferred medicines information source for healthcare professionals in Europe. 
Although some authors consider that healthcare professionals are not aware of the 
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content of SmPCs or they do not even know how to access them (6, 7), the selection of 
SmPCs is reasonable, because they are the official information source for healthcare 
professionals in the European Union. Therefore, it was obvious that our research 
should be focused on these two medicines information sources: medicines compendia 
and SmPCs.   
One of the potential causes for the heterogeneous selection of medicines information 
sources in the world could be the differences in availability and access to national 
medicines compendia. A world web survey was designed to identify which countries 
publish a national compendium and the demographic and socio-economic factors that 
are associated to the publication of medicines compendia. The survey investigated 
which countries publish a national compendium, and whether a foreign compendium 
was used in countries that did not published one. Results showed that slightly more 
than 60% of the world’s population is living in countries with a national compendium. 
Although initially some of the demographic and socio-economic characteristics 
analysed were associated to publishing a national compendium, the subsequent 
multivariate analysis showed that the only covariate associated to publishing a 
compendium was being member of the OECD. It is important to highlight that the 
OECD is an organization devoted to global development. There are not objective 
criteria that define membership of the OECD and its mission is “to promote policies that 
will improve the economic and social well-being of people around the world”.(8) 
Consequently, we can conclude that the only covariate associated to publishing a 
national medicines compendium is the development of a country, in the sense of 
OECD membership. Besides that, our study showed that countries which reported not 
having a national compendium, indicated that they used one published by a country 
with significantly different socio-economic characteristics.  The most cited foreign 
compendium was the British National Formulary (published in the United Kingdom), 
followed by the Dictionnaire Vidal (published in France). The use of these foreign 
compendia may not be appropriate for two reasons: there are drugs available in 
developing countries which are not marketed in countries where the compendia is 
produced, and thus no information about these drugs would be available when using 
compendia from developed countries.(9) Furthermore, as daily practice may differ 
greatly between developed and developing countries, the information needed in 
developed countries may be of no use for developing countries. For example, some 
studies claim the need to include pharmacogenomic biomarker information in drug 
reference books (10), which might be much appreciated in highly developed 
economies, but useless in other countries with completely different needs. In order to 
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overcome this problem, the WHO ‘Expert Committee on the Use of Essential Drugs’ 
recommended in 1995 that the WHO should develop a medicines compendia, 
designated as a ‘Model Formulary’ which would complement the WHO Model List of 
Essential Drugs. The first edition of the Model Formulary was issued in August 2002.(8) 
The WHO Model Formulary is intended to be a starting point for national governments 
to develop their own compendia, as well as serving as an information source for 
individual prescribers. The WHO considered that this Model Formulary would be a 
useful resource for countries wishing to develop their own national formulary or 
compendium, which should be then completed with locally useful information on 
treatment of prevalent diseases, prices, distribution rules and other locally relevant 
details.(8) We should highlight that this Model Formulary was not mentioned by any of 
the respondents to the survey. Especially in countries lacking a national formulary, a 
medicines compendia developed by WHO should be a useful source. 
In our study about preferences of medicines information sources, one of the most 
mentioned sources in Europe was the Summary of Product Characteristics (SmPC), 
which has a differential characteristic, it is an official source approved by European 
Regulatory Agencies previously to be delivered to professionals. Due to the fact that 
our objective was to assess the characteristics of medicines information sources from 
the perspective of the healthcare professional, it was considered highly relevant to 
determine the content of clinical pharmacology information in SmPCs. To perform this 
evaluation, a tool formerly used to analyse the content of clinical pharmacology 
information in the US Physicians’ Desk Reference (PDR) was used.(11) This tool 
included different categories of information such as mechanism of action, 
pharmacodynamics, drug metabolism, pharmacokinetics and dose adjustments. To 
evaluate the content in clinical pharmacology information we compared the obtained 
score in the SmPCs with that from the package inserts, other official information source 
designed for patients. Because package inserts aim at informing patients they were not 
expected to have an extensive content in clinical pharmacology information. Our results 
showed that the content of clinical pharmacology information, although more extensive 
than the content of package leaflets, was clearly insufficient. Moreover, the average 
score of SmPCs was very similar to the average score of the initial study performed in 
the United States with a commercial source of information: the Physician’s Desk 
Reference. . 
We were also interested in evaluating the content of information of the SmPCs about 
the use of medicines in special groups of considerable relevancy in healthcare, such as 
the use of medicines in pregnancy and lactation. To carry out the study, two 
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researchers evaluated independently the content of all SmPCs of medicinal products 
approved by the European Medicines Agency through a centralised procedure using an 
ad hoc created form. Discrepancies were reconciliated by a third different researcher. 
Percentages of agreement between the two independent researchers were 
considerably high, suggesting a substantial and robust analysis. Results from the 
analysis of the content showed that information about post-marketing surveillance is 
sparse, although the average ‘age’ of the medicines was greater than five years. 
Although the collection of toxicity data before a medicinal product is marketed is very 
limited (12), safety data obtained during clinical use should help improve the 
information available. (6) Information about the cross of the placental barrier by the 
medicinal product or the excretion of the drug in human milk is lacking in the majority of 
SmPCs. Other useful information such as management of pregnancies exposed to the 
drug or influence of the drug in fertility are only present in few SmPCs. Apart from the 
lack of information, there were subjects in which SmPCs clearly stated that the 
information was not known (fertility, excretion in human milk, adverse reactions in 
lactating neonates). Despite the lack of information, SmPCs are very restrictive in their 
recommendations for use during pregnancy and lactation. Other authors have 
previously argued that uncertainty about the safety of the majority of drugs may lead to 
under-prescribing for pregnant women. (13) To assess the applicability of the 
information, the conclusiveness of the recommendations provided in SmPCs was 
evaluated. A high percentage of SmPCs contained non-conclusive statements 
regarding the use of the medicinal product during pregnancy. However, for 
breastfeeding, most of the statements were conclusive. 
Finally, analysis of the content of in different information sources is commonly 
performed by comparing the information contained in each source or by using 
checklists or score lists created by the authors for the purpose of their study. The main 
limitation of this last method is that it does not allow comparison among contents in 
different information sources. To overcome this limitation we aimed at developing a 
universal tool for the evaluation of the content of any medicines information source. 
First, we aimed at defining the minimal set of items of information that should be 
present in any medicines information source designed for healthcare professionals. 
Subsequently, we aimed at creating a scoring tool that allows the quantitative 
comparison of the content of different sources of medicines information. A total of 29 of 
the recruited experts from 18 European countries completed a Delphi technique in 
three rounds. From an extensive literature search an initial list containing 162 items of 
information was created. The experts evaluated the items and refined the list, and after 
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three rounds consensus was achieved to define a list of 126 essential items of 
information that any medicine information source should contain. Consensus was also 
achieved in scoring 130 information items to develop a completeness score tool. This 
tool allows the completeness of a medicine information source to be presented as a 
percentage of the ideal source.                          
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Future Implications 
The absence of national medicines compendia in developing countries may constitute 
a major public health problem. Using compendia from more developed countries may 
not be the most appropriate solution for these countries. There is room for creating an 
international medicines compendium, and the WHO should lead the initiative. This 
medicines compendium should be a complete formulary rather than a ‘Model 
Formulary’ and contain at least information about the essential list of medicines. The 
content of this formulary should address the needs of developing countries, which 
would constitute the potential users.  
Our analyses have shown that Summaries of Product Characteristics are not a perfect 
information source. Apparently, a balance between informing healthcare professionals 
and protecting drug industry liability exists in the information in SmPCs. Since the 
European Medicines Agency clearly states that SmPCs are ‘the basis of information for 
healthcare professionals on how to use the medicinal product safely and effectively’, 
not only their content but also their applicability should be revised. Bearing in mind this 
objective and in order to aid healthcare professionals in clinical decision making, 
SmPCs should have conclusive recommendations instead of ambiguous statements. 
This becomes crucial when considering the development of electronic SmPCs, which 
should interface with the electronic health records and decision support systems. If 
conclusive information is important for human reasoning of healthcare professionals, it 
becomes essential to interface with electronic systems that lack relational thinking. 
A universal tool to assess completeness of medicines information sources allows the 
content of different kinds of information sources to be compared, regardless of their 
format.  Due to its standard scoring system, this tool allows the completeness of 
information on different medicinal products to be compared. Further and foremost, this 
tool allows the completeness of medicines information sources to be evaluated and 
improved during their production process.  
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